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Oncogenesis
Cancer is one of the most prevalent multifactorial diseases, characterized by the loss of 
physiological control associated with malignant transformation. Tumor cells show biological 
characteristics that are considered to be drivers of malignancy, and these are described as 
the hallmarks of cancer1. These hallmarks provide an organizing principle for rationalizing 
the complexity of cancers, and they include sustained proliferative signaling, evasion of growth 
suppressors, avoidance of immune destruction, replicative immortality, tumor promoting 
inflammation, activation of invasion and metastasis, induction of angiogenesis, genome 
instability and mutations, resistance to cell death and deregulation of cellular metabolism 
(Figure 1). It is becoming clear that besides a tumor promoting environment (e.g. hypoxia), these 
hallmarks are the result of a range of mutational events that alter signaling pathways. Multiple 
drugs that inhibit the various hallmarks of cancer have been developed. However, increasing 
efforts in high-throughput next generation sequencing show that the mutational load of tumors 
is larger and more heterogeneous than previously thought, and therefore it is questionable if 
blocking individual oncogenic signaling molecules is a practical therapeutic strategy. 
 Alterations in cellular metabolism can be regarded as a hallmark of cancer that is absolutely 
required for malignant transformation. In this thesis, both targeting of tumor metabolism and 
development of a nanomedicine platform for targeting of active signaling pathways are described. 
In the future they could be used in combination therapies to achieve synthetic lethality2. 
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Figure 1. Hallmarks of cancer, adapted from Hanahan, Cell, 2011.
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Tumor metabolism
Cancer cells are different from normal cells because they maintain a high growth rate, 
enabled by altered cellular metabolism. Glucose has been the central metabolite in studies 
on cancer metabolism for a long time, especially since Otto Warburg found that cancer cells 
often show increased glucose consumption and increased lactate production, regardless of 
oxygen availability. This phenomenon was termed the Warburg effect, or aerobic glycolysis3-4, 
and it was thought to be a consequence of compromised mitochondrial function of cancer cells 
rather than a driver of tumorigenesis. 
 Now it is apparent that the metabolic rewiring in cancer cells goes beyond the Warburg 
effect, since cancer cells have been shown to maintain mitochondrial respiration for ATP 
production5-7, and that this is essential for cancer cell survival8. Furthermore other metabolic 
pathways, like the pentose phosphate pathway (PPP), glutaminolysis and fatty acid synthesis, 
are reprogrammed in cancer cells as well. So far, the focus has been on the role of activation 
of oncogenes and inactivation of tumor suppressor genes in this metabolic rewiring. However, 
an increasing number of mutations is found in metabolic genes, and some of these are directly 
involved in tumorigenesis.
Activation of oncogenes and inactivation of tumor suppressor genes in tumor metabolism
Tumor metabolic reprogramming can be a direct result of altered intracellular pathways due 
to mutations in oncogenes and tumor suppressor genes. Tumors frequently contain mutations 
that lead to sustained high signaling levels of the PI3K-AKT-mTORC1 pathway without external 
growth factor stimulation9 (Figure 2). This pathway promotes an anabolic program resulting in 
increased protein synthesis, and increased glycolytic flux and lipid synthesis through activation 
of transcription factors hypoxia inducible factor 1 (HIF-1) and sterol regulatory element-binding 
protein (SREBP), respectively10. 
 Furthermore, gain of function of the transcription factor Myc is often seen. This change 
is known to enhance glycolysis through increased expression of glucose transporters and 
glycolytic enzymes. In addition it promotes lactate production and export, mitochondrial 
oxidative metabolism, nucleotide synthesis and glutaminolysis11-12. Besides oncogenes, tumor 
suppressor genes can also regulate metabolism. Loss of function of tumor suppressor p53 
contributes to the increased glycolytic flux and inhibition of oxidative phosphorylation (OXPHOS) 
to maintain anabolism and redox balance in tumor cells13. 
 Some tumors display constitutive activation of HIF-1 even under normoxic conditions. 
This can be caused by various mechanisms, among which mTORC1 hyperactivation or the 
loss of von Hippel-Lindau (VHL) function. The VHL suppressor gene encodes pVHL, part of a 
multi-protein complex that targets the α subunits of HIF-1 and HIF-2 for ubiquitin-mediated 
degradation, an oxygen mediated process14. Lack of pVHL function results in increased HIF-1 
levels, leading to increased glycolytic flux and decreased mitochondrial metabolism. 
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Figure 2. Signaling pathways that regulate cancer metabolism. Tumor cells have aberrant activation of 
mTORC1 that induces an anabolic growth program resulting in nucleotide, protein and lipid synthesis. Loss 
of tumor suppressors like p53 and pVHL or activation of oncogenes like Myc further promotes anabolism 
through transcriptional regulation of metabolic genes (Gluc = glucose, G6P = glucose-6-phosphate, 3PG = 
3-phosphoglycerate, Ser = serine, Lac = lactate, Pyr = pyruvate, Ac-CoA = acetyl coenzyme A, Cit = citrate, 
ICT = isocitrate, α-KG = α-ketoglutarate, Suc = succinate, Fum = fumarate, OAA = oxalo-acetate, Ac = 
acetate, Gln = glutamine, Glu= glutamate). Red ovals depict transcription factors and other genes involved 
in regulation of metabolic pathways, white rectangles depict metabolic processes and purple rectangles 
depict products of these processes (Adapted from DeBerardinis, Science Advances, 2016).
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Mutations in metabolic genes in tumor metabolism and oncometabolites
Although a combination of loss of tumor suppressor genes and activation of oncogenes can 
dysregulate cellular metabolism, an increasing number of genes encoding metabolic enzymes 
have now been found to carry cancer-inducing mutations. In 2008, genome-sequencing efforts 
in gliomas, the most frequent cancers originating from the brain parenchyma itself, led to 
detection of mutations in genes encoding the key metabolic enzymes isocitrate dehydrogenase 
(IDH) 1 or 215 (Figure 3). IDH enzymes catalyze the oxidative decarboxylation of isocitrate to 
α-ketoglutarate (α-KG) and CO2. Three IDH isoforms exist, IDH1 and 2 are NADP
+ dependent, 
and IDH3 is NAD+ dependent. IDH1 is found exclusively in the cytoplasm and peroxisomes, 
whereas IDH2 and IDH3 are found in the mitochondria. Mutations are found commonly in grade 
II and III diffuse gliomas and secondary glioblastomas (GBMs)15-16, acute myeloid leukemia 
(AML)17, and a limited number of other tumor types18-19. In gliomas, mutations in IDH1 are 
most common16 whereas IDH1 and IDH2 mutations occur with equal frequency in AML20. The 
mutations are somatic and monoallelic, and the large majority of mutations involve an arginine 
to histidine mutation at position 132 in the catalytic site of IDH1, while IDH2 mutations mostly 
involve R17215-16. IDH2 mutations in AML can also involve R140, again in the enzymatically 
active site17. 
 The mutations cause a decrease in the affinity of the enzyme for isocitrate, but an increase 
in the affinity for α-KG21. Additionally the mutant enzymes have acquired a novel function by 
reducing α-KG into D-2-hydroxyglutarate (D-2-HG) with concomitant NADPH oxidation22. D-2-
HG can rise up to millimolar levels, and it interferes with a number of enzymes for which α-KG is 
an essential co-factor, such as the TET (Ten-Eleven-Translocation) family of hydroxymethylases 
and Jumonji-C-domain-containing histone demethylases (JHDMs)23-24. These changes 
ultimately lead to global DNA and histone hypermethylation, altered gene expression and 
inhibition of differentiation25. In addition, D-2-HG serves as a cofactor for Egg Laying defective 
Nine (EGLN), a member of the family of prolyl hydroxylases (PHDs) that hydroxylates specific 
proline residues of HIF-1α, inducing ubiquitination and degradation26 (Figure 3). HIF-1α is 
a transcription factor that regulates expression of a number of hypoxia-related genes such 
as glucose transporter 1 and 3 (GLUT-1, GLUT-3) and vascular endothelial growth factor-A 
(VEGF-A)27, and is a central modulator of angiogenesis and vascular hyperpermeability. 
Increased HIF-1α degradation by D-2-HG fits with the notion that IDH mutations are frequent 
in grade II/III glioma that grow very diffusely and lack hypoxic signaling and angiogenesis28-29. 
Indeed, low-grade IDH-mutant gliomas show less edema and contrast enhancement in MRI. 
As D-2-HG results in increased cell proliferation and exogenous addition of D-2-HG results in 
epigenetic alterations and HIF-1α degradation comparable to the situation in IDH1 mutants, at 
least in leukemic cells30, D-2-HG is now considered to be an oncometabolite. 
 Secondly, loss-of-function mutations have been identified in genes encoding the enzymes 
fumarate hydratase (FH) and the succinate dehydrogenase complex (SDH), that catalyze 
sequential steps in the tricarboxylic acid (TCA) cycle31-32 (Figure 3). These mutations not only 
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impair TCA cycle flux, they also cause accumulation of their substrates fumarate and succinate 
which share structural similarities with α-KG. Both fumarate and succinate inhibit α-KG 
dependent PHDs, resulting in normoxic stabilization of HIF subunits and constitutive activation 
of HIF targets33-34. 
 Another example is the genomic amplification of phosphoglycerate dehydrogenase 
(PHGDH) which is found in breast cancer and melanoma35-36 (Figure 3). PHGDH catalyzes the 
conversion of 3-phosphoglycerate (3PG) to 3-phosphohydroxypyruvate (3POHPyr) as the first 
step of serine metabolism. Serine may donate a methyl group to the one-carbon pool, and is 
thereby converted to glycine. Together these amino acids contribute to nucleotide synthesis, 
methylation reactions and NADPH production, and an accelerated flux through this biosynthetic 
pathway may contribute to oncogenesis. 
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Figure 3. The effects of mutations in metabolic enzymes. Mutations in genes encoding FH and SDH cause 
accumulation of the substrates fumarate and succinate, respectively, whereas IDH1/2 mutant enzymes 
have acquired a novel function of reducing α-KG to D-2-HG. D-2-HG, succinate and fumarate bind 
competitively to α-KG dependent enzymes, thereby reducing activity. Inhibition of TET hydroxymethylases 
leads to hypermethylation of CpG islands in the genome, and inhibition of JHMDs leads to hypermethylation 
of lysines in histone H3. This hypermethylated phenotype results in altered gene expression and a 
dedifferentiated phenotype of the cell. Succinate and fumarate are known to inhibit PHDs, thereby 
increasing HIF-mediated expression of genes, whereas for D-2-HG stimulation of the PDH EGLN has 
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been suggested (Gluc = glucose, 3PG = 3-phosphoglycerate, 3POHPyr = 3-phosphohydroxypyruvate, Pyr 
= pyruvate, Ac-CoA = acetyl coenzyme A, Cit = citrate, ICT = isocitrate, α-KG = α-ketoglutarate, Suc-CoA 
= succinyl-CoA, Suc = succinate, Fum = fumarate, Mal = malate, OAA = oxalo-acetate, D-2-HG = D-2-
hydroxyglutarate, 5mC = 5-methylcytosine, 5hmC = 5-hydroxymethylcytosine) (Adapted from van Lith, BBA 
reviews on cancer, 2014). 
Rewiring in metabolism 
Increasing evidence suggests that tumor cells have rewired their metabolism to create a 
phenotype that enables tumor cells to generate ATP and molecules for biosynthesis while 
maintaining cellular redox balance, processes that are essential for proliferation and survival. 
These changes include altered fluxes among major metabolic pathways like glycolysis, the 
PPP, the TCA cycle and glutaminolysis via altered expression or post-translational modification 
of metabolic enzymes. Two examples are metabolic changes induced by VHL inactivation and 
IDH mutations. 
VHL inactivation
50%-80% of sporadic clear cell renal cell carcinomas (ccRCC) show biallelic loss of VHL37-38 
due to frameshift insertions, missense and nonsense mutations, promoter hypermethylation, 
contralateral allele loss or loss of heterozygosity. This inactivation of pVHL causes sustained 
accumulation of HIF-1α and/or HIF-2α, even under normoxic conditions39. This leads to 
constitutive expression of HIF-α target genes that, amongst others, regulate angiogenesis, 
apoptosis and metabolism40-42. In normal cells, glucose is converted to pyruvate for entry in 
the TCA cycle, however, HIF increases expression of glucose transporters needed for glucose 
internalization, glycolytic enzymes, and lactate dehydrogenase A (LDHA) and monocarboxylic 
acid transporters (MCTs) that promote lactate production and efflux, thereby favoring aerobic 
glycolysis (Figure 4). Furthermore HIF dependent induction of pyruvate dehydrogenase kinase 1 
(PDK1) leads to pyruvate dehydrogenase (PDH) inhibition, thus disconnecting the TCA cycle from 
glycolysis. Although most metabolic pathways besides high glycolytic rate are still maintained 
in most cancers, VHL-deficient renal cell carcinoma has been shown to downregulate energy 
production through the TCA cycle43. To compensate for the reduced conversion of glucose to 
citrate, a source for fatty acid production, via the TCA, VHL inactivated cells use glutamine for 
production of cytosolic Ac-CoA (Figure 4). This occurs through operation of the mitochondrial 
IDH2 in the reductive direction of the TCA cycle44. An additional cytoplasmic route of reductive 
carboxylation is mediated by IDH145-46. Metabolic flux analyses have demonstrated that the 
glutamine-driven reductive carboxylation is increased by hypoxia and dependent on HIF, 
however, the exact mechanism is still unclear. 
 HIF-1α and HIF-2α are highly similar in structure, but HIF-1α is ubiquitously expressed 
while HIF-2α is limited to several organs like, the kidney47. In ccRCC differential expression of 
HIF-1α and HIF-2α is observed, with tumors expressing either both subtypes or exclusively HIF-
2α. Recently, it has been shown that HIF-1 is lost during progression to higher disease stages48. 
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Part of the effects of HIF-1α and HIF-2α are overlapping, but they also regulate expression of 
distinct genes. Examples are the unique involvement of HIF-1α in altering glucose metabolism, 
while HIF-2α plays a role in cell cycle regulation and glutamine metabolism49-50.
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Figure 4. Metabolic rewiring induced by VHL inactivation and HIF-mediated pseudohypoxia. In normal 
cells, glucose is converted to pyruvate, which enters the TCA cycle. Glucose derived citrate is then shuttled 
into the cytosol for lipid synthesis. Increased activity of HIF in VHL-inactivated cells drives aerobic glycolysis 
by activating expression of glycolytic proteins including GLUT-1, HK2, PFKM, ENO, PKM, LDHA and MCT4, 
thereby stimulating production and excretion of lacate. HIF also uncouples aerobic glycolysis from the TCA 
cycle by activating PDK1, which phosphorylates and inhibits PDH, the key enzyme converting pyruvate to 
Ac-CoA. To compensate for the reduced flux of glucose to citrate, reductive carboxylation of glutamine 
generates cytosolic citrate for lipid synthesis. Red proteins indicate HIF target genes, and red arrows 
indicate upregulated pathways induced by HIF activation. (Gluc = glucose, G6P = glucose-6-phosphate, F6P 
= fructose-6-phosphate, F1,6-bPG = fructose 1,6-biphosphate, 1,3-bPG = 1,3-biphosphoglycerate, 3PG = 
3-phosphoglycerate, 2PG = 2-phosphoglycerate, PEP = phosphoenolpyruvate, Lac = lactate, Pyr = pyruvate, 
Ac-CoA = acetyl coenzyme A, Cit = citrate, ICT = isocitrate, α-KG = α-ketoglutarate, Suc = succinate, Fum = 
fumarate, Mal = malate, OAA = oxalo-acetate, Gln = glutamine).
CHAPTER 1
18
IDH mutations 
Besides the described non-metabolic role of D-2-HG in gliomagenesis, IDH1-mutant cells also 
have decreased IDH-mediated cytosolic NADPH production51, ~ 65% of which is produced by 
IDH1 in the human brain52. NADPH is the major metabolite needed for detoxification processes 
that, among others, protect cells from reactive oxygen species (ROS) which are produced 
especially during radiotherapy and chemotherapy53. 
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Figure 5. Described anaplerotic pathways of α-KG production. Pathways which may rescue metabolic 
defects in IDH1-mutated tumors are depicted as red arrows. Mutant IDH1 converts α-KG to D-2-HG. 
Since the cytosolic α-KG pool is depleted, and this metabolite is essential for tumor cell proliferation, 
compensatory mechanisms must occur. First, α-KG which is formed in the mitochondria by IDH2 can 
be transported to the cytosol via the malate-α-KG antiporter. Additionally, glutamate may be imported 
from the microenvironment via the EAAT2 glutamate importer which is expressed in low-grade glioma. 
Glutamate can then be converted to α-KG by GLUD. (ICT = isocitrate, α-KG = α-ketoglutarate, Cit = citrate, 
Glu = glutamate, Gln = glutamine, D-2-HG = D-2-hydroxyglutarate). (Adapted from van Lith, BBA reviews 
on cancer, 2014).
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Furthermore, the excessive consumption of α-KG impairs the reverse reductive carboxylation 
of α-KG to isocitrate, which is subsequently used for the generation of citrate, a precursor of 
acetyl-CoA that reacts with NADPH to generate fatty acids and lipids44,54. Since IDH1-R132H 
lacks the reverse activity22,55, IDH1-mutant cells need to use alternative anaplerotic pathways 
to maintain α-KG production (Figure 5). One of these salvage pathways may be the formation 
of α-KG by the mitochondrial IDH256. Another compensatory mechanisms is the upregulation 
of glutamine import and glutaminase (GLS) activity57. Furthermore, since the effect of GLS 
inhibition on proliferation of IDH1-R132H cells is only modest58 and since low grade glioma 
cells (>80% of which are IDH1-mutant) express the glutamate importer excitatory amino acid 
transporter 2 (EEAT2)59, we proposed previously that import and direct usage of glutamate is 
an efficient anaplerotic pathway for production of α-KG via activity of glutamate dehydrogenase 
(GLUD)60. 
Targeting tumor metabolism
Cancer associated metabolic alterations have been studied as druggable targets, and molecules 
that selectively target cancer cells based on metabolic alterations are now entering clinical 
trials. Since glycolysis is a key metabolic feature, many studies have focused on inhibiting 
enzymes controlling this pathway [e.g. hexokinase-2 (HK2), Pyruvate kinase (PKM)]61. Inhibition 
of key enzymes in the PPP like glucose-6-phosphate-dehydrogenase (G6PD) and transketolase 
(TKT) has also shown promising results62.
 IDH1-mutant cells have been described to exhibit decreased IDH mediated production 
of NADPH. Upon radiation therapy this led to increased ROS levels and double strand DNA 
breaks51, when compared to IDH-wildtype cells. Recently, a specific inhibitor of IDH1-R132H 
was developed. It promoted differentiation of an IDH1-R132H cell line in vitro, and inhibited 
growth of a subcutaneously grown IDH1-R132H glioma xenograft63. However, these inhibitors 
also desensitized IDH1-mutant cells to radiotherapy, probably due to inhibition of D-2-HG 
formation and increase in NADPH levels51.
 There is increasing interest in the inhibition of the glutaminolysis pathway, which has 
been shown to be upregulated as an anaplerotic pathway for citrate and lipid synthesis in 
VHL-impaired and IDH1-mutant tumors. Small molecule inhibitors against GLS have been 
developed, that exhibit anti-tumor activity in numerous pre-clinical studies and in various 
tumor types58,64-65. Another enzyme in the glutaminolysis pathway that could be inhibited is 
GLUD. This is an NAD(P)+-dependent enzyme that converts glutamate to α-KG. Epigallo-
catechin-3-gallate (EGCG), a component of green tea, is a known inhibitor of NADP+-dependent 
enzymes66. It does not only interfere with glutaminolysis flux but also with NADPH levels, and 
thus the redox capacity in cells, probably increasing sensitivity to ROS dependent therapies like 
radiotherapy (Rtx) or photodynamic therapy (PDT). 
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Other means of tumor targeting
As described above, tumor initiation and progression are dependent on multiple factors besides 
alterations in metabolism. During the past decades a wealth of information has been collected 
on the role of membrane receptor tyrosine kinases and the signaling pathways they initiate. 
In order to inhibit these pathways, molecules that target such proteins have been developed. 
Antibodies
One of the more successful immunotherapies developed for treatment of tumors relies on 
tumor-targeting monoclonal antibodies (mAbs). The effector functions of these antibodies may 
rely on several mechanisms: 1) direct action of the mAb (receptor agonist/antagonist activity); 
2) immune-mediated cell killing (antibody-dependent cellular toxicity (ADCC) or complement-
dependent cellular toxicity (CDC); 3) effects on tumor vasculature and stroma. 
 Though unmodified mAbs may show some therapeutic potency, in most cases they are not 
curative. Therefore mAbs conjugated to drugs, toxins or radionuclides have been developed. 
There are, however, some complex issues. Drugs or radionuclides can degrade or decay 
before the tumor cells are reached and conjugation can change binding characteristics, 
pharmacokinetics and biodistribution. Currently, two mAb conjugates are FDA and EMA 
approved for cancer therapies; brentuximab-vedotin, targeting CD3067-68 and trastuzumab-
emtasine (T-DM1), targeting human epidermal growth factor receptor 2 (HER2)69. Furthermore 
over 30 additional mAb conjugates have entered clinical development70-71. Though these 
antibodies and antibody drug conjugates have found their way to the clinic, their distribution 
and tumor penetration are limited due to size (~150 kDa, 10-15 nm long and 7-9 nm wide). 
Furthermore, the long half-life (days to weeks) causes high background levels in molecular 
imaging, and in addition toxicity and immune responses are still an issue. 
VHHs
An interesting alternative for standard antibodies are the variable heavy chain domains of single 
chain llama antibodies, called VHHs or nanobodies (Figure 6). VHHs typically have a molecular 
weight of ~15 kDa and can bind target antigens with affinities down to the low picomolar 
range. The ease of genetic engineering and handling combined with other advantages such 
as high water solubility, low production cost, small size, low immunogenicity in humans and 
high thermo- and pH-stability, make this a highly interesting class of antibody fragments72. A 
number of VHHs with high specificity and affinity against tumor targets (e.g. epidermal growth 
factor receptor (EGFR), tyrosine-protein kinase Met (c-Met), HER2) have been developed73-75, as 
well as VHHs against cognate receptor ligands (e.g. hepatocyte growth factor (HGF), vascular 
endothelial growth factor (VEGF))76-78.
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Therapeutically, VHHs can be used as neutralizing agents, as receptor-ligand antagonists and 
as vehicles for effector delivery or targeted vehicle-based drug therapy79-80. Some VHHs that 
have been developed as antagonist of extracellular targets are now undergoing phase I, II and 
III clinical trials by Ablynx (www.ablynx.com).
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Figure 6. Domain structures of a conventional human immunoglobulin, a heavy chain only llama 
immunoglobulin and a VHH. A conventional IgG antibody is a dimeric molecule consisting of two heavy 
chains and two light chains. The heavy chain consists of the constant domains (CH1, CH2, CH3) and the 
variable domain (VH). The llama immunoglobulin lacks the light chain and contains only one antigen 
binding domain (VHH). 
Non-specific conjugation strategies
Currently, the most common method for covalently conjugating agents to antibodies are cross-
linking agents, which can conjugate functional groups such as amines, thiols and carboxyl 
groups81. Since these reactive groups are usually present in high abundance in targeting ligands, 
this reaction is generally very fast and easy, however, if the conjugation involves residues that 
are critical for antigen binding, functionality can be impaired. Furthermore, labeling leads 
to a heterogeneous population of proteins with various amounts of introduced moieties. 
Carbohydrate side chains of the constant heavy domains are also being used for conjugation, 
however this method cannot be applied to VHHs of which 90% do not contain glycosylation 
sites82, or which are not glycosylated when produced in bacterial expression systems. 
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Site-specifi c conjugation strategies
Site-specifi c chemical conjugation methods employ introduction of functional groups that are 
not present in natural amino acids, like ketones and azides. Furthermore unnatural amino 
acids can be incorporated83, but this method faces practical limitations in terms of scalability 
and effi cacy. Approaches to conjugate VHHs without compromising functionality include intein-
based ligation84, the site-specifi c introduction of a carboxyterminal cysteine allowing maleimide 
chemistry85 and sortase A transpeptidation86.
 Staphylococcal Sortase A is a bacterial transpeptidase that recognizes substrate proteins 
containing a Leucine-Proline-X-Threonine-Glycine (LPXTG) amino acid sequence (Figure 
7). Sortase A harbors a catalytic cysteine residue that cleaves the pentapeptide between 
the threonine and glycine, generating a thioacyl-intermediate. This intermediate is resolved 
by creation of a new peptide bond with the N-terminus of a oligoglycine nucleophile87-89. 
Since recombinantly expressed proteins can easily be equipped with either an N-terminal 
or C-terminal LPXTG tag, the sortase A chemistry is increasingly exploited for site-specifi c 
conjugations. It allows incorporation of functional moieties that cannot be introduced by 
genetic engineering, and furthermore it offers the possibility of generation of N-N or C-C 
dimer proteins, which could be advantageous for reactivity of both subunits. Sortase A has also 
been used to incorporate strain-promoted alkyne-azide cycloadition (SPAAC) click handles to 
enable further modifi cation by cycloaddition click reactions86,90. 
Protein LPXTG
G
LPXT S
O
Sortase A
Sortase A
HS
Protein LPXT-
Protein
H2N-
PEG
PEG XX
XX
H2N- GGG XXor
H2N- GGG XXor
Figure 7. Sortagging principle. A substrate protein containing an LPXTG motif is cleaved between the 
threonine and the glycine by Sortase A. The formed acyl-enzyme intermediate can be resolved by an 
(oligo)glycine or PEG containing nucleophile, resulting in the release of Sortase A and the formation of a 
substrate-nucleophile ligation product. 
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VHH mediated drug delivery
Encapsulation of drugs can overcome numerous issues like poor solubility, limited stability 
and rapid clearance91-92, therefore efforts are undertaken in the field of nanoparticles. Several 
therapeutic nanoparticle platforms (eg. liposomes, albumin nanoparticles, polymeric micelles) 
have already been approved for cancer therapy93. 
 Nanoparticles decorated with VHHs have also been expoited as conduits for delivering toxins 
or drugs to tumor cells. Carriers that have been used are liposomes94-95, micelles96, albumin-
based nanoparticles (NANAPs)75 and polymer-based polymersomes97. Two nanoparticle 
systems that are exploited in this thesis are polycaprolactone (PCL) diblock polymer micelles 
and elastin like peptide (ELP) micelles. 
PCL based micelles 
One attractive class of carriers for therapeutic and diagnostic agents are polymeric micelles. 
They are formed by the self-assembly of amphiphilic block copolymers in aqueous solutions. 
Several micellar formulations are now being evaluated in clinical trials. Because of their small 
size (10-200 nm) they are able to passively target tumors via extravasation and the enhanced 
permeation and retention (EPR) effect. However, to actively target these particles to tumor 
cells, or to induce receptor mediated uptake of the particles, they can also be functionalized 
with antibodies or VHHs96. 
ELP based micelles
ELPs are an artificial biomimetic class of protein polymers, inspired by the hydrophobic motifs 
of the extracellular matrix protein tropoelastin98. They are composed of repeating pentameric 
glycine-X-glycine-valine-proline (GXGVP) units, in which X can be any amino acid99-100. One 
quality of ELPs is that they can reversibly transform from a soluble disordered state below 
their transition temperature to an aggregated state above this transition temperature101. 
This transition temperature highly depends on the nature of the guest residue X, ELP length, 
concentration and presence of salts102. ELP-based nanoparticles have been prepared out of 
amphiphilic block copolymers, either by employing ELP diblock polypeptides with different 
guest residues and hence different transition temperatures, or by coupling ELPs with low 
transition temperature to hydrophilic polymers such as polyethylene glycol103.
VHHs against intracellular targets
VHHs do not suffer from reducing intracellular environments, and therefore they could be 
used for targeting or inhibition of intracellular proteins (e.g. metabolic enzymes) if applied 
systemically. The therapeutic effect would, however, be minimal since VHHs show limited 
membrane penetration. There are several strategies that could be used for the intracellular 
delivery of a protein, such as the use of nanoparticles, disruption of the membrane and cell-
penetrating peptides (CPPs). CPPs are a class of peptides that can cross the plasma membrane, 
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and they have been used for intracellular delivery of siRNA, small molecules, proteins and 
other peptides104. CPPs vary in amino acid composition and 3D structure, leading to different 
modes of uptake. Endocytosis and direct translocation are the major uptake mechanisms. The 
mode of uptake depends on e.g. CPP concentration and composition of the lipid bilayer of the 
cell, as well as on the cargo that is conjugated to the CPP.
VHHs and photodynamic therapy
In photodynamic therapy, a photosensitizer (PS) is administered and activated with light of a 
certain wavelength. Upon activation, the PS gets into an excited triplet state and upon return 
to its ground state energy is released and transmitted to molecular oxygen, leading to the 
formation of reactive oxygen species (ROS)105. ROS damage cellular constituents, ultimately 
leading to cell death106. Because of the local character of this treatment, PDT is more selective 
compared to other therapies like chemotherapy. Various PSs are approved as PDT drugs 
(Photofrin, Visudyne, Levulan, Metvixia, Bremachlorin and Foscan). Problems with the non-
targeted PDT approach, however, are the low water solubility of the currently used PSs, and the 
targeting to healthy tissues leading to side effects like phototoxicity of the skin. Part of these 
problems could be solved by conjugation of the PS to a tumor targeting moiety (e.g. antibody, 
VHH) for so-called photoimmunotherapy (PIT). 
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THESIS OUTLINE
Aims of this thesis were to identify and target altered metabolic pathways in cancer cells, and 
to develop and test a VHH-based nanomedicine platform for targeted therapy.
 The last years, increasing amount of mutations in genes important in cell metabolism 
were found, like mutations in genes encoding the enzymes active in the tricarboxylic acid (TCA) 
cycle succinate dehydrogenase (SDH), fumarate hydratase (FH) and isocitrate dehydrogenase 
(IDH). The majority of mutations in IDH genes are point mutations involving Arg132 in IDH1 and 
Arg172 or Arg140 in IDH2. In chapter two, we present a novel heterozygous IDH1 mutation, 
IDH1R314C, which is identified by targeted next generation sequencing of a high grade glioma. 
IDH1R314C lacks isocitrate-to-α-KG conversion activity due to reduced affinity for NADP+, and 
differs from the IDH1R132 mutants in that it does not produce the oncometabolite D-2-HG.
 Another protein which is often mutated in renal cancer, and causes a rewiring in cellular 
metabolism, is the VHL tumor suppressor protein. In chapter three, we describe the analysis 
of the metabolism of two VHL impaired RCC cell lines. Metabolic phenotypes of the cells are 
identified, and we show that cells have differential sensitivity to metabolic inhibitors of the 
glutaminolysis and PPP. 
 Interesting molecules for tumor targeting are the heavy domains of single chain only 
antibodies (VHHs or nanobodies). They are ten times smaller than conventional antibodies and 
can be easily expressed as recombinant proteins. In chapter four, we describe a novel tumor 
targeting VHH; C-C7, which is identified via in vivo biopanning of a llama VHH phage display 
library in an orthotopic glioma mouse model. We show that it binds dynactin-1-p150Glued on 
activated endothelial cells and macrophages. 
 Conjugation of VHHs with diagnostic or therapeutic nanoparticles, peptides or proteins 
could greatly improve targeted therapy or diagnostics. In chapter five, we discuss a modular 
approach for VHH conjugations, employing sortase A transPEGylation and maleimide chemistry 
for introduction of a chemical click moiety and a fluorescent label, respectively. The resulting 
clickable VHHs are then used for conjugation to other groups employing the Cu+-independent 
strain-promoted alkyne-azide cycloadition (SPAAC) reaction. Using this approach, tail-to-
tail bispecific VHHs and VHH-targeted nanoparticles are generated without affecting VHH 
functionality. 
 To endow the VHH with the capacity to enter the cell, we use the optimized sortase A 
transpeptidation protocols to couple a human lactoferrin-derived cell-penetrating peptide 
(CPP) (hLF38-59) to the EGFR specific VHH 7D12 in chapter six. We observe increased uptake 
of the VHH-CPP complex in EGFR expressing cells compared to VHH alone. Furthermore, the 
conjugate blocks EGF-mediated EGFR activation with higher efficacy than both modalities 
alone, which is caused by both effective receptor blockade and internalization. 
 Besides CPPs all kinds of therapeutic and diagnostic handles can be conjugated to VHHs 
with the described conjugation strategies. One of them are photosensitizers. These molecules 
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cause instant cell death via induction of ROS after illumination with light of a specific wave 
length. In chapter seven, we conjugate 7D12 and 7D12-CPP to a photosensitizer. Using these 
conjugates, we induce EGFR specific phototoxicity in vitro in tumor cell lines and tumor cell 
spheres, and in clinical ascites samples from women diagnosed with serous ovarian carcinoma, 
a cancer type that is accessible to light via laparoscopy. Internalization is disadvantageous, 
since the membrane bound 7D12 variant is more effective than 7D12-CPP. 
 In chapter eight, we report the use of an ELP diblock (ELPDB) polypeptide for creation 
of VHH-decorated nanoparticles that reversibly self-assemble upon heating. The 7D12-
decorated ELPDB micelles are able to selectively target tumor cells that (over)express EGFR. 
Upon incorporation of a third ELPDB to which the photosensitizer IRDye700DX is conjugated, the 
nanoparticles can be used for highly effective and specific photoimmunotherapy (PIT).
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ABSTRACT
The majority of low-grade and secondary high-grade gliomas carry heterozygous hotspot 
mutations in cytosolic isocitrate dehydrogenase 1 (IDH1) or the mitochondrial variant IDH2. 
These mutations mostly involve Arg132 in IDH1, and Arg172 or Arg140 in IDH2. Whereas IDHs 
convert isocitrate to alpha-ketoglutarate (α-KG) with simultaneous reduction of NADP+ to 
NADPH, these IDH mutants reduce α-KG to D-2-hydroxyglutarate (D-2-HG) while oxidizing 
NADPH. D-2-HG is a proposed oncometabolite, acting via competitive inhibition of α-KG-
dependent enzymes that are involved in metabolism and epigenetic regulation. However, much 
less is known about the implications of the metabolic stress, imposed by decreased α-KG and 
NADPH production, for tumor biology. 
 We here present a novel heterozygous IDH1 mutation, IDH1R314C, which was identified by 
targeted next generation sequencing of a high grade glioma from which a mouse xenograft 
model and a cell line were generated. IDH1R314C lacks isocitrate-to-α-KG conversion activity due 
to reduced affinity for NADP+, and differs from the IDH1R132 mutants in that it does not produce 
D-2-HG. Because IDH1R314C is defective in producing α-KG and NADPH, without concomitant 
production of the D-2-HG, it represents a valuable tool to study the effects of IDH1-dysfunction 
on cellular metabolism in the absence of this oncometabolite.
IDH1-R314C
37
2
INTRODUCTION
Diffuse gliomas are primary tumors of the brain that are thought to develop from (precursors 
of) astrocytes or oligodendrocytes. Based on histopathology and according to WHO guidelines, 
these cancers are classified as grade II-IV astrocytomas or grade II-III oligodendrogliomas1-2. 
The disease is essentially incurable and median overall survival of patients with grade IV 
astrocytoma (glioblastoma, the most malignant variant) is only 15 months, despite chemo- and 
radiotherapy3. 
 In 2008, somatic mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 were 
identified in the large majority of low grade gliomas and secondary glioblastomas4. These 
mutations are always heterozygous and mostly involve the same amino acid residues; Arg132 in 
the cytosolic IDH1 and Arg172 or Arg140 in the mitochondrial IDH25-7. In glioma, the majority of 
IDH mutations are found in IDH1, and about 90% are IDH1R132H. Extensive research has revealed 
that these mutations are neomorphic gain-of-function mutations, resulting in the conversion 
of α-ketoglutarate (α-KG), the normal product of IDH-mediated decarboxylation of isocitrate, 
to D-2-hydroxyglutarate (D-2-HG) which can accumulate to millimolar concentrations8. During 
the conversion of α-KG to D-2-HG by the mutant enzyme, NADPH is oxidized.
 Because of the molecular similarity between α-KG and D-2-HG, the latter can 
competitively inhibit the activity of a range of α-KG-dependent dioxygenases, of which over 60 
have been identified9-10. Most important examples are the Ten-Eleven-Translocation 2 (TET2) 
DNA demethylases (resulting in the CpG-island hypermethylator phenotype in IDHMUT cells) 
and Jumonji-C (JMJC) histone demethylases (resulting in histone hypermethylation)11-13. The 
net result is a transcriptional profile that contributes to tumorigenesis via mechanisms that 
are still poorly understood. Although this has been matter of debate, consensus is now that 
D-2-HG can promote degradation of the transcription factor hypoxia-inducible factor (HIF-1α), 
possibly after non-enzymatic oxidation to α-KG14. How this exactly contributes to oncogenesis 
is still an active field of investigation15-17. 
 The effects of expression of IDH1-mutants and/or D-2-HG on tumor metabolism have 
started to receive attention now18. It was recently shown that D-2-HG inhibits the tricarboxylic 
acid (TCA) cycle enzyme succinate dehydrogenase, possibly leading to hypersuccinylation 
of proteins and anti-apoptotic effects19. Because mutant IDH1 lacks isocitrate-to-α-KG 
conversion activity, normally a predominant source of cytosolic NADPH in the brain20, IDHMUT 
cells are predicted to have lower steady state levels of NADPH, an effect that will be augmented 
by NADPH-oxidation during D-2-HG production. Thus, IDH mutations impact the redox status 
of glioma cells. 
 Additionally, IDH mutations may affect anabolic pathways: IDH1/2 can reduce α-KG back 
to isocitrate which may serve as carbon source for fatty acid and lipid synthesis via citrate and 
acetyl-CoA21-22 but IDH1R132H lacks this reverse activity23. It is conceivable therefore, that IDHMUT 
tumors need metabolic salvage pathways to allow tumor progression and this is supported 
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by the finding of relatively normal α-KG levels in a patient-derived orthotopic IDH1R132H 
oligodendroglioma model24. Because IDH1MUT cells display higher sensitivity to glutaminase 
inhibitors than IDHWT cells25, glutamine has been proposed to feed in into the mitochondrial 
TCA cycle as an anaplerotic source of α-KG, via the activities of glutaminase and glutamate 
dehydrogenase (GLUD). We previously postulated that gliomas may resort to direct import of 
glutamate, a ubiquitous neurotransmitter in brain, to allow GLUD-mediated α-KG production26-27. 
NADH/NADPH, generated during this reaction would simultaneously supplement the NAD(P)
H pool. These metabolic changes could all play a role in tumor cell maintenance and therefore 
be an Achilles heel and target for therapeutic inhibition. However, uncoupling the metabolic 
alterations that result from NADPH/α-KG depletion from the pleiotrophic effects of D-2-HG is 
a difficult task.
 In this study we describe a novel heterozygous IDH1 mutation which we uncovered by next 
generation sequencing of a glioblastoma from which a patient-derived xenograft model and 
corresponding cell line were generated. We show that this IDH1R314C mutant does not convert 
isocitrate to α-KG, unless at non-physiological concentrations of NADP+, and does not produce 
D-2-HG. These properties make that IDH1R314C tumor models are valuable tools to study the 
relevance of α-KG/NADPH depletion versus D-2-HG formation in gliomagenesis and tumor 
progression.
RESULTS
E98 cells contain a rare heterozygous IDH1R314C mutation located in the NADP+ 
binding pocket
The patient-derived E98 astrocytoma model carries a number of glioma-typical genetic 
mutations and is phenotypically similar to clinical glioma when grown as orthotopic 
xenografts28-30. This makes this model of high interest as a prototypical glioblastoma model for 
testing of targeted therapeutics31-34. Because the design of rational targeted therapies requires 
a detailed analysis of genetic aberrations, we subjected this cell line to targeted genomic 
next generation sequencing via Ion Torrent analysis using a primer set that allows parallel 
deep sequencing of 409 genes with known involvement in cancer-related pathways. As we 
unfortunately did not have access to blood of the E98 donor, SNPs and variants with mean 
allelic frequency (MAF)>1% were filtered out using sequence data from pooled blood samples 
as reference. Due to our general interest in IDH1, our attention was specifically drawn to a 
heterozygous C to T mutation at position 940 in the IDH1 gene (Figure 1A) which results in the 
p.Arg314Cys substitution. Presence of this mutation was verified in the original patient material 
(Figure 1B). To check for the incidence of this mutation, 103 DNA samples from glioma (Table 1) 
were Sanger sequenced. None of these samples contained the p.R314 mutation. Data mining 
of the Exome Sequencing Project (ESP) database (www.exac.broadinstitute.org/) revealed that 
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this variant has not been identifi ed in 121,410 alleles. Mining of the Cosmic database revealed 
only one reported IDH1 c.941G>A / p.R314H mutation in a gastric carcinoma (mutation ID 
COSM4090677). Thus, the R314C mutation is a rare mutation. 
 Since Arg314 is located in the NADP+ binding pocket35 we studied the experimentally solved 
structure of IDH1WT and IDH1R314C in complex with NADP+ using YASARA. As shown in Figure 
1C, the R314C mutation signifi cantly alters the tertiary structure resulting in an imperfect fi t 
of NADP+ in the binding pocket, mainly due to the lack of interaction between the negatively 
charged 2‘-phosphate of the co-enzyme NADP+ and the positively charged amine group of the 
arginine, and lack of ionic interactions between the Arg314 and glutamate residues on position 
247 and 253 in the other subunit.
A
B
C
Figure 1. Identifi cation of IDH1R314C in a high grade astrocytoma. A) Sequencing trace showing the 
heterozygous C to T mutation at position 940 in the IDH1 gene found in the E98 cell line and B) primary 
tumor material. This mutation leads to the p.Arg314Cys substitution in the IDH1 protein. C) Display of 
the 3D- structure of human IDH1R314C generated with YASARA (PDB-fi le 3inm). The IDH1WT homodimer is 
displayed with bound cofactor NADP+ (yellow), and the arginine residue on position 314 (red), both subunits 
are coloured in a different shade of grey. The inset shows the mutated cysteine (red) superimposed on the 
original arginine (green). 
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Table 1. Overview of glioma samples used for Sanger sequencing of IDH1R314C, with diagnosis and IDH1 status. 
Diagnosis Number of samples Number of samples 
verified IDH1R132H
Number of samples 
verified IDH1WT
GBM 47 1 42
Astrocytoma grade II 13 5 8
Astrocytoma grade III 2 0 1
Oligodendroglioma grade II 18 13 3
Oligodendroglioma grade III 3 0 2
Oligodendroglioma grade IV 1 0 1
Oligoastrocytoma grade II 14 9 3
Oligoastrocytoma grade III 3 0 3
Oligoastrocytoma grade IV 2 2 0
IDH1R314C is defective in isocitrate to α-KG conversion
We first examined the activity of purified IDH1R314C-GST proteins, using IDH1WT-GST and 
IDH1R132H-GST as positive and negative controls. All enzymes could be readily produced and 
purified (Figure 2A). Under the conditions tested, both IDH1R132H-GST and IDH1R314C-GST did 
not show isocitrate-to-α-KG conversion activity whereas IDH1WT-GST did (Figure 2B). The 
absence of α-KG formation by IDH1R132H-GST and IDH1R314C was confirmed with LC-MS (Figure 
2C). Importantly, whereas IDH1R132H-GST was active in converting α-KG to D-2-HG (as revealed 
by oxidation of NADPH) the IDH1R314C-GST mutant was completely devoid of this activity (Figure 
2D). Thus, IDH1R314C homodimers are inactive in converting isocitrate and NADP+ to α-KG and 
NADPH and, unlike IDH1R132H-GST, do not consume NADPH, consistent with the lack of D-2-HG 
production by E98 xenografts that has already been described before36.
 The IDH1R132 mutation in human gliomas always occurs in a heterozygous manner, resulting 
in a theoretical 1:2:1 distribution of IDHWT/WT, IDHWT/MUT and IDHMUT/MUT dimers. This stoichiometry 
may be important for balanced IDH activity, because D-2-HG can only be formed via an intimate 
crosstalk between wild-type and mutant subunits, for which α-KG is a product and substrate, 
respectively. To analyze the effects of IDH1R314C overexpression in eukaryotic cells we performed 
enzymatic assays with cell extracts from HEK293T cells, transiently overexpressing IDH1WT, 
IDH1R132H or IDH1R314C as well as lentivirally transduced LN229 and U251 glioma cells, stably 
expressing the different IDH1 mutants (Figure 3A). To be able to distinguish recombinant from 
endogenous IDHWT and allow statements on IDHWT/MUT ratios we equipped the mutated reading 
frames with a Bap8xHis (biotin-acceptor peptide-8xHis) tag, increasing molecular weight 
with ~3 kDa. Intriguingly, irrespective of the method of genetic modification (transfection or 
lentiviral transduction) expression levels of recombinant enzymes were lower than that of the 
endogenous enzymes, with IDHR132H-Baph8xHis consistently being lowest, possibly a result of 
negative selection for IDH1R132H-Bap8xHis overexpression and associated toxic levels of D-2-
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Figure 2. Homodimeric IDH1R314C-GST is defective in the isocitrate-to α-KG reaction and does not produce 
D-2-HG. A) SDS-page gel stained with coomassie brilliant blue showing expression of purified IDH1-GST 
constructs. B) Fluorescent monitoring of NADPH formation at 340 nm shows that only purified IDH1WT-GST 
is capable to convert isocitrate to α-KG under the reaction conditions tested, whereas IDH1R132H-GST and 
IDH1R314C-GST are inactive. C) α-KG production by IDH1-GST enzymes was measured with LC-MS. Note 
that only IDH1WT-GST is capable of isocitrate-to-α-KG conversion. (n.d. = non detectable, area<150). D) 
Fluorescent monitoring of NADPH reduction shows that only purified IDH1R132H-GST is active in the α-KG-
to-D-2-HG conversion. Both IDH1WT-GST and IDH1R314C-GST lack the capability to produce D-2-HG. 
HG37. Consistent with the absence of activity of purified IDH1R314C-GST homodimers (Figure 
2B), for all cell lines NADP+-dependent oxidative decarboxylation of isocitrate was significantly 
lower in IDH1R314C-Bap8xHis expressing cells than in IDH1WT-Bap8xHis cells (Figure 3B). Of 
note, the reduced activity of IDH1R314C-Bap8xHis in U251 cell extracts could be rescued by 
performing the enzymatic assay in supraphysiological concentrations of NADP+ (Figure 4), 
in line with loss of NADP+-affinity as predicted from the solved structure in Yasara, and as 
described earlier by Lee et. al.35. Consistent with this model, the R314C mutation caused an 
eight-fold increase in Km for NADP+ (318 µM for IDH1R314C vs 38 µM for IDHWT, Figure 3C). This 
predicts that IDH1R314C is inactive under physiological NADP+ concentrations. Of note, activity 
of IDH1R314C-GST homodimers at higher concentrations of NADP+ was too low to calculate the 
Km for isocitrate.
 As expected from the lack of NADPH consumption when incubated with α-KG (Figure 2D), 
IDH1R314C-BAPHIS expressing LN229 and U251 glioblastoma cell lines did not produce 2-HG, in 
contrast to their IDH1R132H-Bap8xHis counterparts (Figure 3D). 
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Figure 3. IDH1R314C-Bap8xHis expression in glioma cell lines leads to reduced forward activity compared 
to IDHWT expression. A) Western blots showing expression of IDH1-Bap8xHis in transiently transfected 
HEK293t and lentivirally transduced LN229 and U251 glioma cells. Blots were stained with anti-IDH1PAN 
and anti-IDH1R132H as indicated, or with anti-GAPDH as a loading control. Since the recombinant proteins 
are ~3 kDa larger than endogenous IDH1 they can be distinguished from the endogenous IDH1. Control 
LN229 and U251 were transduced with empty vector virus (EV). B) Monitoring of NADPH formation after 
isocitrate/NADP+ addition to extracts from transfected/transduced cell lines. NADPH formation was 
monitored by absorbance measurements at 340 nm. Note that IDH1R314C-Bap8xHis was far less effective 
in oxidative carboxylation of isocitrate than IDH1WT-Bap8xHis. C) Km values of IDH1-GST for NADP+. The 
Km value for NADP+ for IDH1R132H-GST could not be determined. D) D-2-HG production by IDH1-Bap8xHis 
expressing cell lines was measured with LC-MS. Only IDH1R132H-Bap8xHis expressing cells were capable 
of D-2-HG production.
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Figure 4. IDH1R314C activity can be rescued by supraphysiological NADP+ levels. Extracts of U251-IDH1R314C 
U251-IDH1R132H or U251-IDH1WT were incubated with isocitrate and 100 µM or 2 mM NADP+, and NADPH 
formation was measured in real time by 340 nm absorbance. The activity of IDH1R314C-Bap8xHis but not 
IDH1R132H-Bap8xHis was partly rescued by increasing NADP+ concentrations to 2 mM.
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Figure 5. The R314C mutation does not shift the cofactor dependency from NADP+ to NAD+. IDH1MUT-
GST enzymes were incubated with isocitrate and NAD+, and NADH formation was measured by 340 nm 
absorbance. All IDH1 enzymes were inactive in the presence of NAD+. As a positive control a liver extract 
was used.  
CHAPTER 2
44
DISCUSSION 
Since their discovery, hotspot mutations in IDH enzymes have become a major focus of 
research. The oncogenic potential of IDH1R132H has been attributed to epigenetic alterations, 
resulting from the production of the alleged oncometabolite D-2-HG9-10,38.  Furthermore it 
has been shown that proliferation of IDH1R132H cells requires metabolic rescue programs that 
depend on in vivo tumor-stroma interactions, possibly involving glutamate import26. 
 We here identify and characterize IDH1R314C, a novel and rare mutation in IDH1 in a high 
grade astrocytoma which has not been reported before. We show that IDH1R314C has a greatly 
reduced affinity for NADP+, in agreement with a previous structure-function relationship study 
on porcine IDH135 and is consequently defective in oxidizing isocitrate to α-KG. The R314C 
mutation did not shift the cofactor dependency from NADP+ to NAD+ (Figure 5) as was previously 
reported for mutated IDH1 from the halobacterium Haloferax Volcanii 39. 
 To define an exact role for IDH1R314C in tumor formation and biological behavior of cancer 
cells is impossible in the context of the many more mutations that are found in E9840. To study 
this further, isogenic E98 cell lines with a repaired IDH1R314R allele are required and such 
technically challenging cell lines are not yet available. 
 The decreased potential of IDH1R314C cells to produce α-KG and NADPH in the cytosol 
may directly impact on redox potential, lipid synthesis and membrane production and may 
explain the slow growth rates of E98 cells in vitro (doubling time of 46 hrs, data not shown). 
Interestingly, despite these very slow growth rates, in vivo E98 xenografts represent the most 
aggressive diffuse infiltrative brain tumor model in our lab, killing mice within 4-5 weeks after 
intracerebral implantation28. This illustrates that the brain micro-environment is crucially 
involved in allowing growth of E98 cells. Since the redox status of cells may particularly impact 
on cell migration41 it would be of high interest to investigate how relatively low NADPH/NADP+ 
ratios in E98 cells In vivo are associated with active cell migration, leading to the diffuse 
infiltrative phenotype. Further unraveling of the specific in vivo metabolic salvage pathways that 
are adapted by E98 cells and may be involved in its aggressive behavior may lead to potential 
novel ways for therapeutic intervention.
 In oncology, most NGS protocols aim for detection of actionable hot spot mutations in 
known genes only, leaving a potentially huge amount of mutations with significance for tumor 
biology, undetected and this is the reason why we only now recognized that E98 cells carry 
the IDH1R314C mutation24. Alterations in genes encoding metabolic enzymes may be directly or 
indirectly involved in tumorigenesis based on subtle distortions in equilibria between metabolic 
intermediates and/or oxidative milieu.
 In conclusion, we identified a novel IDH1R314C mutant that shares with the common IDH1R132H 
mutant a defect in isocitrate-to-α-KG conversion activity, but lacks the capacity to produce D-2-
HG. Future comparative profiling studies using isogenic cell lines expressing IDHWT, IDH1R132H 
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or IDH1R314C will allow us to distinguish between epigenetic and metabolic alterations, resulting 
from NADPH/α-KG depletion or D-2-HG accumulation. 
METHODS
E98
Generation of the E98 model which was derived from a grade IV astrocytoma, was described 
before28. All animal experimental work was performed in accordance with the guidelines of and 
was approved by the local ethical committee for animal experimentation of Radboud University. 
An adherent E98 cell line was generated from mouse xenografts via routine procedures29,40 
and cultured in DMEM (Lonza, Basel, Switzerland) supplemented with 10% FCS (Gibco, 
ThermoFisher Scientific, Watlham, MA, USA) and 40 µg/ml gentamycin (Centrafarm, Etten-
Leur The Netherlands).
Next generation sequencing
Genomic DNA from E98 cells and from original tumor material was analyzed by semi-conductor 
sequencing (IonPGM, Life Technologies, ThermoFisher Scientific, Watlham, MA, USA) using the 
comprehensive cancer panel (Life Technologies, ThermoFisher Scientific, Waltham, MA, USA) 
detecting copy number variations and mutations in 409 cancer-related genes. An IonPGM E98 
library was generated according to the manufacturer’s protocol. In short, 10 ng of DNA per pool 
was amplified in 21 cycles by PCR using the Ion AmpliSeqTM mastermix, followed by barcode and 
adapter ligation. Amplified products were purified with Agencourt AMPure XP beads (Beckman 
Coulter Genomics, High Wycombe, UK). The library was diluted to 20 pM and emulsion PCR was 
performed using the Ion OneTouchTM 200 Template kit following the manufacturer’s protocol. 
Next, Ion Sphere Particles (ISPs) were recovered and enriched for template positive ISPs 
using Dynabeads MyOne Streptavidin C1 beads (Life Technologies, ThermoFisher Scientific, 
Waltham, MA, USA) in the Ion OneTouchTM ES instrument (Life Technologies, ThermoFisher 
Scientific, Waltham, MA USA). ISP enrichment was quantified using the Qubit 2.0 fluorometer 
(Life Technologies, ThermoFisher Scientific, MA, USA). Sequencing primer and polymerase 
were added to the final enriched spheres before loading onto an Ion 318 chip according to the 
Ion PGMTM 200 sequencing kit protocol. Variants were called using NextGene (JSI) and filtered 
for common variants (MAF>1%) in the general population. 
 
Visualization of IDH1 structure with YASARA
The structure of human IDH1 has been experimentally solved and can be found in PDB-file 
3inm8. We used the WHAT IF & YASARA twinset for visualization and analysis42-43.
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PCR and cloning of IDH1 constructs
Total RNA was isolated from cell lines using TRIzol reagent (Life Technologies, ThermoFisher 
Scientific, Waltham, MA, USA) and converted to cDNA using oligo-dT and MMLV reverse 
transcriptase (New England Biolabs, Ipswich, MA, USA) using standard protocols. Open reading 
frames for IDH1WT , IDH1R132H and IDH1R314C were PCR amplified from HT29, E478 and E98 cDNA, 
respectively, using primers IDH-EcoRIFw [‘5’-CGAATTCACTGTCAAGGTTTATTGAAGTC-3’] 
and IDH-AgeIRev [5’-CACCGGTAAGTTTGGCCTGAGCTAG-3’] and Phusion DNA polymerase 
(Finnzymes, ThermoFisher Scientific, Watlham, MA, USA). PCR products were digested with 
EcoRI and AgeI (New England Biolabs, Ipswich, MA, USA) and cloned in fusion to a C-terminal 
biotin-acceptor peptide (BAP) and an 8xhis tag (8xHis) in vector PHLsec-BAPHIS AgeI/EcoRI, 
derived from PHLsec-HIS (Addgene, Cambridge, MA, USA) using T4 DNA ligase (New England 
Biolabs, Ipswich, MA, USA). The BAPHIS tags were added to distinguish recombinant from 
endogenous IDH by molecular weight and to allow Ni-bead purification. Clones containing 
the respective mutations were selected via Sanger sequencing. For generation of lentiviral 
constructs, the different ORFs were recloned in vector pENTRY which was recombined with 
pLENTI using the GATEWAY system via standard procedures. In parallel, IDH ORFs were cloned 
in fusion with GST in E.coli expression vector pDEST15 as described before37. 
GST fusion protein expression and purification 
GST fusion proteins were expressed in E. coli strain ER2566 via standard induction protocols. 
Briefly, 2xTY medium supplemented with 50 µg/ml ampicillin (Roche, Basel, Switzerland) was 
inoculated with 1% v/v overnight culture. Protein expression was induced with 1 mM IPTG 
(Serva, Heidelberg, Germany) at OD600~0.6. After 3 hours at 30°C, bacteria were harvested 
by centrifugation and resuspended in 300 mM NaCl, 50 mM TRIS/HCL pH 8.0 supplemented 
with Complete protease inhibitor (Roche, Basel, Switzerland). Cells were lysed by 3 freeze-
thaw cycles, followed by sonication (4 x 15 seconds, 25% amplitude, Bioruptor, Diagenode) 
and centrifugation (3500 rpm, 20 min). Proteins were purified using glutathione beads (Pierce, 
ThermoFisher Scientific, Waltham, MA, USA), eluted with 10 mM glutathione and dialyzed 
extensively against 150 mM NaCl, 25 mM TRIS/HCL pH 7.5. Expression and purity were checked 
by SDS-PAGE gel electrophoresis and Coommassie Brilliant Blue staining.
Transient transfection experiments
HEK293T cells were grown to 30% confluence in 6 wells plates in DMEM supplemented with 
10% FCS and 40 µg/ml gentamycin. Cells were transfected with 2 µg pHLsec-IDH1MUT-Bap8xHis, 
IDH1WT-Bap8xHis or pIRESneo-EGFP using Fugene HD reagent according to the manufacturers’ 
protocol (Roche, Basel, Switzerland). After 2 days, cells were harvested and processed to cell 
lysates by scraping in 150 µl sucrose buffer (0.32 M sucrose in 10 mM TRIS-HCL pH 7.5) and 
sonicating on ice (3 cycles of 30 sec max power and 30 sec off in Bioruptor, Diagenode). Lysates 
were centrifuged (14000 rpm, 10 min, 4°C) and supernatants were subjected to BCA assays 
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(Pierce, ThermoFisher Scientific, Waltham, MA, USA) for protein concentration measurements 
and stored at -20°C until further analysis. To quantify IDH1 protein expression, 20 µg of total 
cytosolic protein was subjected to 10% SDS-PAGE and electroblotted onto a nitrocellulose 
membrane (Whatman Optitran BA-S85, GE healthcare, Little Chalfont, UK). After blocking in 
Odyssey Blocking buffer (LI-COR biosciences, Licoln, NE, USA) in PBS (1:1) the membrane 
was incubated with rabbit-anti-IDH1 (1:1000, HPA035248, Sigma-Aldrich, St. Louis, MO, USA) 
and mouse-anti-IDH1R132H (1:400, H09L, Dianova, Hamburg, Germany) in blocking buffer, 
followed by incubation with goat-anti-mouseDyLight800 (1:10.000, ThermoFisher Scientific, 
Waltham, MA USA) or goat-anti-rabbitAlexa680 (1:10.000, Invitrogen, ThermoFisher Scientific, 
Waltham, MA, USA). After washing, blots were analyzed on the Odyssey scanner (LI-COR 
biotechnology, Lincoln, NE, USA).
Generation of stable IDH1MUT overexpression glioma cell lines
LN229 and U251 cells were transduced with lentiviral vectors encoding IDH1WT-Bap8xHis, 
IDH1R132H-Bap8xHis, IDH1R314C-Bap8xHis or an empty vector (EV) control as described before44. 
Transduced cells were selected using blasticidin and cultured in DMEM supplemented with 
10% FCS and 40 µg/ml gentamycin. Cells were grown to 80% confluency in 10 cm ø culture 
plates (Corning, Corning, NY, USA). Cell culture media were collected and stored at -20°C until 
later analysis. Cells were collected and cytosolic extracts were prepared in 400 µl sucrosebuffer 
as described before. Twenty µg of protein was subjected to SDS-PAGE gel electrophoresis and 
western blot to quantify protein expression.
IDH activity measurements
Isocitrate-to-α-KG and α-KG-to-2-HG conversion rates of the purified IDH1-GST enzymes 
were determined by monitoring NADPH generation over time. Assays were performed in 
100 µl freshly prepared assay solution (2 mM MgCl2 in 100 mM TRIS/HCL pH 7.4) containing 
10 mM NADP+ (Sigma-Aldrich, St. Louis, MO, USA) and 10 mM isocitrate (Sigma-Aldrich, 
St. Louis, MO, USA) (forward assay) or 10 mM NADPH (Sigma-Aldrich, St. Louis, MO, USA) 
and 10 mM α-KG (Sigma-Aldrich, St. Louis, MO, USA) (reverse assay). Four µg of purified 
IDH1-GST fusion proteins were incubated with assay solution in a 96 wells plate at 37°C (BD 
Falcon, Franklin Lakes, USA) and fluorescence (Ex. 340 +/− 10 nm, Em. 440 +/− 10 nm), was 
measured every 15 seconds over a period of 5 minutes with an Omega FluoStar (BMG Labtech, 
Ortenberg, Germany). To examine enzyme kinetics in more detail, 4 µg of IDH1-GST proteins 
were incubated with varying NADP+ concentrations (0-500 µM) and 100 µM isocitrate at 22°C. 
Absorbance at 340 nm was measured every 20 seconds with a Benchmark Plus Microplate 
Spectrophotometer (Bio-Rad, Hercules, CA, USA). Non-linear regression analysis (Michaelis-
Menten) was performed in Graphpad Prism 5.03. 
 To determine NAD+ dependency, 4 µg of IDH1-GST proteins were incubated with 100 µl 
assay solution containing 2 mM MgCl2, 500 µM isocitrate and 2,5 mM NAD
+ (Sigma-Aldrich, St. 
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Louis, MO, USA) in 100 mM TRIS-HCL pH 7.4 at 22°C. A sucrose extract made from human liver 
was taken as a control. Absorbance at 340 nm was monitored as described. 
 For enzyme measurements in extracts of eukaryotic cells, 50 µg of total cytosolic protein 
were incubated with assay solution (2 mM MgCl2, 500 µM isocitrate in 100 mM TRIS/HCL pH 
7.4) containing 100 µM NADP+ in 96 wells plates (Greiner) at 22°C and NADPH generation was 
quantified as described before. 
D-2-HG, α-KG and isocitrate measurements by isotope dilution LC-MS
D-2-HG levels in cell culture media were measured using stable isotope dilution liquid 
chromatography tandem mass spectrometry (LC-MS) as described before36. α-KG and 
isocitrate levels were determined in in vitro IDH1 reaction mixtures. 4 µg of IDH1-GST proteins 
were incubated in 150 µl freshly prepared assay solution (2 mM MgCl2 in 100 mM TRIS/HCL 
pH 7.4) containing 500 µM isocitrate and 100 µM NADP+. After 20 min incubation at 22°C the 
reaction was stopped using 20 µl 4% HCOOH. 25 µl of this solution was mixed with 25 µl 9 
µM 13C5-2-HG stable isotope (Chiralex, Nijmegen, The Netherlands) in deionized water and 
75 µl deionized water before passing it through an Amicon Ultra 30 kDa Centrifugal Filter 
(Merck Millipore, Billerica, MA, USA) by centrifugation (14000 g, 30 min). 2 µl of the filtrate 
was injected onto a Atlantis T3 HPLC Column (2.1*100 mM dp 3µ) and run with 12.5% MeOH in 
87.5% 0.3%HCOOH in water. The column was connected to a Waters Quattro Premier tandem 
mass spectrometry fitted with an ESI probe operated in negative mode, recording the following 
MRM transitions, as summarized in Table 2. 
Statistics
All experiments were performed in triplicate. Data were processed in Excell (Microsoft, 
Redmond, WA, USA) and enzyme kinetics were determined by fitting of Michaelis Menten in 
Graphpad Prism 5.03 (Graphpad Software, La Jolla, CA, USA). 
Table 2. MRM transitions for metabolite detection
MRN Compound name Cone V (V) Coll eV (eV) Ret. Time (min)
191>111 Isocitrate 22 13 1.28
145>101 α-KG 22 8 1.53
147>129 D-2-HG 19 11 1.54
152>134 13C5-2-HG 19 11 1.54
Note: t0=0.8min
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ABSTRACT
In approximately 80% of clear cell renal cell carcinomas (ccRCCs) the von Hippel-Lindau (VHL) 
tumor suppressor gene is mutated or silenced, resulting in stabilization of hypoxia inducible 
transcription factors- (HIF) 1α and/or 2α. This results in gene expression profiles that stimulate 
use of glucose for aerobic glycolysis and lactate production, rather than for synthesis of citrate 
in the tricarboxylic acid cycle (TCA). To accommodate the demand of growing cells for citrate, 
a precursor of fatty acids and membranes, VHL-defective ccRCC cells feed the TCA cycle with 
glutamine, a process that is mediated primarily via HIF-2α. Additionally, sustained growth 
requires synthesis of nucleic acid precursors and NADPH in the pentose phosphate pathway 
(PPP). We hypothesize that altered metabolism in RCC may provide handles for (adjuvant) 
therapies with metabolic inhibitors.
 We investigated the cellular metabolism of VHL-impaired ccRCC cell lines SKRC-17 
and SKRC-7 with differential HIF-1α and HIF-2α activity by carbon source depletion studies, 
measurement of oxygen consumption rates, and RNA sequencing. Furthermore we exposed 
the cells to metabolic inhibitors epigallocatechin-3-gallate (EGCG) and 6-aminonicotinamide 
(6-AN), and determined the effect on proliferation and sensitivity to radiotherapy. 
Both SKRC-7 and SKRC-17 cells could still proliferate, albeit slower, upon depletion of 
D-glucose. Only SKRC-17 cells were fully dependent on L-glutamine for cell proliferation, 
and this was accompanied by increased sensitivity to EGCG and 6-AN. Furthermore EGCG 
sensitized only SKRC-17 cells to ionizing radiation. 
 We show that SKRC-7 cells and SKRC-17 cells display marked differences in metabolism 
that translate into differential sensitivity to the metabolic inhibitors. These data show a potential 
role for EGCG as (adjuvant) therapy in ccRCC, however the mechanism of action should be 
unraveled further to select subgroups of ccRCC patients that could benefit from this therapy. 
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INTRODUCTION
Clear cell renal cell carcinoma (ccRCC) represents the most common subtype of RCC1. In 
approximately 80% of these cancers the von Hippel-Lindau (VHL) tumor suppressor gene is 
inactivated by mutations or gene silencing2-3. Under normoxic conditions pVHL forms a multi-
protein complex with E3-ubiquitin ligase that targets prolyl-hydroxylated hypoxia-inducible 
factors HIF-1α and HIF-2α for ubiquitin mediated degradation4. Under hypoxia HIF1/2α cannot 
be hydroxylated, leading to stabilization and accumulation of these transcription factors. The 
same events occur under normoxic conditions if VHL function is compromised5. This results 
in ccRCC transcriptional profiles that are normally seen under hypoxia, including elevated 
expression levels of genes involved in angiogenesis, regulation of apoptosis and metabolism2 6-7. 
 Activation of the HIF-1 pathway equips the cells with a specific set of enzymatic machineries 
that favor aerobic glycolysis over the mitochondrial tricarboxylic acid (TCA) cycle. Increased 
uptake of glucose and its phosphorylation to glucose-6-phosphate leads to an increased flux 
through the pentose phosphate pathway (PPP)8. The PPP provides the cell with NADPH, the 
most important form of reducing power in cells and an intermediate in lipid synthesis, and 
additionally produces ribose-5-phosphate (R5P), a precursor of nucleotides8. Since oxidative 
glucose metabolism is inhibited in RCC cells9, they are reliant on alternative carbon sources 
for fatty acids and lipid synthesis. The glutamine-glutamate pathway is one of the important 
anaplerotic pathways in VHL-mutated cancers10. Increased dependency on pathways like the 
PPP and glutamine metabolism translates into increased sensitivity to metabolic inhibitors 
of enzymes in these pathways8,11. Furthermore, the metabolic phenotype of RCC is correlated 
to disease prognosis, both on transcriptome level, where low activity of TCA genes12 in 
combination with high activity of PPP genes13 correlates with poor survival, as on metabolome 
level, where high levels of metabolites related to the biosynthesis of glutathione correlates with 
poor survival14. 
 The differential roles of HIF-1α and HIF-2α in ccRCC development and progression 
is receiving increasing interest. Both proteins are highly similar in structure, but HIF-1α 
expression is ubiquitous in hypoxic cells whereas HIF-2α expression is restricted to few organs 
among which the kidney15. In ccRCC differential expression of HIF-1α and HIF-2α may be 
observed as HIF-1α can be lost during progression to higher disease stages16. Whereas HIF-
1α and HIF-2α share some target genes, they have differential effects on cell metabolism: 
HIF-1α stimulates glycolysis and restrains mitochondrial pyruvate consumption17-19, while 
HIF-2α promotes reductive carboxylation of α-KG to isocitrate, rendering cells dependent on 
glutamine for proliferation10.
 Unraveling the metabolic pathways that cancer cells have adopted to facilitate malignant 
behavior is of high importance, since these may be appropriate targets for (adjuvant) therapy. 
Inhibition of tumor-specific metabolic pathways may impair cell growth or interfere with the 
capacity of cells to maintain redox potential, overriding the insensitivity of these cancers to 
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radiotherapy or chemotherapy. Here we investigated the metabolism of two ccRCC cell lines 
carrying endogenous non-sense mutations in VHL. These cells have differential HIF expression 
(SKRC-17 expresses HIF-2α and SKRC-7 expresses HIF-1α and HIF-2α)20-21. Furthermore, we 
investigated sensitivity of these cell lines to metabolic inhibitors epigallocatechin-3-gallate 
(EGCG, an inhibitor of glutamate dehydrogenase and other NADP+-dependent enzymes ) and 6 
aminonicotinamide (6-AN, an inhibitor of the PPP-enzyme G6PD).
RESULTS
The metabolic phenotype of SKRC-7 and SKRC-17
Previous research has shown that in VHL-deficient RCC aerobic glycolysis is enhanced, 
and glucose oxidation in the TCA is mitigated. Glutaminolysis is an important salvage 
pathway to supply the TCA with α-KG and to maintain Acetyl-CoA and lipid production in 
VHL deficient cells, a prerequisite for membrane production during cell division10,22. First, 
we determined dependency of SKRC-7 and SKRC-17 on D-glucose and L-glutamine for 
cell proliferation. Deprivation of either D-glucose or L-glutamine restricted proliferation 
of SKRC-7 cells significantly with 44% or 33%, respectively (Figure 1A, left graph).
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Figure 1. Cell proliferation in complete medium or medium without L-glutamine or D- glucose as 
determined with a SRB assay (A). Basal and maximal mitochondrial oxygen consumption in all cell types 
was measured with the Oroboros (B). * p < 0.05, ** p < 0.01, *** p < 0.001.
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In SKRC-17, D-glucose deprivation also inhibited cell proliferation with 43%, while L-Glutamine 
deprivation completely inhibited growth of these cells (Figure 1A, right graph). Of note, the 
proliferation rate of SKRC-17 in glucose and glutamine proficient medium was higher than 
of SKRC-7 cells and this was accompanied by a 3-fold higher basal and maximal oxygen 
consumption by SKRC-17 cells (Figure 1B).
Effect of metabolic inhibitors on cell proliferation and radiosensitivity
The dependency on glutamine for mitochondrial anaplerosis is expected to make VHL-deficient 
RCC cells sensitive to inhibitors of glutamine processing enzymes10. Epigallo-catechin-3-gallate 
(EGCG), a polyphenol compound that is extracted from green tea, is an inhibitor of NADP+-
dependent enzymes glucose-6-phosphate dehydrogenase (G6PDH; the rate limiting enzyme 
in the PPP)23, and glutamate dehydrogenase (GLUD; converting glutamate to α-KG). SKRC-17 
was more sensitive to EGCG with an IC50 concentration of 10.55 µM compared to 28.77 µM for 
SKRC-7. This was reflected in proliferation assays, where 10 µm EGCG significantly inhibited 
proliferation of SKRC-17 cells with 20%, but not that of SKRC-7 (Figure 2A). Strikingly, while 
lower concentrations of EGCG (5 µM) had no effect on proliferation rates of SKRC-17, it induced 
a 22% increase in cell proliferation of SKRC-7. Similar observations were made for 6-AN. 
IC50 concentrations of 18.02 µM were observed for SKRC-7 and 1.76 µM for SKRC-17. 6-AN 
significantly inhibited proliferation of SKRC-17 at both 1 µM and 10 µM with 18.4% and 87.4%, 
respectively, while 1 µM 6-AN induced cell proliferation of SKRC-7 with 22.1% (Figure 2B). 
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Figure 2. Effects on cell proliferation of EGCG (A) and 6-AN (B) as determined in SRB assays. * p < 0.05, 
** p < 0.001, *** p < 0.001. 
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Inhibition of NADP+-dependent enzymes is expected to result in decreased cellular NADPH 
levels, and inhibition of glutamine metabolism is expected to impair glutathione (GSH) 
synthesis. Altogether this is expected to result in diminished reductive potential of the cells. To 
investigate this, we tested the effects of EGCG treatment on the capacity of cells to scavenge 
reactive oxygen species (ROS). In line with the proposed hypothesis, 24 hours of EGCG treatment 
reduced the capacity of SKRC-17 cells to protect against H2O2 (Figure 3A). In contrast, EGCG 
increased the capacity of SKRC-7 cells to neutralize ROS. 
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Figure 3. A) Effects of 10 µM EGCG on ROS-scavenging capacity of H2O2- treated SKRC7 an SKRC17 cells. 
ROS formation was determined by measuring CM-H2DCFDA induced fluorescence. B) DNA double strand 
breaks induced 30 min (left) or 24 hrs (right) after irradiation with 0, 2 or 4 Gy in presence or absence of 10 
µM EGCG as detected with western blot stained for γH2AX. Expression is corrected for β-actin expression. 
* p < 0.05, ** p < 0.01. 
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The decreased capacity of SKRC-17 cells to scavenge ROS after EGCG treatment implies 
increased sensitivity of these cells to radiation therapy (RTx). In line with this, EGCG treatment 
increased initial DNA damage (30 min after RTx) and residual DNA damage (24 hrs after RTx) 
in SKRC-17 cells upon irradiation with 2 and 4 Gy (Figure 3B). EGCG did not consistently alter 
initial irradiation-induced DNA damage in SKRC-7 cells. Residual DNA damage was absent in 
SKRC-7 cells, suggesting higher DNA damage repair capacity in this cell line than in SKRC-17 
cells (Figure 3B). 
Relation between metabolic phenotype and sensitivity to inhibitors with gene 
expression of metabolic pathways
To explore differences in gene expression that can explain the metabolic phenotype and the 
differential sensitivities of SKRC-7 and SKRC-17 cells to EGCG and 6-AN, we performed 
gene set enrichment analysis (GSEA, using the Kyoto Encyclopedia of Genes and Genomes) 
to identify possibly relevant metabolic pathways in both cell lines. Significantly enriched 
metabolic pathways are listed in Table 1. One of the top listings in pathways enriched in SKRC-
17 compared to SKRC-7 was ‘oxidative phosphorylation’, corroborating our finding of high 
oxygen consumption in SKRC-17. Furthermore, in SKRC-17 the gene sets ‘pentose phosphate 
pathway’ and ‘purine and pyrimidine metabolism’ were significantly enriched compared to 
SKRC-7. In SKRC-7, ‘glycolysis and gluconeogenesis’ and ‘pyruvate metabolism’ pathways 
were most significantly enriched compared to SKRC-17.
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Table 1. GSEA of pathways that are enriched in SKRC-7 compared to SKRC-17 and vice versa. GSEA was 
run on genes using KEGG pathways as a geneset. The enrichment score (ES), Normalized enrichment 
score (NES), Nominal P-value (NOM p-val) and False Discovery Rate q-value (FDR q-val), using http://
software.broadinstitute.org/gsea/index.jsp. An FDR value of 0.1 was chosen as a cutoff to identify 
significantly upregulated pathways. 
Enriched in SKRC-17 compared to SKRC-7
Name of pathway # genes in 
pathway
ES NES NOM p-val FDR q-val
OXIDATIVE PHOSPHORYLATION 115 -0.379 -4.791.779 0.0 <0.0001
PURINE METABOLISM 155 -0.292 -41.392.727 0.0 <0.0001
N GLYCAN BIOSYNTHESIS 46 -0.513 -40.980.806 0.0 <0.0001
GLYCOSAMINOGLYCAN BIOSYNTHESIS  
HEPARAN SULFATE
26 -0.523 -32.705.708 0.0 <0.0001
PYRIMIDINE METABOLISM 96 -0.264 -3.078.896 0.0 <0.0001
SELENOAMINO ACID METABOLISM 26 -0.496 -29.956.176 0.0 <0.0001
AMINO SUGAR AND NUCLEOTIDE SUGAR 
METABOLISM
44 -0.385 -29.713.745 0.0 0.0001
ARGININE AND PROLINE METABOLISM 53 -0.262 -22.265.048 0.0018 0.0019
CYSTEINE AND METHIONINE METABOLISM 34 -0.286 -201.192 0.0059 0.0065
BIOSYNTHESIS OF UNSATURATED FATTY ACIDS 22 -0.339 -19.078.964 0.0061 0.0117
OTHER GLYCAN DEGRADATION 16 -0.383 -18.811.492 0.0079 0.0132
SPHINGOLIPID METABOLISM 40 -0.247 -18.714.112 0.0040 0.0140
HISTIDINE METABOLISM 28 -0.258 -16.304.612 0.0338 0.0425
PENTOSE PHOSPHATE PATHWAY 26 -0.245 -15.040.808 0.0562 0.0726
FATTY ACID METABOLISM 42 -0.193 -14.870.046 0.0730 0.0775
NITROGEN METABOLISM 23 -0.249 -14.447.575 0.0864 0.0929
Enriched in SKRC-7 compared to SKRC-17
Name of pathway # genes in 
pathway
ES NES NOM p-val FDR q-val
GLYCOLYSIS GLUCONEOGENESIS 61 0.330 2959917 0.0 <0.0001
ARACHIDONIC ACID METABOLISM 58 0.314 27.986.128 0.0 <0.0001
GLYCOSPHINGOLIPID BIOSYNTHESIS LACTO AND 
NEOLACTO SERIES
26 0.394 24.064.589 0.0 0.0012
BUTANOATE METABOLISM 34 0.352 24.026.713 0.0 0.0011
GLUTATHIONE METABOLISM 50 0.238 2018984 0.0020 0.0090
PYRUVATE METABOLISM 39 0.243 18042277 0.0100 0.0227
ONE CARBON POOL BY FOLATE 17 0.340 17.081.867 0.0163 0.0352
GLYCINE SERINE AND THREONINE METABOLISM 31 0.275 1808924 0.0164 0.0227
FRUCTOSE AND MANNOSE METABOLISM 34 0.237 16287769 0.0293 0.0494
NICOTINATE AND NICOTINAMIDE METABOLISM 22 0.283 15995301 0.0398 0.0552
STARCH AND SUCROSE METABOLISM 52 0.183 15702217 0.0482 0.0606
GALACTOSE METABOLISM 26 0.246 15214988 0.0624 0.0719
PHENYLALANINE METABOLISM 18 0.292 15213037 0.0647 0.0705
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DISCUSSION
For patients with localized or locally advanced ccRCC, surgical resection followed by observation 
is the current standard of care24, however up to 30% of these patients will develop metastases25. 
Patients with metastatic disease are candidate for surgical resection and local therapy after 
multidisciplinary review, or they are treated first-line with agents targeting the VEGF (e.g. 
sunitinib, bevacizumab, pazopanib, sorafenib) or mTOR (e.g. temsirolimus) pathways24. Though 
these systemic therapies can provide significantly increased progression free survival, most 
patients develop treatment resistance and therefore effects on long-term response or survival 
are rarely induced26. Both effective neo-adjuvant treatment options and treatment options for 
metastatic disease are therefore a major unmet clinical need. When considering RCC as a 
metabolic disease, characterized by enhanced glycolysis, decreased glucose oxidation and 
increased reductive metabolism of glutamine9,17-19, this could provide alternative targets for 
therapy. In this work we analyzed the metabolism of two different RCC cell lines, SKRC-7 and 
SKRC-17, and we determined if altered metabolic pathways provide handles for (adjuvant) 
therapy with metabolic inhibitors. 
 Relative to SKRC-7 cells, SKRC-17 cells presented with increased cellular respiration levels 
and proliferation rates. Both cell types were equally sensitive to glucose deprivation while only 
SKRC-17 cells showed an absolute requirement for glutamine for their proliferation, consistent 
with the observation that HIF-2 induces lipid synthesis via reductive carboxylation of glutamine 
derived α-KG10. The glutamine dependency of SKRC-17 cells was accompanied by inhibition 
of proliferation upon treatment with EGCG. This could be explained by several mechanisms 
such as impaired lipid synthesis, NADPH and GSH synthesis and inhibition of gluthathione 
peroxidase activity (GPX)27. Decreased glutamine availability due to EGCG treatment can also 
impair de novo pyrimidine synthesis28, which hypothetically causes growth inhibition and DNA 
replication stress in SKRC-17. This potentially explains the extreme sensitivity of SKRC-17 cells 
to 6-AN, inhibitor of PPP, which is the main supplier of R5P, a precursor for synthesis of purine 
and pyrimidine. In line with this observation, RNA sequencing revealed increased expression of 
the genes active in the PPP and purine and pyrimidine synthesis, possibly indicating sensitivity 
of these cells to inhibitors of these pathways. 
 In sharp contrast with the findings in SKRC-17, EGCG increased proliferation and reductive 
potential of SKRC-7. Since EGCG affects many cellular processes, such as cell surface receptor 
signalling, intracellular signalling, nuclear function, mitochondrial function and autophagy29, it 
is difficult to identify the exact mechanism by which changes in proliferation are induced. EGCG 
is also known as an anti-oxidant and induces expression of anti-oxidant enzymes such as 
superoxide dismutase (SOD) and catalase30. Increased expression of the latter enzymes could 
protect the cells against oxidative insults such as ROS production induced by RTx or H2O2, as 
we have observed in SKRC-7 cells. GSEA analyses indicated increased expression of the gene 
set ‘glycolysis gluconeogenesis’ in SKRC-7 when compared to SKRC-17, so it is interesting 
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to determine sensitivity of these cells to glycolysis inhibitors such as 3-Bromopyruvic acid or 
2-Deoxy-D-glucose.
 The observation that EGCG sensitized SKRC-17 cells to radiotherapy, demonstrated by 
increased residual DNA damage upon EGCG treatment and ionizing radiation, emphasizes 
the usefulness of metabolic inhibition for a synthetic lethality approach with other treatment 
modalities. In view of the observation that a high-gluthatione cluster corresponds to a poor-
survival subgroup14, EGCG may provide an interesting personalized treatment option for these 
patients, and targeted sequencing of metabolic pathways31 could be used as a stratification 
tool. The opposing effects of EGCG in SKRC-7 and SKRC-17 however show that it is essential 
to gain more information about tumor metabolism before an upregulated general pathway like 
glutaminolysis can be inhibited in a clinical setting. 
CONCLUSIONS
RCC cell lines SKRC-7 and SKRC-17 display marked differences in metabolism that translate 
into differential sensitivity to the metabolic inhibitors EGCG and 6-AN. Furthermore these data 
show a potential role for EGCG as (adjuvant) therapy in ccRCC, however the mechanism of 
action should be investigated further to select the subtype of RCC that is sensitive to this 
therapy. 
METHODS
Cell culture
Cell lines SKRC-7 and SKRC-17 carrying endogenous non-sense mutations in VHL31-32 were 
cultured in RPMI 1640 medium (Lonza Group, Switzerland) supplemented with 10% fetal calf 
serum (FCS) (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) and 40 µg/ml gentamycin 
(Centrafarm, Etten-Leur, The Netherlands). 
Cell proliferation assays
To determine the sensitivity of cells to glutamine or glucose deprivation, cells were seeded at 
1,000 cells per well in 96-wells plates (Nunc, Roskilde, Denmark) in standard medium. After 
one day medium was substituted for D-glucose depleted (0 g/L D-glucose/ 4 g/L L-glutamine), 
L-glutamine depleted (5 g/L D-glucose/ 0 g/L L-glutamine) or regular RPMI medium (5 g/L 
D-glucose/4 g/L L-glutamine), supplemented with 10% FCS and antibiotics. At different 
periods of culture, protein contents were measured with sulforhodamine blue (SRB) assays33 
as a measure of cell proliferation. 
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Epigallocatechin-3-gallate (EGCG) and 6-aminonicotinamide (6-AN) were purchased from 
Sigma (Saint Louis, MO) and dissolved in DMSO. First the IC50 was determined for both 
inhibitors. 1,000 cells were seeded per well in 96-wells plates (Nunc, Roskilde, Denmark) and 
various concentrations of inhibitors in medium were added one day after seeding. After 3 days, 
protein contents were measured with SRB assays as a measure of cell proliferation. Secondly 
the effect of two concentrations of both compounds on cell proliferation was investigated. 
Inhibitors were added one day after seeding 1,000 cells per well in 96-wells plates (Nunc, 
Roskilde, Denmark), and protein content was determined at day 4, 5, 6 and 7. Two independent 
experiments were performed with internal quadruplicates, and statistical significance was 
determined with an unpaired Student’s T test. 
Cellular and mitochondrial respiration 
Cells were grown to 80% confluency in culture flasks. Cells were harvested and 1.5*106 cells 
were resuspended in culture medium and transferred to the temperature-controlled (37°C) 
chamber of an Oxygraph-2k equipped with Datlab recording and analysis software (Oroboros 
Instruments, Innsbruck, Austria). The basal respiration was recorded after which mitochondrial 
respiration was inhibited with 2.5 µM oligomycin (an inhibitor of complex V of the electron 
transport chain). Then, maximal respiration rate was measured after sequential addition of 
0.5 µM trifluoromethoxy carbonylcyanide phenylhydrazone (FCCP, mitochondrial uncoupler). 
Subsequently 0.5 µM Rotenone (an inhibitor of complex I) and 2.5 µM complex III inhibitor 
Antimycin A were added to completely shut down the electron transport chain. The remaining 
oxygen consumption is due to non-mitochondrial respiration. Two independent experiments 
were performed. P-values were calculated with an unpaired Student’s T test.
Quantification of ROS levels
Intracellular reactive oxygen species (ROS) levels were measured using the CM-H2DCFDA 
probe (Molecular probes, Eugene, OR, USA). Cells were seeded at 10,000 cells per well in black 
clear-bottom 96 well plates. The next day medium was replaced with medium containing 10 µM 
EGCG or DMSO solvent. Two days after seeding, cells were incubated with 1 µM CM-H2DCFDA 
in assay buffer (132 mM NaCl, 4.2 mM KCL, 1 mM CaCl2, 1 mM MgCl2, 5.5 mM D-glucose and 
10 mM HEPES, pH 7.4) for 10 minutes at 37°C. After washing twice with warm assay buffer, 
100 µM H2O2 in assay buffer was added to all wells, and fluorescence intensity (Ex/Em ~492-
495/~517-527) was measured for 12 minutes with 12 seconds intervals on the Clariostar (BMG 
Labtech, Ortenberg, Germany). The experiments were performed with an internal triplicate 
and significance was determined with an unpaired Student’s T test. 
Detection of double strand DNA breaks
Cells were seeded in 6 well plates at 200,000 cells per well, treated with EGCG or DMSO control 
and irradiated with 2 or 4 Gy (IR, 3.1 Gy/min; XRAD 320 ix; Precision XRT; N. Brandford, CT, 
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USA). At 30 min and 24 hrs after irradiation, cytosolic extracts were prepared in RIPA buffer 
(Cell Signaling, Danvers, MA, USA). Protein concentrations were determined using the BCA 
kit (Thermo Fisher Scientific, Waltham, MA USA) and 25 µg of total protein was subjected 
to SDS-PAGE and electroblotting. Western blots were blocked with Odyssey blocking buffer 
and incubated with rabbit-anti-γH2AX (1:2000, Ser139; #9718, Cell Signaling, Danvers, MA, 
USA) and mouse-anti-β-Actin (1:1000; Santa Cruz, Dallas, TX, USA). Primary antibodies 
were detected with goat-anti-rabbit Alexa680 and goat-anti-rabbit Alexa800 (both 1:10.000, 
Invitrogen, Waltham, MA, USA) diluted in blocking buffer. 
 Blots were analyzed on the Odyssey scanner (LI-COR biotechnology, Lincoln, NE, USA). 
Signals were normalized to those for housekeeping protein β-actin. All analyses were 
performed in duplicate (biological replicas). Statistical significance was determined with an 
unpaired Student’s T-test.
Whole RNA next generation sequencing
RNA was isolated from 80% confluent SKRC-7 and SKRC-17 cells using TRIzol reagent (Life 
Technologies, ThermoFisher Scientific, Waltham, MA, USA) according to the manufacturers’ 
instructions. RNA (RIN scores > 8) was subjected to whole transcriptome sequencing at the 
genomics core facility of the Netherlands Cancer Institute according to standard protocols. 
RNA was sequenced on an Illumina Hiseq (paired end sequencing protocol), yielding 30-50 
million reads per sample. Data were analyzed using the ‘Tuxedo’ protocol; reads were mapped 
against the RefSeq human genome GRCh37.55 (hg19) with TopHat and final transcript assembly 
was done with the Cufflinks package 34. Data were normalized with Cuffquant. Gene counts 
were extracted from BAM files with FeatureCount, and these were transformed to transcript 
per million mapped reads (TPM) to obtain relative expression values35. Gene Set Enrichment 
Analysis (GSEA) was run based on genes sorted on the ratio of their TPMs between SKRC-7 
and SKRC-17. The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were used as 
gene set and the analysis was run with a false discovery rate (FDR) of 0.1 and in the classic 
mode (http://software.broadinstitute.org/gsea/index.jsp)
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ABSTRACT 
Diffuse gliomas are primary brain cancers that are characterised by infiltrative growth. 
Whereas high-grade glioma characteristically presents with perinecrotic neovascularisation, 
large tumor areas thrive on pre-existent vasculature as well. Clinical studies have revealed that 
pharmacological inhibition of the angiogenic process does not improve survival of glioblastoma 
patients. Direct targeting of tumor vessels may however still be an interesting therapeutic 
approach as it allows pinching off the blood supply to tumor cells. Such tumor vessel targeting 
requires the identification of tumor-specific vascular targeting agents (TVTAs). 
 Here we describe a novel TVTA, C-C7, which we identified via in vivo biopanning of a 
llama VHH phage display library in an orthotopic mouse model of diffuse glioma. We show 
that C-C7 recognizes a subpopulation of tumor blood vessels in glioma xenografts and clinical 
glioma samples. Additionally, C-C7 recognizes macrophages and activated endothelial cells in 
atherosclerotic lesions. By using C-C7 as bait in yeast-2-hybrid screens we identified dynactin-
1-p150Glued as its binding partner. The interaction was confirmed by co-immunostainings with 
C-C7 and a commercial anti-dynactin-1-p150Glued antibody, and via co-immunoprecipitation/
western blot studies. Normal brain vessels do not express dynactin-1-p150Glued and its 
expression is reduced under anti-VEGF therapy, suggesting that dynactin-1-p150Glued is a 
marker for activated endothelial cells.
 In conclusion, we show that in vivo phage display combined with Y2H screenings provides 
a powerful approach to identify tumor-targeting VHHs and their binding partners. Using this 
combination of methods we identify dynactin-1-p150Glued as a novel targetable protein on 
activated endothelial cells and macrophages.
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INTRODUCTION
In order to grow and disseminate, tumors depend on an adequate blood supply1-2. Based on 
the assumption that tumors arrange their own blood supply via induction of angiogenesis, 
in the last decade angiogenesis inhibitors (e.g. the anti-VEGF-A antibody bevacizumab 
or VEGFR2-specific tyrosine kinase inhibitors) have been widely implemented in clinical 
practice for a number of tumor types3-4. Effects of anti-angiogenesis (mostly in combination 
with chemotherapy) are however mostly transient5-6 and cancer patients who undergo anti-
angiogenic treatment mostly experience recurrences, one possible cause being that tumors 
adopt an invasive phenotype to accommodate their metabolic needs7-10. Resistance to anti-
angiogenic treatment may also be related to heterogeneity of the tumor vasculature. Vessel 
formation in cancer is a multistep process and consequently cancers contain neovessels in 
different stages of development11-12. Because endothelial cells in matured vessels are less 
dependent on VEGF-VEGFR2 signalling, these are also more refractory to VEGF inhibition13. 
 Vessel heterogeneity is especially prominent in glioblastoma, a highly malignant brain 
tumor of glial origin14. One hallmark of glioblastoma is the presence of large areas of diffuse 
infiltrative growth in which tumor cells thrive on pre-existent vessels (co-option) without the 
need for angiogenesis15-16. Another characteristic of glioblastoma is focal angiogenesis in the 
vicinity of areas of necrosis, and this has been rationale for preclinical and clinical testing 
of anti-VEGF therapy for recurrent and primary diagnosed glioblastoma. Such studies have 
shown effective inhibition of angiogenesis, however without preventing tumor progression in 
areas of diffuse infiltrative growth17-19. This growth pattern thus provides tumors with a route 
of escape from anti-angiogenic therapies5,20-21 and recent clinical trials confirmed a lack of 
prolonged survival of glioblastoma patients upon treatment with bevacizumab22-23.
 An alternative approach to deprive cancers from blood is direct anti-vascular therapy 
that aims at tumor-specific thrombosis and infarction. Such an approach requires that 
tumor vascular targeting agents (TVTAs) are developed with high enough specificity for tumor 
vasculature. Available TVTAs (e.g. RGD peptides or cilengitide, targeting endothelial αvβ3 
integrin24-25, the L19 single chain antibody that targets the ED-B fragment of fibronectin26, anti-
V-CAM antibodies27, anti-plexinD1 antibodies28) are directed against newly formed vessels and 
do not target tumor vessels in more matured stages of development.
 Biopanning of peptide or single chain-antibody phage display libraries is a powerful 
technique that allows identification and isolation of tumor endothelium binding partners29-32. 
VHHs (Variable Heavy chain domains of Heavy chain antibodies or Nanobodies®) are 
recombinant antibodies, cloned from cameloid IgG2 and IgG3 heavy chain-only antibodies (V-
H) and consist of a single polypeptide chain, making this class of antibodies suitable for display 
on phages without significant loss of affinity33-34. Their small size (15-18 kDa) and stability make 
VHHs to an attractive class of diagnostic and therapeutic compounds35. VHH against epidermal 
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growth factor receptor (EGFR) or carcinoembryonic antigen (CEA) have already successfully 
been used for in vivo diagnosis and therapy36-38. 
 In a search for novel relevant VHH-based TVTAs we performed in vivo biopannings with a 
VHH phage display library29. As a tumor model we utilized mice carrying orthotopic E98 human 
glioma xenografts that characteristically display both angiogenesis-dependent growth and 
diffuse infiltrative growth18,39. We identified a novel VHH, C-C7, that targets a subpopulation 
of tumor blood vessels. Using C-C7 as a bait protein in yeast-2-hybrid screens we identified 
dynactin-1-p150Glued as its binding partner.
RESULTS
In vivo selection of tumor vessel binding phages in cerebral E98 xenografts
A VHH-displaying phage library28 was intravenously injected in mice carrying intracerebral 
E98 xenografts and irrelevant phages were removed from the circulation by cardiac perfusion. 
We chose to use mice carrying orthotopic E98 xenografts because these tumors display both 
areas of angiogenesis and diffuse infiltrative growth39. Similarly to our previous work using 
different tumor xenograft models and other phage libraries29, anti-M13 immunostainings 
demonstrated already a tumor-specific vessel localization of phages after the first round of 
biopanning (Figure 1, compare the anti-M13 immunostaining in panel A to the endothelial 
cell CD34 staining in panel B). After collection of tumor areas from brain sections by laser 
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 Figure 1. In vivo biopanning of a Llama phage library in an animal model of orthotopic glioma. Anti-M13-p8 
(A) and anti-CD34 (B) immunostainings of sections of E98 xenografts in mouse brain after intravenous 
injection of 1012 phages of the VHH-phage display library, and cardiac perfusion. Note that phages are 
associated with tumor vasculature, but to a lesser extent with blood vessels in normal brain. N = normal, 
T = tumor. Bars correspond to 100 µm.
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capture dissection microscopy and subsequent trypsin treatment, a total of 453 colony-forming 
phages was rescued of which 192 clones were randomly picked and analysed for full length 
VHH expression and diversity. Dot blot analysis revealed that 95% of clones expressed VHH 
and restriction enzyme finger print analysis resulted in five different restriction patterns (not 
shown). As there is some chance of VHH clones with similar restriction patterns being different 
on the nucleotide level, we arbitrarily chose to analyze from each group the 30% of clones with 
highest VHH expression levels. 
Immunohistochemistry
Immunohistochemical stainings were performed on sections of intracerebral E98 xenografts 
to select for VHHs that specifically recognize tumor vessels. Because interpretation of staining 
of delicate capillaries requires optimal morphology, we chose to perform immunostainings on 
sections of FFPE-tissue blocks instead of cryosections, and accepted that potentially interesting 
VHH (recognizing conformational epitopes that are disrupted during formalin fixation) could be 
lost during analyses. Positive staining of blood vessels was observed with 27 of the 39 analyzed 
VHH of which 10 were not tumor-specific. The remaining 17 VHHs stained subsets of tumor 
vessels. Of these, VHH C-C7 showed most prominent staining of tumor vasculature in E98 
xenografts and was analyzed in more detail. C-C7 stained both small and medium-sized tumor 
vessels in the diffuse infiltrative component of E98 xenografts39-40 (Figure 2A). Interestingly, not 
all tumor associated vessels were recognized (compare the C-C7 staining pattern with the anti-
CD34 staining of the serial sections in the inset in Figure 2A). VHH C-C7 did not stain normal 
vasculature in mouse brain (Figure 2B). The observation that C-C7 stained only a subpopulation 
of tumor vessels prompted us to further characterize C-C7 by immunohistochemistry in other 
mouse tumor models. VHH C-C7 showed delicate staining of the vasculature in colorectal 
cancer xenografts (Figure 3). Interestingly, blood vessels in angiogenic brain metastases of the 
human melanoma cell line Mel57-VEGF165
41 were homogeneously positive (see representative 
example in Figure 2C) while staining was absent in Mel57-VEGF165 tumors after treatment 
with the VEGFR2 inhibitor vandetanib42 (Figure 2D). This suggests that C-C7 recognizes VEGF-
activated endothelial cells.
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Figure 2. C-C7 recognizes tumor vessels in glioma xenografts and brain metastasis. Immunohistochemical 
analysis of VHH C-C7 in a diffuse-invasive part of cerebral E98 xenografts (A), normal mouse brain 
parenchyma (B), a representative brain metastasis of Mel57-VEGF165 melanoma (C) and a Mel57-VEGF-A 
xenograft after treatment with the VEGFR2 inhibitor vandetanib42 (D). C-C7 recognizes subsets of tumor 
vessels in cerebral E98 lesions, while normal mouse brain vessels are negative. Insets in A and B show 
CD34 immunostainings of serial sections. Note that inhibition of VEGFR2 activity in panel D results in loss 
of C-C7 reactivity. N = normal, T = tumor. Bars correspond to 50 µm.
To investigate whether VHH C-C7 might have clinical relevance, we performed immunostainings 
on 9 clinical glioblastoma samples as well as normal human brain tissue. Subpopulations of 
tumor vessels in most glioma tissues stained positive for C-C7 (see representative examples in 
Figure 4A-E) while C-C7 did not stain vasculature in normal human brain (inset in Figure 4A). In 
this set only one grade II glioma did not show any immunoreactivity towards C-C7 (Figure 4D). 
Of interest, paired glioma samples collected before and after avastin treatment21, showed that 
vascular expression of the C-C7 ligand was absent after anti-angiogenic treatment (compare 
Figure 4E and F).
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Figure 3. C-C7 recognizes tumor vessels in colon carcinoma xenografts. Immunohistochemical analysis 
shows that C-C7 recognizes vasculature in subcutaneous colorectal cancer xenografts C26 (A) and C38 (B). 
Bars correspond to 50 µm.
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Figure 4. C-C7 recognizes tumor vessels in human glioblastoma multiforme. Subsets of vessels in human 
glioma are strongly positive for C-C7 (A-C,E). Panels E and F represent a paired primary and recurrent 
tumor from a patient before (E) and after (F) treatment with bevacizumab and temozolomide. Note the 
absence of C-C7 reactivity on vasculature a low grade glioma (D) (arrow). The inset in panel A illustrates 
absence of C-C7 reactivity in the vasculature of normal brain. Bars in A-C correspond to 50 µm, in panels 
D-F 100 µm.
Vessel activation is not exclusive for cancers but also occurs in a number of other pathologies, e.g. 
atherosclerosis. Also in atherosclerotic lesions obtained from human carotid artery we observed 
CC7 immunostaining of endothelial cells, but also prominent staining of macrophages (compare 
C-C7 stainings in Figure 5A,D to CD68 stainings in Figure 5B,E and the CD31 staining in Figure 
5C). Staining with anti-dynactin-1-p150Glued (Figure 5F, see later for identifi cation of dynactin-
1-p150Glued as the C-C7 target) showed clear colocalization with C-C7 (compare D and F). 
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Figure 5. C-C7 recognizes blood vessels and macrophages in human atherosclerosis. Immunostainings 
on areas of surgical samples of atherosclerotic lesions from carotid arteries, immunostained with CC7 
(A,D) the macrophage marker CD68 (B,E) and the endothelial marker CD31 (C) and anti-dynactin-1 (F, the 
anti-dynactin-1 antibody was implemented in this staining based on identifi cation of dynactin-1-p150Glued
as a binding partner of C-C7). A-C and D-F represent serial sections from two different leisons. Note the 
similarity in staining profi les for C-C7 and dynactin-1-p150Glued (D and F, respectively). Tissues in A-C were 
stained with AEC, tissues in D-F with DAB. NC = nectrotic core, I = intima, L = lumen. Bars correspond to 
100 µM in panels A-C and to 50 µm in panels D-F.
To further investigate whether macrophage staining could be reproduced, we stained in vitro 
differentiated mouse HoxB8 macrophages with C-C7 and anti-dynactin-1-p150Glued. Both 
antibodies showed similar staining profi les. Control VHH A9 did not stain these cells (Figure 6).
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Figure 6. C-C7 recognizes dynactin-1 epitopes on macrophages. Immunostainings with C-C7 (A), anti-
dynactin-1-p150Glued antibody (B) and an irrelevant control VHH A9 (C) on differentiated HoxB8 mouse 
macrophages. Note the similarity in staining profi les of C-C7 and dynactin-1 stainings.
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C-C7 can be used for targeting of cancer and atherosclerosis
C-C7 was isolated from an in vivo biopanning experiment after intravenous injection, suggesting 
that it recognizes epitopes that are accessible to circulating VHHs. To confirm the ability of C-C7 
to target tumor vasculature, we injected monoclonal C-C7-phages in mice carrying orthotopic 
E98 xenografts, using the in vivo biopanning protocol which was used for its selection. C-C7-
phages accumulated in subsets of vessels in E98 xenografts, but not in normal brain blood 
vessels (compare the phage localization in Figure 7A and C with the anti-CD34 staining of serial 
sections in Figure 7B and D). Control phages did not show specific tumor vessel localization, 
although some aspecific extravasation from leaky vessels was detected (data not shown). 
Similar experiments in LDLR-/- ApoB100/100 mice carrying atherosclerotic lesions showed 
prominent homing of C-C7-phages to luminal endothelium, intraplaque neovasculature and 
macrophages (Figure 7E). C-C7-phages colocalized with dynactin-1-p150Glued as shown by 
immunostainings (compare panels 7E and 7F).
C-C7 recognizes the carboxyterminal domain of dynactin-1-p150Glued
Since endothelial proteins are greatly underrepresented in tumor extracts, we argued that a 
proteomic approach to identify the C-C7 ligand would be unlikely to succeed. Therefore we 
decided to use VHH C-C7 as bait protein in a Y2H screen against a large yeast expression 
library, using histidine (HIS3), adenine and β-galactosidase (LacZ) as reporter genes43. Three 
independent clones were identified from these screens which represented the carboxyterminal 
part of the p150Glued subunit of dynactin-1. Clones C-C7-INT1 and C-C7-INT3 were composed 
of the carboxyterminal 432 amino acids of p150Glued (aa 808-1240) and included 150 nucleotides 
of the 3’-untranslated region, while clone C-C7-INT2 spanned aa 890-1238 of the p150Glued 
sequence (Figure 8A). A comparison of bovine dynactin-1-p150Glued with the human homologue 
revealed 96% sequence identity in this region (not shown). 
 To confirm the interaction between C-C7 and human dynactin-1-p150Glued, the region 
encompassing aa 816-1278 (human numbering) was RT-PCR-cloned from human glioblastoma 
tissue and transiently expressed in COS-1 cells. Confocal microscopy of transfected cells, co-
stained with VHH C-C7 (visualized using FITC) and anti-dynactin-1 (visualized using TRITC) 
showed that both antibodies co-localized to cytoplasmic vesicular structures (Figure 8B). Non-
transfected cells did not stain with both antibodies (see Figure 8C).
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Figure 7. In vivo targeting of glioma xenografts and atherosclerotic lesions by C-C7-displaying M13 phages. 
Monoclonal C-C7 phages were injected intravenously in mice carrying orthotopic E98 xenografts and phage 
distribution was analyzed by M13-p8 immunostaining after cardiac perfusion (A). A serial section was 
stained with CD34 to highlight vasculature (B). Phages displaying C-C7 home to a subpopulation of tumor 
vessels in E98 xenografts. Phages do not accumulate in normal vasculature in non-affected brain parts, 
as illustrated by M13-p8 (C) and CD31 (D) immunostainings. E) M13-p8 immunostaining of atherosclerotic 
lesions of LDLR-/- ApoB100/100 mice after an in vivo biodistribution experiment. Note that C-C7-phages home 
to luminal endothelium, intraplaque neovasculature (arrows) and macrophages (arrowheads). The M13-p8 
immunostaining colocalizes with anti-Dynactin-1 immunostaining (F). T= tumor, I = intima, L = lumen. 
Bars in panels A,B correspond to 100 µm, in panels C-F: 50 µm
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Figure 8. Dynactin-1-p150Glued is identifi ed as a C-C7 binding partner by a yeast-2-hybrid screen. 
Structural domains of dynactin-1-p150Glued and p150 domains identifi ed by yeast-2-hybrid screens as C-C7 
interactants (A). The aminoterminal domain contains a CAP-Gly domain and a coiled-coil domain which are 
responsible for microtubule (MT) binding and dynein binding (DIC = dynein intermediate chain). A second 
coiled-coil domain (CC2), encompassing a binding site for Arp1, is present in the carboxyterminal part of 
the protein and mediates binding to membrane components. Confocal microscopy showed colocalization 
of C-C7 (green) and commercial anti-dynactin-1-p150Glued (red) in COS-1 cells, transfected with the 
recombinant carboxyterminal domain of dynactin-1-p150Glued (B). Non-transfected cells did not stain with 
both antibodies (C, see negative DAPI-stained cells surrounding one transfected cell in this panel). C-C7 
immunoprecipitates from extracts from CHO-s cells transfected with recombinant p135Glued were analyzed 
on western blot using commercial anti-dynactin-1-p150Glued as indicated (D). Note that p135 is readily 
precipitated by C-C7 (lane 2) but not by an irrelevant VHH F8 (lane 4).
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C-C7 specifically precipitates p150 Glued and recombinant p135Glued 
Because colocalization of C-C7 with commercial antibodies as shown in figure 8B and 8C 
formally does not exclude indirect interactions with other proteins than p150Glued in the same 
vesicular structures, we wanted to further validate binding via immunoprecipitation. Under 
the conditions of cell lysis used in our experiments, the majority of carboxyterminal p150Glued 
816-1278 protein ended up in the pellet fraction (data not shown). As this problem did not 
occur with the P135-isoform of P150Glued44 we performed immunoprecipitation on extracts of 
P135-overexpressing CHO-s cells. P135 differs from p150 only in the N-terminal region, and 
hence contains the binding sites for both C-C7 and the commercial antibody. Furthermore, this 
variant can be readily distinguished from endogenous p150Glued based on molecular weight. 
Figure 8D shows effective precipitation of p135 by C-C7 but not by irrelevant VHH F8. Also, 
small amounts of endogenous p150Glued were precipitated. In summary, these results confirm 
binding of C-C7 to p150Glued and indicate that it is not an artefact of the Y2H screen. 
 To further validate that p150Glued is expressed in tumor vasculature we performed 
immunostainings on clinical glioma samples with a commercially available rabbit anti-
dynactin-1-p150Glued antibody. In all tumors examined this antibody gave a similar staining 
profile as VHH C-C7 (see figure 9A and B respectively, note that these figures contain serial 
sections of the tissues presented in the C-C7 stainings in Figure 4E and 4F). Normal brain 
vasculature did not stain with anti-dynactin although positivity could be found on neurons, 
consistent with literature data44 (Figure 9C).
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Figure 9. Immunostaining with anti-dynactin-1 of human glioblastoma before (A) and after bevacizumab 
treatment (B). Note the similarity with C-C7 immunostainings in Figure 3E and F. Panel C shows an anti-
dynactin staining of normal brain, showing positive neurons, confirming literature data. Bars correspond 
to 100 µm.
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DISCUSSION
In human tumors the vasculature is in general highly heterogeneous with glioblastomas 
as a prime example45-46. The diffuse infiltrative growth of human gliomas and the relatively 
undisturbed blood-brain barrier in these areas contribute to their poor response to surgery 
and radio- and chemotherapy14,47. Gliomas do not adequately respond to anti-angiogenic 
therapies either16,21-23,48 which is likely a consequence of angiogenesis-independent progression 
of diffusely infiltrating tumor cells. Therefore, a strategy of tumor-vessel targeting aiming at 
the induction of tumor infarctions is worth investigating. To this end (combinations of) targeting 
agents that specifically and selectively recognize tumor vasculature are needed. 
 Here we employed in vivo biopanning of a VHH phage display library in the E98 orthotopic 
mouse model of diffuse glioma19,39. This approach resulted in the isolation of a set of VHH of 
which 44% specifically recognized tumor blood vessels, indicating tumor-specific enrichment 
already during one round of biopanning.. Presumably during the in vivo selection procedure, 
phages that bind to the surplus of common epitopes on quiescent endothelial cells in the 
circulation are competitively depleted, enriching for tumor-vessel specific binders in the tumor 
tissue. In vivo biopanning of phage display libraries therefore appears to be a relatively quick 
and efficient method to identify tumor targeting VHH.
 In this study we concentrated on VHH C-C7 because it proved to be the most suitable for 
immunostainings on formalin-fixed tissues. In line with the complexity of neovascularization 
and the resulting molecular heterogeneity of tumor blood vessels, we found that C-C7 
stained only a subpopulation of blood vessels in glioma xenografts and human glioma, but 
also neovasculature and macrophages in atherosclerotic plaques. Interestingly, C-C7 stained 
VEGF-A- activated endothelial cells in cerebral Mel57-VEGF-A xenografts, but not endothelial 
cells in blood vessels in these xenografts after treatment with the VEGFR2 inhibitor vandetanib49. 
In line, cerebral metastases of Mel57 xenografts that do not express VEGF-A and grow 
entirely via vessel co-option41 also did not show vascular staining with C-C7 (not shown). This 
suggests that VEGF activation of endothelial cells is involved in expression of the C-C7 ligand, 
and this was corroborated in staining of paired surgical samples of a human glioblastoma 
before and after bevacizumab treatment. Of note, these data predict that tumor-vascular 
targeting with C-C7-like TVTAs should not be combined with anti-angiogenesis, as this would 
reduce the ‘activation-status’ of the vasculature and reduce targeting potential. Whatever the 
molecular underpinnings of C-C7 ligand expression, the approach of in vivo biopanning with 
VHH-phage display libraries may yield proper candidates for further development of anti-
vascular therapies, e.g. by generating VHH fused to truncated tissue factor, inducing tumor-
vessel specific thrombosis27,50-51. A similar approach has been employed using phage libraries 
displaying peptides52.
 Using yeast-2-hybrid screens we identified dynactin-1-p150Glued as the binding partner of 
C-C7 and we verified this interaction via co-immunostainings with VHH C-C7 and commercial 
anti-dynactin-1 antibodies on tumor tissues, on atherosclerotic plaque tissues and dynactin-1-
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p150Glued transfected cells. Further validation came from immunoprecipitations of recombinantly 
expressed domains of dynactin-1-p150Glued.
 Dynactin-1-p150Glued is involved in vesicular trafficking along microtubules, mitotic 
spindle assembly, cell migration and nuclear envelope breakdown during mitosis53-55. Co-
immunostaining of COS-1 cells transiently overexpressing the carboxyterminal part of p150Glued, 
with VHH C-C7 and a commercial anti-p150Glued antibody showed a vesicular pattern, in 
agreement with a previous study on a dynactin-p150Glued mutant that is defective in microtubule 
binding56. 
 Since our biopanning protocol was designed to identify tumor-vessel associated proteins 
that are targetable via intravenous injection, the binding of VHH C-C7 to the alleged intracellular 
protein p150Glued was unexpected. Which mechanisms are involved in extracellular presentation 
of dynactin-1-p150Glued making it accessible to intravenously administered phages, is unclear. 
However, a number of proteins have been shown to use non-conventional ways of trafficking 
in the cell57. Extracellular presentation of otherwise cytoplasmic or even nuclear proteins 
in a tumor context has been described before, examples being transglutaminase, fatty acid 
binding protein 3, and GRP78, although also for these targets the molecular basis for their 
extracellular localization is still enigmatic52,58-61. A possible mechanism explaining extracellular 
presentation of p150Glued involves exocytosis of dynactin-decorated vesicles via multivesicular 
endosomes62-63. After exocytosis of these vesicles, fusion with activated endothelial cells may 
lead to extracellular p150Glued presentation. This resembles the horizontal transmission of tumor 
targets via exosomes that has been proposed as an explanation for endothelial expression of 
tumor-derived EGFRvIII64-66. Of note, we also observed high expression of dynactin-1-p150Glued 
in macrophages in atherosclerotic lesions. Based on our immunohistochemical analyses we 
conclude that dynactin-1-p150Glued is not expressed at high levels in tumor cells. The actual 
source of dynactin-1-150Glued may therefore be activated macrophages/ microglial cells. These 
issues are currently under investigation.
 In conclusion, in vivo biopanning of phage VHH-display libraries in animal models of cancer 
in combination with Y2H technology represents a powerful platform to identify novel TVTAs and 
their binding ligands. We identified C-C7 as a targeting VHH against dynactin-1-p150Glued in a 
glioma xenograft model and in a model of atherosclerosis. It remains to be seen whether this 
VHH can be used for therapeutic anti-vascular targeting purposes. 
VASCULAR TARGETING VHH CC7
83
4
METHODS
Tumor models
All animal experiments were approved by the Animal Experiment Committee of the 
RadboudUMC. Orthotopic E98 glioma xenografts were established in 6-8 week old Balb/c nude 
mice by intracerebral injections of E98 tumor cell suspensions as described previously18. In 
this model mice characteristically start to display weight loss and neurological symptoms due 
to tumor growth 3-4 weeks after tumor implantation. When tumor-related symptoms were 
apparent, mice were used for in vivo biopanning. 
In vivo biopanning
Hundred µl of phosphate buffered saline (PBS) containing 1012 phages of a VHH-displaying 
phage library (cloned from lymphocytes of non-immunized Llama glama in phagemid pHENIX-
8xHis-Vsv28) was injected in the tail vein of nude mice, carrying cerebral E98 tumors (n=2). 
Phages were allowed to circulate for 15 minutes. Mice were subsequently put under deep 
anaesthesia with a mixture of isoflurane/N2O and chests were opened. Cardiac perfusion was 
performed with 10 ml sterile 0.9% NaCl solution to remove unbound phages from the circulation. 
Brains were removed and snap frozen in liquid nitrogen. Sections of 4 µm were stained with 
anti-M13 p8 antibody (Abcam Limited, Cambridge, UK) to assess phage distribution. Using a 
laser dissection microscope (Leica AS LMD, Wetzlar, Germany) tumor areas were dissected 
from 10 µm brain sections. Phages were eluted from these sections by incubation with trypsin 
(10 mg/ml in PBS) for 30 min at room temperature. Following infection in 10 ml of log-phase E. 
coli TG1 culture, bacteria were seeded on 2xTY plates containing 100 mg/L ampicillin and 2% 
glucose. After overnight incubation, individual clones were picked and analyzed via colony-PCR 
for the presence of full-length VHH insert using flanking primers M13rev (5`-TCA CAC AGG 
AAA CAG CTA TGA-3`) and Fedseq3 (5`-GTA ACG ATC TAA AGT TTT GTC G-3`). Subsequently, 
PCR products were digested with the 4-cutter restriction enzyme BstNI (New England Biolabs, 
Ipswich, MA, USA) to analyze the diversity of the phage population. Small scale production 
of soluble VHH by independent clones was induced in log-phase TG1 cells by culturing at 
30oC in 2xTY medium, containing 100 mg/L ampicillin and 1 mmol/L isopropylthiogalactoside 
(IPTG, Serva, Heidelberg, Germany). Expression of VHHs was verified by dot blot analysis of 
medium using anti-Vsv antibodies, as previously described28. Based on combined data of full 
length PCR, BstNI restriction digestion and dot blot analysis, expression of selected individual 
VHH was induced in 50 ml log-phase TG1 cells with 1 mM IPTG for 3 hours at 30oC. VHH 
were isolated from the periplasm by osmotic lysis and purified by Ni-NTA sepharose (IBA Life 
Sciences, Gottingen, Germany) as described previously 28.
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Immunohistochemistry
VHHs were tested in immunohistochemical stainings on 4 µm sections of formalin-fixed 
paraffin-embedded (FFPE) tissues and tumor xenografts of different origin (intracerebral E98 
xenografts; brain metastases of Mel57-VEGF165 melanoma after treatment with vandetanib 
or controls49, subcutaneous Mel57-VEGF 165 xenografts and subcutaneous xenografts of the 
colon carcinoma cell lines C26 and C3867). Human gliomas, classified by an experienced 
neuropathologist as grade II (n=2) and grade IV (n=7) gliomas, as well as normal brain tissue 
(n=2) were retrieved from the archives of the departments of Pathology of RadboudUMC and 
of the Academic Medical Center. GBM patients provided written informed consent, and the 
study was conducted in accordance with the Declaration of Helsinki and was approved by the 
Academic Medical Center Institutional Review Board and the Dutch Central Committee on 
Research investigating Human Subjects (ISRCTN23008679). Use of the other archival tissues 
was in accordance with institutional guide lines.
 Following deparaffinization, endogenous peroxidase activity was blocked by incubation 
with 3% H2O2. Antigen retrieval was performed by boiling in 10 mmol/L citrate buffer (pH 
6.0). Sections were pre-incubated with normal goat serum to block non-specific binding 
sites, followed by overnight incubation with 3 µM VHH in PBS/2%BSA at 40C. Detection was 
performed by sequential incubations with rabbit anti-Vsv-G antibody (for mouse tissues, Sigma-
Aldrich Chemie B.V., Zwijndrecht, The Netherlands,) or anti-Vsv-G P5D4 (for human tissues), 
biotinylated anti-rabbit antibody (Vector, Burlingame, CA) and avidin-biotin peroxidase complex 
(Vector). Peroxidase was visualized with 3-amino-9-ethylcarbazole (AEC, ScyTek, Utah, USA) 
with haematoxylin as counterstain. Tumor vessels in mouse xenograft tissues were visualized 
in serial sections with rat-anti-mouse CD34 antibody (Hycult, Uden, The Netherlands). Rabbit 
antibodies against dynactin-1-p150Glued were from Abcam (Cambridge, UK).
C-C7 in atherosclerosis
Carotid artery atherosclerotic tissue from patients at risk for ischemic stroke was obtained 
from routine surgical procedures at the department of Vascular Surgery of RadboudUMC (kindly 
provided by Dr. J. Pol). Directly after surgery tissues were processed to FFPE blocks. Four µm 
sections were deparrafinized and pretreated as described, and incubated with 3 µM C-C7 in 
normal antibody diluent (Immunologic, Duiven, The Netherlands). Then slides were incubated 
with anti-VSV-G P5D4, PolyHRP-anti-Ms/Rt/Rb (Immunologic, Duiven, The Netherlands), and 
peroxidase was visualized with bright 3’3Diaminobenzidine (DAB) (Immunologic, Duiven, The 
Netherlands). 
 Furthermore, specificity of C-C7 was assessed by staining on mouse macrophages, 
obtained by differentiating ER-HoxB8 myeloid precursor cells by 25 ng/ml GM-CSF on 8-well 
Lab-Tek Chamber Slide™ System (Nunc, Roskilde, Denmark)68. Cells were fixed with 2% 
paraformaldehyde for 10 min, and pre-incubated with normal goat serum. Then cells were 
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incubated with 3 µM C-C7 or rabbit-anti-Dynactin-1-P150Glued in PBS/2%BSA. Detection was 
performed as described above in immunohistochemistry.
 In another set of experiments hypercholesterolemic (low-density lipoprotein receptor 
(LDLR)-/- apolipoprotein B (ApoB) 100/100) mice69 were subjected to high-cholesterol diet (TD 88137, 
Harlan Laboratories, Indianapolis, IN, USA) for 8 weeks after which a peri-adventitial collar 
was placed around a carotid artery. Hundred µl PBS containing 1012 M13-phages displaying 
VHH C-C7 or helper phages as control, was injected via the tail vein and allowed to circulate for 
15 minutes after which a cardiac perfusion with 10 ml PBS was performed. Lesions from the 
carotid artery were harvested and processed to FFPE blocks, sections of which were stained 
with anti-M13 p8 or with anti-dynactin-pGlued150 antibody.
Y2H screens
All cloning steps were performed using the Gateway System (Invitrogen, Carlsbad, CA). The 
cDNA encoding VHH C-C7 (without pelB leader) was flanked by attB sites via PCR and cloned in 
vector pDONR201 before transfer into destination vector pBD-GAL4-CAM/DEST, generating a 
C-C7 fusion protein with the GAL4 DNA binding domain. After sequence-verification this vector 
was transfected into yeast strain PJ69 (A-mating type) using standard protocols43. Generation 
of a randomly primed bovine retina cDNA library in pAD-GAL4, transfected in PJ69 (α-mating 
type, 2x106 clones) has been previously described43. The yeast strain containing pBD-GAL4-
C-C7 was mated with this library and diploid cells in which C-C7-prey interactions led to 
functional GAL4 transcription factor, were selected based on histidine and adenine prototrophy 
and transactivation of ß-galactosidase activity. Production of ß-galactosidase by activation 
of the LacZ reporter gene was detected by a filter-lift assay43. From positive yeast clones, 
pAD-GAL4 library expression plasmids were rescued and amplified in E. coli. Plasmids were 
sequenced using flanking forward and reverse primers. Sequences were blasted (http://www.
ncbi.nlm.nih.gov/blast/Blast.cgi) and aligned with multalin software (http://bioinfo.genotoul.fr/
multalin/ multalin.html). All sequenced clones contained intact reading frames in fusion with 
the GAL4-activation domain.
Verification of the C-C7-dynactin-1 interaction
The carboxyterminal part of dynactin-1-p150Glued was RT-PCR-cloned from human glioblastoma 
cDNA using primers attB1-dyn 2532 (5’-AAA AAG CAG GCT TCA CCA TGG CAG CTG CTG CTG 
CC-3’, sense) and attB2-dyn 3837 (AGA AAG CTG GGT GTT AGG AGA TGA GGC GAC TGT G-3’, 
antisense). AttB1 and attB2 sites were extended in a second PCR and products were cloned via 
pDONR201 in p3xflg-CMV (Invitrogen, Carlsbad, CA, USA) to generate p3xflg-CMV-dyn 2532-
3837. Plasmids were transfected into COS1 cells in 8-well glass slides (Lab-Tek Chamber 
Slide™ System, Nunc, Roskilde, Denmark). Forty-eight hours later, cells were fixed with ice-
cold acetone and incubated with VHH C-C7 for 1 hr, followed by sequential incubations with 
mouse anti-Vsv and goat-anti-mouse FITC (Invitrogen, Carlsbad, CA, USA). After washing, slides 
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were stained with rabbit-anti-dynactin-1 which was detected with donkey-anti-rabbit TRITC 
(Invitrogen, Carlsbad, CA, USA). Images were processed on a Leica Discovery Fluorescence 
Microscope and a Leica confocal microscope.
Immunoprecipitation studies  
In another set of experiments, the p135 variant of dynactin44 was obtained via RT-PCR from 
glioblastoma RNA using primers P135fw-ClaI (5’-CATCGATACCATGATGAGACAGGCACC-3’) and 
P135rev-NotI (5’ CAGCGGCCGCTTAGGAGATGAGGCGACTG-3’) and digested and cloned in ClaI-
NotI digested pIRESneo (Clontech, Mountain View, CA). Suspension cultures of Chinese Hamster 
Ovary cells (CHO-s) in SFM4CHO medium with L-glutamin (ThermoFisher, Landsmeer, The 
Netherlands) were transfected with pIRES-Dynactin-p135 using the Amaxa Nucleofactor kit 
according to the manufacturer’s instructions (Lonza, Cologne, Germany). Cells were harvested 
48 hours later and lysates prepared in lysis buffer [50 mM Tris-HCl, pH 7.4, 1% Triton-X100, 150 
mM NaCl and protease inhibitors (CompleteTM protease inhibitor cocktail, Roche, Mannheim, 
Germany)] with untransfected CHO-s cells serving as control. Lysates were clarified at 13,000 
g for 10 min at 40C. Dynactin-p135 expression was verified on western blot using rabbit-anti-
Dynactin (AbCam Cambridge, UK). 
 For immunoprecipitations, periplasmic extracts of His-tagged C-C7 or irrelevant control 
VHH F8 were diluted five times in IPP500 (50 mM phosphate buffer pH 8.0, 500 mM NaCl) and 
incubated with Ni-NTA sepharose for 2 hours at 4°C. After washing three times with IPP500 and 
three times with IPP150 (50 mM phosphate buffer, pH 8.0, 150 mM NaCl) beads with immobilized 
C-C7 were incubated with cleared cell lysates for 2 hours at RT. Beads were washed two times 
with IPP150 incubated with 5 mM imidazole in IPP150 for 10 min at RT, boiled for 5 minutes 
in reducing sample buffer and loaded on a 7% SDS-PAGE gel for Western blot analysis with 
rabbit anti-Dynactin and goat anti-rabbit IRDye800 (LI-COR, Lincoln, NE, USA) using the Odyssey 
infrared imaging system (LI-COR, Lincoln, NE, USA).
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ABSTRACT
Conjugation of llama single domain antibody fragments (Variable Heavy chain domains of 
Heavy chain antibodies, VHHs) to diagnostic or therapeutic nanoparticles, peptides, proteins 
or drugs offers many opportunities for optimized targeted cancer treatment. Currently, mostly 
nonspecific conjugation strategies or genetic fusions are used that may compromise VHH 
functionality. 
 In this paper we present a versatile modular approach for bioorthogonal VHH modification 
and conjugation. First, sortase A mediated transPEGylation is used for introduction of a 
chemical click moiety. The resulting clickable VHHs are then used for conjugation to other 
groups employing the Cu+-independent strain-promoted alkyne-azide cycloadition (SPAAC) 
reaction. Using this approach, tail-to-tail bispecific VHHs and VHH-targeted nanoparticles 
are generated without affecting VHH functionality. Furthermore, this approach allows the 
bioconjugation of multiple moieties to VHHs for simple and convenient production of VHH-
based theranostics. 
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INTRODUCTION
The challenge in cancer therapy is to specifically deliver therapeutic agents to tumor cells with 
minimal delivery to and effects on healthy tissues. Targeted delivery of drugs with antibody 
drug conjugates (ADCs) has received a lot of attention in the last decades. Also, nanoparticles 
have been used for drug delivery. Liposomes can carry hydrophilic drugs in the lumen1,2 
while micelles are suited for carrying hydrophobic drugs3. Liposomes and micelles however 
distribute relatively randomly in the body after intravenous injection1 and introduction of tumor 
specificity in these nanoparticles could greatly increase local delivery and efficacy of cancer 
therapeutics4-6.
 A number of therapeutic antibodies with relative tumor specificity are now applied clinically 
(e.g. trastuzumab and cetuximab against HER2 and EGFR)7,8. Effects of treatments with these 
targeted drugs are often limited because of recurrences of drug-resistant tumors9-12. The 
challenge should therefore be to develop a multispecific tumor-targeting nanoparticle platform 
that can deliver cytotoxic payload to all cancer cells in a tumor, resulting in specific and acute 
death of all cells in a tumor.
 Conventional protein conjugation strategies mostly use relatively nonspecific methods, 
e.g. N-hydroxysuccinimide (NHS) chemistry utilizing ε-NH2 groups from lysines. Depending on 
number and distribution of lysines in the active binding domain of the targeting agent, these 
conjugation protocols may compromise functionality. This specifically applies to single domain 
antibody fragments (VHHs, Nanobodies®) due to their small size. VHHs are recombinant 
antigen-binding domains that are derived from cameloid heavy chain-only antibodies and 
receive increasing interest as therapeutic or diagnostic compounds13,14. VHHs typically have 
a molecular weight of 15-20 kDa and may bind target antigens with pM to nM affinity, similar 
to conventional antibodies. The ease of genetic engineering and handling of VHHs, combined 
with a number of other advantages such as high water solubility, low production cost, small 
size, low immunogenicity in humans and high thermo- and pH stability15 makes this class of 
antibodies a highly interesting alternative to conventional antibodies. 
 A number of VHHs with high specificity and affinity against tumor targets (e.g. EGFR, 
HER2, MET) have been developed16-18. Approaches to conjugate VHHs without compromising 
functionality include the site specific introduction of a carboxyterminal cysteine allowing 
maleimide chemistry19 and introduction of a carboxyterminal five amino acid sequence (LPXTG) 
allowing sortase A transpeptidation20.
 Here we present a versatile modular approach for bioorthogonal VHH conjugations, 
using sortase A mediated transPEGylation to introduce a carboxyterminal click moiety, 
and subsequent Cu+-independent strain-promoted alkyne-azide cycloadition (SPAAC) for 
conjugation of a functional group that may be connected to another VHH and/or polymeric 
micelles. Furthermore, introduction of a cysteine before the LPXTG tag allows maleimide 
chemistry to introduce a second diagnostic or therapeutic compound. This method allows 
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the production of highly uniform VHH-based conjugates that can consist of multiple 
modular moieties, examples being labeled bispecific VHHs, bivalent VHHs and VHH-targeted 
nanoparticles. Because all chemistry occurs at the carboxyterminus, this method does not 
affect VHH functionality. Furthermore, concomitant with conjugation, carboxy-terminal tags 
that allow purification of the VHHs after bacterial expression are removed, a prerequisite for 
future clinical applications. 
RESULTS AND DISCUSSION
VHHs were successfully expressed and purified as VHH-C-LPETG-8xHis-Vsv or VHH-
LPETG-8xHis-Vsv fusion proteins with yields of 5-10 mg/L E.coli culture (see Figure 1A for a 
representative Coomassie Brilliant Blue (CBB) stained SDS-PAGE gel of 7D12-C-LPETG-8xHis-
Vsv (referred to as 7D12), the anti-EGFR VHH that was used as a prototype in this study). Since 
the 8xHis-Vsv tags are substituted by compounds of interest during the sortase A reaction, 
loss of these tags was compensated for by introducing a cysteine residue directly upstream 
of the LPETG-8xHis-Vsv sequence, allowing maleimide-based labelling with alternative tags 
for detection. Liquid chromatography mass spectrometry (LC-MS) indicated the correct mass 
for expressed 7D12 and it showed that the free thiol group of this cysteine was oxidized, 
presumably by glutathione based on its molecular weight of 307 Da (Figure 1B). After a mild 
TCEP reduction, the thiol was available for conjugation (Figure 1C). The reaction of the 7D12 
protein with fluorescein-5-maleimide was efficient, resulting in a pure preparation of 7D12[Fluo] 
(Figure 2A+B, lanes 1). LC-MS confirmed the conjugation of one fluorescein residue per VHH 
in 7D12[Fluo] (Figure 2C), demonstrating that the two native framework cysteine residues that 
are involved in an intramolecular disulfide bridge21 were not reactive towards fluorescein-5-
maleimide under the used conditions. This was further confirmed in additional experiments 
that showed absence of maleimide reaction with multiple VHHs lacking the C terminal cysteine 
(Figure 3). 
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Figure 1. A) CBB stained SDS-PAGE gel of samples obtained during 7D12 production. 1 = bacterial lysate, 2 
= fl ow-through Ni-NTA purifi cation, 3 = pre-eluate Ni-NTA purifi cation, 4 = eluate post Ni-NTA purifi cation 
and dialysis. B) LC-MS characterization of 7D12 (with an expected mass of 17837 Da, observed 17962 
and 18137 Da) before TCEP reduction. C) LC-MS characterization of 7D12 after 20 min incubation with 20 
mM TCEP. A pure product of 17831 Da was detected, suggesting that the thiol before TCEP reduction was 
oxidized by small molecules, among which presumably glutathione. The left graphs show the ultraviolet 
absorbance chromatograms (at 215 nm) and the middle and right graphs show the total mass spectra and 
deconvoluted spectra of the UV-peaks bracketed by the arrowheads, respectively. 
CHAPTER 5
98
A B
C
D
7D12[Fluo]-N3
7D12[Fluo]
sortase A Δ59
15 kDa
10kDa
20 kDa
25 kDa
37 kDa
50 kDa
75 kDa
1 32 1 32
17000 17500 18000 18500 19000 19500
18278
Mass (Da)
14500 15000 15500 16000 16500 17000
15806
Mass (Da)
Figure 2. A) Fluorescent image and B) CBB staining of an SDS-PAGE gel of samples obtained during 
the procedure of sortagging. 1 = 7D12[Fluo], 2 = 7D12[Fluo]/sortase A/H2N-PEG3-N3 reaction mixture after 
overnight reaction, 3 = purified 7D12[Fluo]-N3. Note the molecular shift between lanes 1 and 2, 3 that is a 
result of removal of the G-8xHis-Vsv tag and simultaneous addition of the small PEG3-N3 group. C) LC-
MS characterization of 7D12[Fluo] (expected 18265 Da, observed 18278 Da) D) LC-MS characterization of 
7D12[Fluo]-N3 (expected 15790 Da, observed 15806 Da). The left graphs show the ultraviolet absorbance 
chromatograms (at 215 nm) and the middle and right graphs show the total mass spectra and the 
deconvoluted spectra of the UV-peaks bracketed by the arrowheads, respectively. 
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Figure 3. Only the C-terminally introduced thiol in VHHs is avalaible for maleimide chemistry. A) Western 
blot stained with Avidin Alexa680. 1 = A12-C-LPETG-8xHis-Vsv after incubation with biotin-maleimide. 2 = 
the same amount of A12-LPETG-8xHis-Vsv as a control, incubated under the same conditions. Note absence 
of maleimide labelling of A12, indicating that the 2 cysteines involved in an intramolecular disulphide bond 
are not available for this reaction B) Deconvoluted spectra (left) and total mass spectra (right) showing 
incorporation of fl uorescein-5-maleimide only in bihead N7D12C-[G4S]10-
N4E4C with a c-terminal cysteine. 
Upper graphs depict N7D12C-[G4S]10-
N4E4C-Flag-6xHis incubated with fl uorescein-5-maleimide (expected 
29164.89 Da, observed 29165 Da), lower graphs depict N7D12C-[G4S]10-
N4E4C-C-Flag-6xHis incubated with 
fl uorescein-5-maleimide (expected 29713.4 Da, observed 29724 Da). 
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The LPETG-8xHis-Vsv tag in 7D12[Fluo] allows sortase A mediated transpeptidation which 
releases the G-8xHis-Vsv tag in exchange for an H2N-GGG-containing peptide (the prototypical 
substrate of sortase A). This allows rapid and easy purification of the reaction product to 
homogeneity, because the G-8xHis-Vsv cleavage product and the 6xHis-tagged sortase A 
enzyme can be removed from the reaction mixture by Ni-bead depletion. Because a wide 
variety of chemically modified monodisperse PEG compounds is nowadays available, sortase 
A mediated conjugation of such compounds to the carboxyterminus is a highly attractive 
approach. 
 Using H2N-PEGx-X as a nucleophile for sortase A mediated PEGylation, a range of VHH-
PEGx-X constructs can be generated in which X represents a drug or a reactive group. In this 
work we used the combination of H2N-PEG3-N3 and H2N-PEG3-DBCO in the SPAAC reaction
22. 
In an attempt to improve the reaction with H2N-PEGx-X we tested recently described mutants 
of sortase A with optimized LPETG cleavage activity23, and compared them to the variants with 
a N-terminal deletion of either 25 or 59 amino acids (supporting information, Figure S1 + S2). 
These optimizations were performed using the anti-PlexinD1 VHH A1224. Sortase A Δ59 was 
ultimately selected as most optimal since despite increased LPETG cleavage rates, the low 
affinity of the mutant sortases for H2N-GGG or H2N-PEGx-X resulted in high levels of hydrolysis 
at the threonine. Furthermore, we found that the sortase A Δ25 variant, that contains an 
N-terminal 6xHis-tag, experienced unexplained proteolysis just downstream of the His-tag 
during the sortase A reaction (supporting information and Figure S2D). Since this precluded 
complete removal of sortase A activity, we discarded this variant. 
 Further experimentation using different molar ratios of H 2N-PEGx-X or H2N-GGG revealed 
that H2N-PEGx-X was incorporated less efficiently than H2N-GGG, requiring a 200-fold molar 
excess of H2N-PEGx-X over VHH-(C)-LPETG-8xHis-Vsv as compared to a 25-fold excess of H2N-
GGG (under conditions of 4 hrs reaction at 30oC with sortase A Δ59). Lower concentrations of 
both nucleophiles in the reaction resulted in formation of VHH-LPET-OH hydrolysis products, 
as observed with LC-MS (supporting information, Figure S3A). These results were in line with 
those of Parthasarathy et al, who showed that conjugation of H2N-PEGx to EGFP in a ratio of 
1:1 by sortase A Δ59 was highly inefficient25. Yet, the use of H2N-PEGx-X nucleophiles instead 
of triglycine-containing substrates would have an important advantage: conjugation of H2N-
PEGx-X yields VHH-(C)-LPETG-PEGx-X in a one-way reaction, unlike conjugation of H2N-GGG-X 
that reconstitutes a sortase A substrate site in the VHH-(C)LPET-GGG-X reaction product. 
Indeed we could show that VHH-LPET-PEGx-X is not a substrate for sortase A, in contrast to 
VHH-LPETGGG-peptide (Figure 4).
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Figure 4. Conjugation of H2N-PEG3-X does not reconstitute the sortase A recognition site. 7D12
[Fluo], 7D12[Fluo]-
PEG3-N3-DBCO-biotin or 7D12-LPETGGG-peptide were incubated with sortase A without nucleophile to 
investigate which are sortase A substrates. Panel A= fl uorescent image of SDS-PAGE gel, panel B= CBB 
stained gel of panel A, panel C= western blot of a similar gel as in A,B, stained with avidin-AlexaFluor680.
1 = 7D12[Fluo], 2 = 7D12[Fluo] after incubation with sortase A, 3 = 7D12[Fluo]-N3-DBCO-biotin, 4 = 7D12
[Fluo]-N3-
DBCO-biotin after incubation with sortase A, 5 = 7D12-LPETGGG-peptide, 6 = 7D12-LPETGGG-peptide 
after incubation with sortase A. Note that incubation of 7D12-LPETGGG-peptide with sortase A leads to 
formation of the smaller hydrolyzed product 7D12-LPET, whereas 7D12[Fluo]-LPET-PEG3-N3-DBCO-biotin 
remains intact as can be seen in panel C.
Using the optimized conditions, 7D12[Fluo] was conjugated to H2N-PEG3-N3 with sortase A Δ59 
to yield 7D12[Fluo]-N3 (Figure 2A+B). After removal of sortase A Δ59, G-8xHis-Vsv and unreacted 
7D12[Fluo] by Ni-NTA depletion, 7D12[Fluo]-N3 was obtained in a 66% yield with a >95% purity 
based on LC-MS (Figure 2D). Similar results were obtained when H2N-PEG3-DBCO was used 
in the reaction with sortase A Δ59 (Figure 5A+B). Furthermore, the methodology has been 
successfully tested and validated for three more VHHs in our lab (supporting information, 
Figure S4) demonstrating the versatility of this approach.
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Figure 5. A) CBB stained SDS-PAGE gel of samples obtained during the sortagging procedure. 1 = 7D12, 2 
= 7D12/sortase A/H2N-PEG3-DBCO reaction mixture, 3 = purified 7D12-DBCO. B) LC-MS characterization 
of 7D12-DBCO showing the deconvoluted spectrum (left) and total mass spectrum (right) (expected 15565 
Da, observed 15562 Da).
Bispecific or bivalent antibody conjugates are valuable compounds for targeted cancer 
therapy26,27. Current approaches to make bispecific or bivalent VHHs often involve genetic 
fusion of VHH open reading frames, allowing production only in head-to-tail fusion format. 
It has already been shown that the affinity of the second VHH in such bispecific constructs 
may be dramatically affected by the presence of the first VHH28. Sortase A technology allows 
the generation of tail-to-tail dimers, leaving antigen binding sites of the individual composing 
VHHs intact20 (Figure 6 and 7A). We tested the validity of this hypothesis by using sortase A 
Δ59 in combination with H2N-PEG3-X linkers to generate 7D12
[Fluo]-N3 and 4E4-DBCO, 4E4 
being a low-affinity Transferrin receptor (TfR)-binding VHH (unpublished results) that is 
used here as a control. After the click reaction (see Figure 7B+C for analysis of the reaction 
products), heterodimer N7D12C[Fluo]-C4E4N could be readily purified from residual monomers 
by size exclusion chromatography, resulting in >90% pure product of 36 kDa (Figure 7D). In 
parallel, we generated conventional head-to-tail bispecific VHHs, with 7D12 and 4E4 separated 
by a [G4S]10 linker or a [G4S]20 linker and a C-terminal C-Flag-6xHis (compounds 
N7D12C-[G4S]
n-
N4E4C and N4E4C-[G4S]n-
N7D12C, Figure 6 and 7A). E.coli expression of these bispecific VHHs 
was successful as shown with SDS-PAGE analysis (Figure 7E+F). Yields were 2-4 mg/L E.coli 
culture. The bispecifics were labeled on the C-terminal cysteine with fluorescein-5-maleimide 
as described for monomeric VHHs, and the correct mass was confirmed with LC-MS (data not 
shown). 
LEGOMEDICINE
103
5
 
VHHA
 
VHHB
 
VHHA
 
VHHB
N C N C
N CC N
G4Sn  nVHHA
c-[G4S]n- 
nVHHB
c
 nVHHA
c- cVHHB
n
C-Flag-6xHis
 
VHHA
N C
C-LPETG-8xHis-Vsv  VHHA
C-LPET-PEG3-N3-DBCO-PEG3-TEPL
 
Figure 6. Schematic representation of the monomeric VHH, head-to-tail bispecific VHH and tail-to-tail 
bispecific VHH and their nomenclature in this report. 
Importantly, in this context both the head-to-tail and the tail-to-tail bispecific VHHs contain 
only one fluorescein molecule, allowing quantitative comparison of the EGFR-binding capacity 
of these formats with 7D12[Fluo]. Constructs were tested in flow cytometry analyses using the 
high EGFR expressing squamous carcinoma cell line A431 (Figure 7G). Compounds N7D12C-
[G4S]n-
N4E4C[Fluo] with both G4S linker lengths and 
N7D12C[Fluo]-C4E4N were equally effective as 
7D12[Fluo] in binding to A431 cells. In contrast, binding to EGFR was reduced with a factor 10 
for compounds N4E4C-[G4S]n-
N7D12C[Fluo] with both G4S linker lengths, confirming that, at least 
for VHH 7D12, epitope binding is hindered by the presence of a VHH at the amino-terminus. 
Thus, bispecific VHHs generated via tail-to-tail click fusion are more robust than head-to-tail 
bispecific VHHs. 
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Figure 7. A) Schematic overview of bispecifi c tail-to-tail (Structure 1) or head-to-tail (Structure 2) VHH 
constructs. In panels B and C SDS-PAGE is shown (fl uorescence signal and CBB staining, respectively) 
depicting the products of the sortase A reaction to produce bispecifi c N7D12C[Fluo]-C4E4N. 1 = 7D12[Fluo], 2 = 4E4, 3 = 
7D12[Fluo]-DBCO, 4 = 4E4 –N3, 5 = 
N7D12C[Fluo]-C4E4N before sephadex G75 purifi cation. D) CBB stained SDS-PAGE 
gel showing subsequent fl ow-through fractions from the sephadex G75 packed column that is used to separate 
bihead N7D12C[Fluo]-C4E4N from monomeric 7D12[Fluo]-DBCO and 4E4-N3. The bracketed lanes contain >95% pure 
N7D12C[Fluo]-C4E4N and are pooled and used for experiments. In panels E and F the expression of bispecifi c head-
to-tail VHHs is depicted with E) fl uorescence signal and F) CBB staining of an SDS-PAGE gel. 1 = N7D12C-
[G4S]10-
N4E4C[Fluo], 2 = N4E4C-[G4S]10-
N7D12C[Fluo], 3 = N7D12C-[G4S]20-
N4E4C[Fluo], 4 = N4E4C-[G4S]20-
N7D12C[Fluo]. F) Flow 
cytometry histogram derived from A431 cells incubated with the various bispecifi c constructs and controls. 
PEGylation is an important modifi cation of nanoparticles that is applied to increase half life in 
the circulation by avoiding rapid clearance by spleen, liver and kidney29. PEGylation of VHHs, 
accomplished by clicking DBCO-PEG to VHH-N3 indeed results in better in vivo characteristics
30. 
Sortase A mediated conjugation of H2N-PEGx yields the interesting option to decorate PEGylated 
nanoparticles with functionally active VHHs. To test this hypothesis we applied click chemistry 
to conjugate 7D12[Fluo]-N3 to benzoyl-poly(ε-caprolactone)-methoxypoly(ethyleneglycol) (ben-
PCL7-mPEG2000) diblock-based micelles, equipped with a small percentage of DBCO groups. 
Ben-PCL7-mPEG2000 diblock-based micelles are biocompatible and biodegradable, and can 
be used as carrier of hydrophobic drugs that can be incorporated in the micellar core31. The 
decoration of micelles with VHHs may increase affi nity of the nanoparticles to targets by an 
avidity effect. Also, this approach allows the generation of multispecifi c drug-loaded targeting 
nanoparticles by simply decorating these with different tumor-targeting VHHs. 
LEGOMEDICINE
105
5
 1H-NMR spectra showed that synthesis of intermediate products (data not shown) and end 
products ben-PCL7-mPEG2000 and ben-PCL7-mPEG2000-DBCO (Figure 8A+B) was successful. 
Micelles were prepared by film-hydration of a mixture of 90% ben-PCL7-mPEG2000 diblock 
polymers and 10% ben-PCL7-mPEG2000-DBCO, resulting in micelles that contain a calculated 
20-30 DBCO click groups per particle. Dynamic light scattering (DLS) experiments of the 
resulting micelles revealed a mean particle size of 28±2 nm and a polydispersity index (PDI) of 
0.32±0.02. 
Figure 8. Chemical structures and corresponding 1H-NMR-spectra of A) Ben-PCL7-mPEG2000 and B) Ben-
PCL7-PEG2000-DBCO measured in CDCl3.
CHAPTER 5
106
DBCO-micelles were decorated with 7D12 via a click chemistry reaction with 7D12[Fluo]-N3 in a 
2:1 DBCO:N3 ratio, to minimize amounts of residual unconjugated 7D12
[Fluo]-N3 after the click 
reaction. To confirm that during handling and experimentation micelles remained intact, we 
included the hydrophobic photosensitizer Meta-tetra(hydroxyphenyl)chlorin (mTHPC) during 
micel formation, equipping the micelles with a fluorescent signal that is readily distinguishable 
from 7D12-associated fluorescein (Figure 9A). SDS-PAGE of the 7D12 conjugated micelles 
revealed a shift of ~3 kDa as compared to the starting material 7D12[Fluo]-N3, indicating 
successful conjugation of 7D12[Fluo]-N3 to the DBCO-block-copolymer with a conjugation yield 
of >85% (Figure 9B,C). Again this conjugation method was verified for other available VHHs in 
our lab (supporting information, Figure S5A+B), showing its versatility. 
 We next tested whether 7D12 on the decorated micelles had retained EGFR affinity by 
performing flow cytometry after incubation with EGFR-positive A431 squamous cell carcinoma 
or EGFR-negative E98 glioma cells32, using 7D12[Fluo] as reference. 7D12[Fluo]-micelles showed 
efficient binding to A431 cells but negligible binding to E98 cells (Figure 9D). Importantly, 
binding of 7D12[Fluo]-micelles led to 70% higher cell-associated fluorescein-fluorescence 
than binding of monomeric 7D12[Fluo]. This may reflect the loading of individual micelles 
with multiple fluorescein-labeled 7D12 moieties or may be due to cooperative binding and 
an avidity effect. Increased binding of 7D12[Fluo]-micelles to A431 cells was confirmed with 
fluorescence microscopy, using the fluorescein signal as readout (Figure 9E, green signal in 
panel 2, compare to 7D12[Fluo] in panel 1). The increase in fluorescein signal was accompanied 
by an increased association of mTHPC fluorescence in 7D12[Fluo]-micelles as compared to 
non-decorated micelles (Figure 9D, right graph and Figure 9E, cyan signal). There was no 
difference in binding of 7D12[Fluo]-micelles and non-decorated micelles to E98 cells, suggesting 
that 7D12[Fluo]-micelles bound as intact particles to A431 cells in an EGFR-dependent manner. 
It must however be noted that there was also some non-specific association of mTHPC with 
both A431 cells and E98 cells. Whether this reflects non-specific binding of micelles or of free 
mTHPC that is released from micelles is difficult to discriminate. 
 These results indicate that the multivalency induced by coupling multiple VHHs to a 
micelle, increased uptake of these particles and their payload in target positive cells. Although 
we restricted ourselves in this study to micelles, this conjugation approach is predicted to work 
with many other types of protein- or PEG-based nanoparticles (e.g. liposomes, polymersomes) 
once a controlled percentage of the building blocks is equipped with a chemical click group. 
Interestingly, this procedure will also allow the controlled synthesis of multi-specific targeting 
nanoparticles, e.g. by preparing nanoparticles with a defined number of non-compatible 
clickable agents such as DBCO and tetrazine moieties, allowing simultaneous conjugation of 
VHH-PEG3-N3 and VHH-PEGx-TCO (trans-cyclooctene). Whereas the free thiol group in VHH-
C-LPET-PEGx-X may be used for maleimide-based conjugation of hydrophilic drugs, micelles 
may be used to simultaneously carry hydrophobic drugs, making this to a versatile approach.
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Figure 9. A) Cartoon of VHH[Fluo]-decorated mTHPC loaded micelles. B) Fluorescein visualization and C) 
CBB staining of the SDS-PAGE analysis of SPAAC reaction between 7D12[Fluo]-N3 and DBCO-micelles. 1 
= 7D12[Fluo], 2 = 7D12[Fluo]-N3, 3 = 10% DBCO-micelles with 5% mTHPC and 4 = 10% DBCO-micelles with 
5% mTHPC and 5% 7D12[Fluo]. D) Median values of fl uorescence intensity as measured in fl ow cytometry. 
Left bargraph = fl uorescein total signal on A431 (EGFR+) and E98 (EGFR -) cells after incubation with 
7D12[Fluo] as a positive control and 7D12[Fluo]-micelles. Right bargraph = mTHPC total signal on both A431 
and E98 cells after incubation with targeted or non-targeted micelles. * indicates signifi cance with p<0.05. 
E) Fluorescence microscopy of A431 cells immediately after incubation with 1 = 7D12[Fluo], 2 = 7D12[Fluo]-
micelles and 3 = non-targeted micelles. Cyan depicts mTHPC, incorporated in the micelles, green depicts 
fl uorescein. The scale bar depicts 20 µM. 
CONCLUSION
Conjugations of VHHs to diagnostic or therapeutic compounds should involve the VHH’s 
carboxy-terminus, distant from the antigen binding site, in order to retain full VHH functionality. 
Here, a bioorthogonal site-specifi c conjugation approach is presented based on sortase A 
and click chemistry, combined with cysteine-maleimide conjugation. This approach allows 
the preparation of molecularly defi ned targeted nanoparticles, preserving targeting potential 
and concomitantly removing unwanted tags from VHHs, a prerequisite for potential clinical 
applications. The potential to perform controlled dual labelling of proteins without loss of 
protein function is an important next step to the preparation of optimized theranostics. 
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METHODS
VHH production and purification
VHH 4E4 is a low affinity VHH (Kd~500 nM) directed against transferrin receptor (TfR) and 
was used as an inert VHH in this study. VHH 7D12 against EGFR has been described in detail 
before17,33. The VHH coding sequences were cloned in frame behind the pelB leader sequence 
in modified pHEN-IX vectors in which the sortase A recognition sequence LPETG, either or not 
preceded by a cysteine, was inserted just upstream of the 8xHis-Vsv tags, resulting in pHENIX-
VHH-LPETG-8xHis-Vsv and pHENIX-VHH-C-LPETG-8xHis-Vsv. Plasmids were transformed 
in E. coli strain ER2566 for standard protein expression. Cells were grown in 2xTY medium 
containing 3.5% (w/v) glycerol and 50 µg/ml ampicillin at 37ºC. At an OD600 between 0.6 and 0.8, 
recombinant protein expression was induced with 1.0 mM isopropyl β-D-thiogalactoside (IPTG, 
Serva, Heidelberg, Germany) at 30ºC for 2.5 hrs. Cells were harvested by centrifugation at 2830 
g for 20 min at 4oC and the periplasmic protein fraction was isolated via osmotic lysis. Cells 
were resuspended in ice cold TES buffer (200 mM Tris pH 8.0, 0.5 mM EDTA, 20% w/v sucrose, 
protease inhibitors (Complete cocktail, Roche, Basel, Switzerland)) and incubated for 20 min 
on ice, followed by centrifugation (4424 g , 20 min, 4oC). After collection of the supernatant the 
bacterial pellet was resuspended in TES buffer containing 15 mM MgSO4 and incubated on 
ice for 20 min. After centrifuging, both supernatants were pooled and incubated with Ni-NTA 
sepharose (IBA, Goettingen, Germany), pre-equilibrated with 50 mM phosphate pH 7.4, 500 
mM NaCl, for 1 hr at 4oC. After washing of the beads with 50 mM phosphate pH 7.4, 500 mM 
NaCl and 10 mM imidazole, 8xHis-tagged proteins were eluted with 500 mM imidazole in 50 
mM phosphate pH 7.4 and 500 mM NaCl. The eluate was dialyzed against 50 mM TRIS pH 7.5 
and 150 mM NaCl in a 3.5 kDa dialysis membrane (Spectrum labs, Los Angeles, CA, USA). 
VHHs were analyzed by SDS-PAGE under reducing conditions (coomassie brilliant blue (CBB) 
staining), followed by analysis on the Odyssey CLx infrared imaging system (LI-COR, Lincoln, 
NE, USA)) and liquid chromatography and mass spectrometry (LC-MS, Shimadzu HPLC 
and Thermo Finnigan LCQ Fleet) on a C4 column. Protein concentrations were determined 
by absorbance at 280 nm using a Nanodrop spectrophotometer (Thermo Fisher Scientific, 
Waltham, MA, USA).
Generation and production of in tandem VHH dimers
In tandem bispecific N7D12C-N4E4C and the converse orientation N4E4C-N7D12C VHHs 
connected by [G4S]10 of [G4S]20 linkers and one C-terminal cysteine and Flag-8xHis-tags 
were synthesized as described before32. In short, reading frames encoding 7D12 and 4E4 
were PCR amplified with primer sets that allowed fusion of the two VHHs, separated 
by [G4S]10 or [G4S]20 linkers. The N-terminal VHH was amplified with M13rev and primer 
(Rev10GS agtaGGATCCGCCACCTCCACTGCCACCGCCACCtgaggagaccgtgacctgggtccc) 
annealing to the VTVSS sequence of the VHH thereby introducing the linker including 
LEGOMEDICINE
109
5
a BamHI site. The C-terminal VHH was amplified with M13 and a primer (Forw10GS 
tcttGGATCCGGCGGGGGAGGTAGTGGGGGTGGGGGCTCAgaggtgcagctggtggagtctggg) annealing 
to EVQLV of the VHH introducing the rest of the linker and also including a BamHI site. The 
resulting fragments were respectively cut with SfiI/BamHI and BamHI/Eco91I and subsequently 
ligated into the vector (SffiI/Eco91I) in a three point ligation. Plasmids were validated by Sanger 
sequencing, and proteins expressed in E.coli strain TG1 and purified as described above. VHHs 
were analyzed by SDS-PAGE under reducing conditions. 
Sortase A production and purification
Plasmid pGBMCS-SortA (Addgene, Cambridge, MA, USA, plasmid #21931), encoding sortase 
A with a deletion of amino acids 1-59 and an N-terminal Gb1 domain was transformed into 
E. coli ER2566 and protein expression induced using standard conditions as used for VHHs. 
After harvesting cells by centrifugation and resuspension in 50 mM TRIS pH 8.0, 150 mM NaCl 
and Cocktail protease inhibitor (Roche), cells were lysed by sonication at 4oC using a Bandalin 
Sonopuls HD2070 sonicator. The bacterial extracts were cleared by centrifugation and the 
6xHis-tagged sortase A Δ59 was purified with Ni-NTA sepharose as described for VHHs. The 
purified sortase A Δ59 was dialyzed in a 3.5 kDa membrane against 50 mM TRIS pH 7.5 and 150 
mM NaCl. The protein was analyzed by SDS-PAGE under reducing conditions (CBB staining) 
and LC-MS. Protein concentration was determined by absorbance at 280 nm using a Nanodrop 
spectrophotometer.
Fluorescein-5-maleimide conjugation 
Monomeric VHH-C-LPETG-8xHis-Vsv and in-tandem bispecific NVHHa
C-[G4S]n-
NVHHb
C-C-Flag-
6xHis (typically ~50-250 µM) were incubated for 15 min at RT with 20 mM tris(2-carboxyethyl)
phosphine (TCEP, Thermo Fisher Scientific, Waltham, MA, USA) to reduce the free thiol group. 
TCEP was removed by filtration over a 10 kDa MWCO centrifugal unit (Amicon, Millipore, 
Billerica, MS, USA) employing 5 washing cycles with 20 mM phosphate pH 7.0, 150 mM NaCl, 
and 5 mM EDTA. Fluorescein-5-maleimide (Thermo Fisher Scientific, Waltham, MA, USA) from 
a 10 mM stock in dimethylformamide was reacted with the reduced VHH construct in a 3:1 molar 
ratio, shielded from light and at RT for 2 hrs to yield VHH[Fluo] or NVHHA
C-[G4S]10/20
NVHHB
C[Fluo]. 
Excess fluorescein-5-maleimide was removed by filtration in a 10 kDa MWCO centrifugal unit 
employing 4 washing cycles with 50 mM Tris pH 7.5 and 150 mM NaCl. Reaction products 
were analyzed by SDS-PAGE under reducing conditions and/or LC-MS. Fluorescein signal was 
visualized on a Chromato-vue TM-20 Transilluminator (UVP) after which the gel was stained 
with CBB. Protein concentration was determined by ultraviolet absorbance at 494 nm (ε494,7D12-
FLUO = 70.000 M
-1cm-1) using a Nanodrop spectrophotometer.
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Sortase A mediated conjugation of click moieties
To produce clickable fluorescent VHHs, 50 µM VHH[Fluo] was incubated overnight at RT in the 
dark with 50 µM sortase A Δ59 and 4.0 mM H2N-PEG3-N3 or H2N-PEG3-DBCO (Jena Biosciences, 
Jena, Germany) in 50 mM Tris pH 7.5, 150 mM NaCl supplemented with 10 mM CaCl2. This 
reaction induces the covalent linkage of PEG linkers via the amine group to the threonine in 
the LPETG tag, releasing G-8xHis-Vsv. Sortase A Δ59, the cleaved G-8xHis-Vsv tag from the 
reacted VHH, and residual intact VHH were removed by adsorption to Ni-NTA sepharose, pre-
equilibrated with 50 mM phosphate pH 7.4 and 500 mM NaCl, for 1 hr at 4oC. Then the excess 
of unreacted PEG linkers was removed by filtration in a 10 kDa MWCO centrifugal unit. The 
reaction product was washed three times with 50 mM phosphate pH 7.4 and 500 mM NaCl, 
and two times with 50 mM phosphate pH 7.4 and 500 mM NaCl containing 20% w/v glycerol. 
The protein constructs were analyzed by SDS-PAGE under reducing conditions and LC-MS, and 
protein concentration was determined by ultraviolet absorbance at 494 nm. 
 To check if LPET-PEG-X is a substrate for sortase A, 20 µM 7D12[Fluo], 20 µM 7D12[Fluo]-N3-
DBCO-biotin and 7D12-GGG-peptide were incubated with 50 µM sortase A Δ59 for 4 hours at 
30°C. Reaction products were analyzed on a CBB stained SDS-PAGE gel and a western blot 
stained with 1:10.000 Avidin-Alexa680 (Invitrogen). 
Generation of VHH dimers via C-to-C conjugation
Tail to tail coupled bispecific VHHs were produced by incubating 4E4-N3 with 7D12
[Fluo]-DBCO 
in a 1:1 molar ratio o/n at RT. Bispecific N7D12C[Fluo]-C4E4N was separated from single VHHs by 
separation on a G75 Sephadex (Pharmacia fine chemicals, Uppsala, Sweden) column. Fractions 
were analyzed on a SDS-PAGE gel under reducing conditions (CBB staining).
Synthesis of diblock copolymers 
Ben-PCL7-PEG2000-methoxy: The amphiphilic diblock copolymer consisting of the hydrophobic 
poly-ε-caprolactone (PCL) and the hydrophilic methoxy-polyethylene glycol (mPEG) were 
synthesized using a method described by Wennink et al. (submitted for publication). Briefly, 
Ben-PCL-OH macromers were prepared using benzyl alcohol as the initiator in the Tin(II) 
ethylhexanoate (Sn(Oct)2) catalyzed ring opening polymerization of ε-caprolactone (CL) (Figure 
10A). The monomer to initiator ratio was chosen such that the average degree of polymerization 
was 7 CL units. The hydroxyl end groups of ben-PCL7-OH were subsequently reacted with 
p-nitrophenyl chloroformate to form p-nitrophenyl carbonate substituted polymers (PNC) 
(Figure 10B). The diblock copolymers were obtained by reacting ben-PCL7-PNC and mPEG2000-
NH2 at 1:1 ratio in toluene at RT (Figure 10C). Average molecular weights of the polymers were 
determined by NMR.
 Ben-PCL7-PEG2000-DBCO: NH2-PEG2000-NH-Boc (1.00 g, 0.5 mmol)(Layson Bio, Arab, 
AL, USA) was added to a solution of ben-PCL7-PNC (0.707 g, 0.5 mmol) in 20 mL dry toluene. 
This mixture was stirred for 1 hr at RT under nitrogen atmosphere (Figure 10D). The mixture 
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was washed at least 6 times with diethyl ether to remove p-nitrophenol. The product was dried 
in a vacuum oven and obtained as a white powder (yield: 97%). Subsequently, 0.2 g of the 
powder was dissolved in 20 ml of DCM and the Boc group was removed by bubbling HCL 
gas through the solution for 15 min (Figure 10E). The product, ben-PCL7-PEG2000-NH2 (0.187 g, 
0.063 mmol), was purified by precipitation in diethyl ether and subsequently dissolved in 20 ml 
of dry DCM. To produce clickable copolymers, dibenzocyclooctyne (DBCO)-NHS (0.025 g, 0.063 
mmol)(Jena Biosciences, Jena, Germany) was added to this ben-PCL7-PEG2000-NH2 solution, 
and the reaction mixture was stirred for 24 hrs at RT under a nitrogen atmosphere (Figure 
10F). The mixture was carefully washed with diethyl ether to remove unreacted DBCO-NHS. 
The product was dried in a vacuum oven and obtained as a white powder (yield: 61%). 
1H (300MHz) NMR spectra were recorded using a Gemini NMR spectrometer (Varian Associates 
Inc. NMR instruments, Palo Alto, CA). Polymers were dissolved in CDCl3 at a concentration of 
0.015 g.ml-1. 
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Figure 10. Synthesis routes for ben-PCL7-mPEG2000 and ben-PCL7-mPEG2000-DBCO. Synthesis of both 
molecules starts with A) ring opening polymerization of ε-caprolactone with benzyl alcohol which affords 
ben-PCL7-OH and B) activation of the hydroxyl end group with p-nitrophenylchloroformate. Then for 
synthesis of amphiphilic ben-PCL7-mPEG2000, C) mPEG2000-NH2 is coupled to the activated ben-PCL7-PNC. 
For synthesis of clickable ben-PCL7-mPEG2000-DBCO D) NH2-PEG2000-NHBoc is coupled to the activated 
ben-PCL7-PNC, E) the Boc protection group is removed with HCl gas, and F) NHS-DBCO is conjugated to 
ben-PCL7-mPEG2000-NH2.
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Dynamic light scattering
The size and the size distribution of empty particles were measured by dynamic light scattering 
(DLS) using a Malvern CGS-3 multiangle goniometer (Malvern ltd., Malvern), consisting of a 
HeNe laser source (λ=632.8nm, 22mW output power), temperature controller (Julabo water 
bath) and a digital correlator ALV-5000/EPP. Time correlation functions were analyzed using 
the ALV-60X0 Software V.3.X provided by Malvern, to obtain the Z-average hydrodynamic 
diameter of the particles (Zave) and the particle size distribution (polydispersity index, PDI). 
The samples were analyzed at 25°C.
7D12 functionalized mTHPC loaded micelle preparation
Micelles were formed by film-hydration. To prepare micelles with 10% functional groups on the 
surface, ben-PCL7-PEG2000 and ben-PCL7-PEG2000-DBCO were dissolved in dichloromethane 
(DCM, Sigma Aldrich, Saint Louis, MS, USA) and mixed in a 9:1 weight ratio in a 5 ml glass 
vial (VWR, Radnor, PA, USA). To this mixture, the hydrophobic photosensitizer mTHPC (meta-
tetra(hydroxyphenyl) chlorine, Biolitec AG, Jena, Germany) in tetrahydrofuran (THF, Sigma 
Aldrich, Saint Louis, MS, USA) was added at a 5% w/w mTHPC/polymer ratio. DCM and THF 
were evaporated under vacuum. The obtained polymer film was hydrated to a 20 mg/ml solution 
in PBS for 2 hrs at RT, gently heated to 60°C, and filtered through a 0.22 µm filter. To obtain 
micelles with 5% surface coverage with VHH 7D12[Fluo], the DBCO-micelles were reacted with 
7D12[Fluo]-N3 in a 2:1 molar DBCO:N3 ratio. To ensure efficient click reaction kinetics, we kept 
the N3 and DBCO concentration >100 µM. Reactions were allowed to proceed overnight in the 
dark at 4oC with continuous shaking at 450 rpm. The final product was analyzed by SDS-PAGE 
under reducing conditions (Fluorescein signal and CBB staining). Non-targeted mTHPC-ben-
PCL7-PEG2000 micelles were prepared according to the same procedure, but without incubation 
with 7D12[Fluo]-N3.
Cell culture
The EGFR-overexpressing squamous carcinoma cell line A431 and the EGFR-negative glioma 
cell line E9834 were cultured in DMEM (Lonza, Basel, Switzerland) supplemented with 10% fetal 
calf serum (FCS, Gibco, Thermo Fisher Scientific, Waltham, MA USA) and 40 µg/ml gentamycin 
(Centrafarm, Etten-Leur, The Netherlands). Cells were incubated at 37°C in 5% CO2 in a 
humidified atmosphere.
Flow cytometry and confocal fluorescence microscopy analysis
Cells were dissociated from culture flasks with 10 mM EDTA, counted and transferred to 
V-bottom shaped 96-well microplates (BD Biosciences, Franklin Lakes, NJ, USA) at 5x105 
cells/well. All subsequent steps were done on ice and all washing steps were executed by 
centrifugation of the plates at 1,500xg for 2 min. Cells were washed twice with PBS and aspecific 
binding sites were blocked by preincubating cells for 10 min with PBA (PBS, 0.5%BSA, 2% 
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FCS). Subsequently cells were incubated with 1 µM fluorescein-labeled VHHs in PBA for 20 
min, washed and resuspended in PBA and analysed using the CyAn ADP analyzer (Beckman 
Coulter, Fullerton, CA, USA).
 To analyse uptake of VHH-micelles with flow cytometry, cells were grown to 80% 
confluency in 8 well chambered glass slides (NUNC, Thermo Fisher Scientific, Waltham, MA, 
USA) and incubated with 20 µM (= 0.6 mg/ml) targeted or non-targeted mTHPC-micelles or 
equimolar VHH concentrations at 37°C for 30 min. Cells were washed twice with warm DMEM 
and dissociated with trypsin at 37°C. Then cells were taken up in PBA and analyzed using the 
CyAn flow cytometer. mTHPC was quantified with parameter FL-8, fluorescein was quantified 
with parameter FL-1. To visualize binding and uptake with confocal microscopy A431 and E98 
cells were grown in 8 wells Lab-Tek borosilicate coverglass chambers (Nunc, ThermoFisher 
Scientific, Waltham, MA, USA), and incubated with the micelles and controls as described for 
flow cytometry. After washing, cells were kept in phenol red free DMEM supplemented with 20 
mM HEPES, and imaged on a TCS SP8 microscope (Leica Microsystems, Mannheim, Germany) 
equipped with a HC PL APO C5 40x/0.85 dry objective. During imaging, cells were maintained 
at 37°C. The UV405 laser was used for excitation, and emission was collected between 500 and 
600 nm for fluorescein and 630 and 730 nm for mTHPC.
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SUPPORTING INFORMATION - 
COMPARISON OF SORTASE A VARIANTS AND APPLICABILITY TO OTHER 
VHHS 
Results: effi ciency of H2N-PEG3-N3 conjugation by sortase A variants
Various variants of S.Aureus wild-type sortase A have been generated, with either an N-terminal 
deletion of 25 amino acids (sortase A Δ25)1 or 59 amino acids (sortase A Δ59)2,3. The molecular 
weight is different, but the enzymatic activity is stated to be identical4. Furthermore, sortase A 
mutants have been developed which show faster LPETG cleavage rates but have lower affi nity 
for H2N-GGG
5.
 It has been shown that H2N-PEGx-X is substrate for sortase A Δ59, but it is not clear how 
the sortase A mutants behave in this respect. Therefore we tested the following variants for 
their capability to use H2N-PEG3-N3 as a substrate: N-terminal 6xHis-tagged sortase A Δ25
1, 
C-terminal 6xHis-tagged sortase A Δ59 with an N-terminal Gb1 domain to enhance solubility of 
the protein6, tri-mutant sortase A (P94S/D160N/D165A), tetra-mutant sortase A (P94S/D160N/
D165A/K196T) and penta-mutant sortase A (P94R/D160N/D165A/K190E/K196T). Sortase A 
variants were expressed and purity and correct mass was confi rmed with CBB stained SDS-
PAGE gels and LC-MS (Figure S1A+B).
75 kDa
50 kDa
37 kDa
25 kDa
20 kDa
A
1 2 3
sortase A ∆25 sortase A ∆59 mutant sortase A
Calculated mass (Da) Observed mass (Da)
sortase A Δ25 21947 21948
sortase A Δ59 24352 24353
tri-mutant sortaseA 17810 17809.8
tetra-mutant sortase A 17783 17783
penta-mutant sortase A 17853.1 17852.5
B
Figure S1. A) CBB stained SDS-PAGE gels showing expression and purity of the sortase A variants, 1 = tri-
mutant sortase A, 2 = tetra-mutant sortase A, 3 = penta-mutant sortase A. B) Size of the various sortase 
A variants as verifi ed with LC-MS. 
Subsequently, they were tested for their capacity to conjugate VHH-LPETG-8xHis-Vsv to H2N-
PEG3-N3 at a molar ratio of 1:500. For penta-mutant sortase A, complete hydrolysis of the 
acyl intermediate was observed within 15 minutes, but there was no incorporation of H2N-
PEG3-N3 (data not shown). The tetra,- and tri-mutant showed effi cient incorporation of H2N-
PEG3-N3 at these concentrations (Figure S2A). Further optimalization showed that at a sortase 
A:VHH-LPETG-8xHis-Vsv ratio of 1:5, <50% and >90% conversion to hydrolyzed VHH-LPET was 
observed after reacting for 4 hours for tri-mutant and tetra-mutant sortase A, respectively 
(Figure S2B). Furthermore >90% and ~50% incorporation of H2N-PEG3-N3 was observed at a 
Calculated 
mass (Da)
Observed mass 
(Da)
Sortase A Δ25 21947 21948
Sortase A Δ59 24352 24 53
tri-mutant sortas  A 17810 17809.8
tetra-mutant sorta  17783 17783
penta-mutant sortase A 17853.1 17852.5
LEGOMEDICINE
115
5
100-fold molar excess of H2N-PEG3-N3 over VHH-LPETG-8xHis-Vsv (Figure S2C). Results of 
these experiments and further optimalization resulted in best effi ciencies with sortase A:VHH-
LPETG-8xHis-Vsv:H2N-PEG3-N3 ratios of 1:2:400 and 1:4:2,000 for tri-mutant and tetra-mutant 
sortase A, respectively. 
 The N-terminally 6xHis-tagged sortase A Δ25 effi ciently incorporated H2N-PEG3-N3, 
however, during the reaction, hydrolysis of sortase A Δ25 at the N-terminus was observed 
(Figure S2D). The fi nal reaction mixture therefore contained non-6xHis-tagged sortase A Δ25 
that could not be removed with Ni-NTA beads. This variant was therefore excluded from further 
work. 
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Figure S2. A) Western blot (left) and CBB stained SDS-PAGE gel (right) showing time-dependent cleavage 
of VHH-LPETG-8xHis-Vsv and subsequent incorporation of H2N-PEG3-N3 by different sortase A mutants, 
followed by chemical clicking with DBCO-biotin. The control represents intact VHH-LPETG-8xHis-Vsv and 
the other lanes contain the reaction mixture of 10 µM VHH-LPETG-8xHis-Vsv with 5 µM sortase A and 5 
mM H2N-PEG3-N3 at various incubation times. On the western blot the VHH-LPETG-8xHis-Vsv is stained in 
green with anti-Vsv and anti-mouse DyeLight800. VHH-LPET-PEG3-N3-DBCO-Biotin is stained in red with 
Streptavidin Alexa680 conjugate. Since during sample heating the sortase A protein reacts with DBCO-
CHAPTER 5
116
biotin as well, this product is also visible as a red band on the blot . B) CBB stained SDS-PAGE gel showing 
the rate of hydrolysis of the acyl intermediate formed when incubating 10 µM VHH-LPETG-8xHis-Vsv with 
0.5 and 2 µM tri-, and tetra-mutant sortase A. C) CBB stained SDS-PAGE gel showing either hydrolysis or 
incorporation of 200 µM or 1000 µM H2N-PEG3-N3 when incubating 10 µM VHH-LPETG-8xHis-Vsv with 5 
µM tri,- or tetra-mutant sortase A. 1 = tri-mutant sortase A reaction mixture, 2 = control reaction mixture 
without NH2-PEG3-N3, 3 = tetra-mutant sortase A reaction mixture. D) LC-MS deconvoluted spectrum 
showing the intact sortase A Δ25, and the 18226 Da product resulting from cleavage of the N-terminal 
domain. E) CBB stained SDS-PAGE gel showing the rate of hydrolysis of the acyl intermediate formed 
when incubating 20 µM VHH-LPETG-8xHis-Vsv with increasing concentrations of sortase A Δ59 for either 
overnight at room temperature or 4 hours at 30ºC. Lane 1 = intact VHH-LPETG-8xHis-Vsv, lane 2 to 6 
represent ratios of sortase A Δ59:VHH-LPETG-8xHis-Vsv of 1:20, 1:4, 1:2, 1:1 and 2.5:1, respectively. 
For sortase A Δ59, the optimal sortase A:VHH-LPETG-8xHis-Vsv ratio was 2.5:1 when reacting 
for 4 hours at 30°C (Figure S2E). Incorporation of H2N-PEG3-N3 was found to be >90% complete 
when adding an 100-fold molar excess over VHH-LPETG-8xHis-Vsv (Figure S3A). From these 
experiments we deduced a sortase A:VHH-LPETG-8xHis-Vsv:H2N-PEG3-N3 ratio of 2.5:1:200. 
When using these conditions in an overnight reaction at room temperature however, we still 
observed uncleaved VHH-LPETG-8xHis-Vsv, so we increased the VHH concentration and found 
that a sortase A:VHH-LPETG-8xHis-Vsv:H2N-PEG3-N3 ratio of 1:1:80 led to complete probe 
incorporation. 
Results: comparison of H2N-GGG to H2N-PEG3-N3 incorporation 
 Incorporation of H2N-PEG3-N3 by tri-mutant sortase A and sortase A Δ59 was compared 
to incorporation of H2N-GGG, the classical substrate of the enzyme. For sortase A Δ59 >90% 
incorporation was observed at a 25-fold molar excess of H2N-GGG over VHH-LPETG-8xHis-
Vsv, and at a 100-fold molar excess for H2N-PEG3-N3 (Figure S3A). H2N-GGG incorporation by 
tri-mutant sortase A is 10x more efficient than H2N-PEG3-N3 incorporation, since complete 
incorporation of H2N-GGG was already observed at a 20-fold molar excess of H2N-GGG over 
VHH-LPETG-8xHis-Vsv compared to a 200-fold molar excess of H2N-PEG3-N3 (Figure S3B).
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Figure S3. A) LC-MS analysis showing total mass spectra of the total reaction mixture of 20 µM VHH-
LPETG-8xHis-Vsv, 100 µM sortase A Δ59 and either 0.05 mM H2N-GGG, 0.5 mM H2N-GGG, 0.5 mM H2N-
PEG3-N3 or 2 mM H2N-PEG3-N3 after 4 hours at 30°C. B) LC-MS analysis showing deconvoluted (left) and 
total mass (right) spectra of the total reaction mixture of 20 µM VHH-LPETG-8xHis-Vsv, 10 µM tri-mutant 
sortase A and either 0.2 mM or 2 mM of H2N-GGG or H2N-PEG3-N3 after 4 hours at 30°C.
Results: applicability of sortase A conjugations to other VHHs 
Sortase A as a method to produce clickable VHHs can also be applied to other VHHs, as 
is shown by successful production of A9-N3, A9-DBCO, CC7-N3
7 and CC7-DBCO (Figure 
S4A+B+C+D, respectively). The azide functionalized A9 and CC7 could also be conjugated 
successfully to ben-PCL7-mPEG2000-DBCO polymers as observed on CBB stained SDS-PAGE 
gels (Figure S5A+B). Furthermore NCC7C-CCC7N dimers could be produced with the 2 clickable 
VHHs, as was verified with LC-MS (Figure S5C), and this product was stable over 50 hours at 
37°C (Figure S5D).
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Figure S4. CBB stained SDS-PAGE gels (1 = unconjugated VHH-LPETG-8xHis-Vsv, 2 = sortase A reaction 
mixture, 3 = purifi ed VHH-DBCO or VHH-N3) and LC-MS deconvoluted (upper) and total mass (lower) 
spectra showing successful conjugation of (A) A9-N3 (expected 14809.5 Da, observed 14808.8 Da and a 
small fraction of unknown composition of 14985.3 Da), (B) A9-DBCO (expected 15114.9 Da, observed 15115 
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Da and a small fraction of unknown composition of 15636 Da), (C) CC7-N3 (expected 15425.1 Da, observed 
15427.9 Da and a small fraction of unknown composition of 15604.4 Da), (D) CC7-DBCO (expected 15730.5 
Da, observed 15730 Da). 
1           2           3          1            2           3           
A
20 kDa
25 kDa
75 kDa
37 kDa
50 kDa
15 kDa
20 kDa
25 kDa
75 kDa
37 kDa
50 kDa
15 kDa
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D
20 kDa
25 kDa
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1                  2       3        4C
VHH-N3-DBCO-
mPEG2000-PCL7-Ben
VHH-N3
B
VHH-N3-DBCO-
mPEG2000-PCL7-Ben
VHH-N3
Figure S5. A) CBB stained SDS-PAGE gel showing the SPAAC reaction between A9-N3 and DBCO micelles. 
1 = A9-N3, 2 = 10% DBCO micelles, 3 = 10% DBCO micelles and 10% A9-N3. B) CBB stained SDS-PAGE gel 
showing the SPAAC reaction between CC7-N3 and DBCO micelles. 1 = 10% DBCO micelles, 2 = CC7-N3, 3 
= 10% DBCO micelles and 10% CC7-N3. C) LC-MS analysis showing deconvoluted (upper) and total mass 
spectrum (lower) of NCC7C -CCC7N before sephadex purifi cation (expected 31151 Da, observed 31151 Da 
and 15729 Da (excess of CC7-DBCO)). D) CBB stained SDS-PAGE analysis showing the stability of NCC7C
-CCC7N. 1, 2, 3, 4 = NCC7C-CCC7N after 0, 4, 20 and 50 hours incubation at 37°C, respectively.
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Methods: efficiency of H2N-PEG-N3 conjugation by sortase A Δ25 and sortase A 
mutants
pQE30-SortA (sortase A Δ25) and pQE29-penta-mutant sortase A, pQE29-tetra-mutant 
sortase A or pQE29-penta-mutant sortase A were transformed into E.Coli ER2566 and protein 
was produced and purified as described for pGBMCS-SortA (sortase A Δ59). Purity of the 
protein was assessed by CBB stained SDS-PAGE gel under reducing conditions and LC-MS. 
Concentration was determined by absorbance at 280 nm using a Nanodrop spectrophotometer. 
 To check the capacity of the tri,- tetra,- and penta,- mutant sortase A and sortase A Δ25 to 
incorporate H2N-PEG3-N3, 10 µM VHH-LPETG-8xHis-Vsv was incubated with 5 µM of the sortase 
A variants and 5 mM H2N-PEG2-N3 in presence of 10 mM CaCl2 in 50 mM TRIS-HCL pH 7.5, 
NaCl 500 mM. Samples of the reaction mixture were taken after various incubation times, and 
excess H2N-PEG3-N3 was removed by filtration over a 10 kDa MWCO centrifugal unit employing 
4 washing cycles with PBS. EDTA was added to a final concentration of 20 mM, to inactivate 
sortase A. Then VHHs were incubated with a 500 fold molar excess DBCO-biotin (Sigma) for 2 
hours at 30°C, and these samples were run on a 15% SDS-PAGE gel under reducing conditions, 
after which they were blotted onto nitrocellulose. The blot was blocked with LI-COR blocking 
buffer and incubated with 1:20,000 Streptavidin AlexaFluor680 (Invitrogen) and 1:2,000 mouse-
anti-Vsv and goat-anti-mouse IgG Dylight800 (Thermo). Signal was visualized on the Odyssey 
CLx infrared imaging system.  
 The effect of sortase A enzyme concentrations was determined by incubating 10 uM VHH-
LPETG-8xHis-Vsv with 2 or 0.5 µM tri-mutant or tetra-mutant sortase A for 7 hours at RT. 
Again samples were taken after various incubation times, and the presence of hydrolyzed acyl 
intermediate was analyzed on CBB stained 15% SDS-PAGE gels under reducing conditions. 
The effect of H2N-PEG3-N3 was determined by incubating 10 µM VHH-LPETG-8xHis-Vsv with 5 
µM sortase and either 200 µM of 1000 µM H2N-PEG3-N3 for 4 hours at 30°C. Reaction products 
were analyzed on CBB stained SDS-PAGE gel.
 For sortase A Δ59 the optimal sortase A:VHH ratio was determined by incubating 20 µM 
VHH-LPETG-8xHis-Vsv with increasing concentrations of sortase A Δ59 for 4 hours at 30°C or 
overnight at room temperature. Reaction products were analyzed on CBB stained SDS-PAGE 
gel. 
Methods: comparison of H2N-GGG to H2N-PEG3-N3 incorporation 
To compare efficiency of H2N-GGG versus H2N-PEG3-N3 incorporation by sortase A Δ59, 20 µM 
VHH-LPETG-8xHis-Vsv was incubated with 100 µM sortase A Δ59 and either 0.05 mM or 0.5 
mM of H2N-GGG or 0.5 mM or 2 mM of H2N-PEG2-N3 in presence of 10 mM CaCl2 in 50 mM 
TRIS-HCL pH 7.5, NaCl 500 mM for 4 hours at 30°C. Similar experiments were performed 
for tri-mutant sortase A by incubating 20 µM VHH-LPETG-8xHis-Vsv with 10 µM tri-mutant 
sortase A and either 0.2 mM or 2 mM of H2N-GGG or H2N-PEG3-N3 for 4 hours at 30°C. Whole 
reaction mixtures were analyzed using LC-MS. 
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Methods: applicability of sortase A conjugations to other VHHs 
VHHs CC77 and A9 (non-published) were expressed and purified as described for 7D12 and 4E4. 
Conjugation of SPAAC click probes was done by incubating 50 µM VHH-LPETG-8xHis-Vsv with 
50 µM sortase A Δ59 and 4 mM H2N-PEG3-X in presence of 10 mM CaCl2 in 50 mM Tris-HCL 
pH 7.5 and 150 mM NaCl overnight at RT. VHH-N3 was conjugated to DBCO micelles and VHH-
DBCO as described for 7D12 in the main text. 
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ABSTRACT
Overexpression of (mutated) receptor tyrosine kinases is a characteristic of many aggressive 
tumors and induction of receptor uptake has long been recognized as a therapeutic modality. 
A conjugate of a synthetically produced cell penetrating peptide (CPP), corresponding to amino 
acids 38-59 of human lactoferrin, and the recombinant llama single-domain antibody (VHH) 
7D12 that binds the human epidermal growth factor receptor (EGFR), was generated via sortase 
A-mediated transpeptidation. The conjugate blocks EGF-mediated EGFR activation with higher 
efficacy than both modalities alone, a phenomenon that is caused by both effective receptor 
blockade and internalization. Thus, the VHH-cell penetrating peptide (VHH-CPP) conjugate 
shows a combination of activities that implements a highly powerful new design principle to 
block receptor activation by its clearance from the cell surface.
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INTRODUCTION
The last decade has been characterized by enormous efforts to personalize the treatment 
of cancer patients via specific targeting of cancer cells, thereby reducing the adverse effects 
of chemotherapies that affect all proliferating cells in the body1. An important prototypic 
tumor target is the epidermal growth factor receptor (EGFR), a receptor tyrosine kinase 
which regulates many cellular processes such as proliferation, survival, cell motility and 
differentiation2. Deregulation of EGFR signaling caused by amplifications, activating point 
mutations, and truncations occurs in a wide range of tumor types, and it correlates with 
shortened disease-free and overall survival3-5. EGFR-targeting monoclonal antibodies (e.g. 
panitumumab, cetuximab) have become part of routine cancer treatment6-7. These monoclonal 
antibodies mainly act by blocking ligand binding and receptor dimerization8, and by promoting 
internalization of EGFR and its degradation9. 
 However, tumors acquire resistance to these agents via multiple mechanisms10-12. Also, 
because of their large size antibodies can only poorly penetrate tumors after extravasation. 
Thus, there is dire need to add new therapeutic modalities with novel molecular characteristics 
to the repertoire. 
 Single variable domains of heavy chain llama antibodies (VHHs) are an interesting 
alternative for standard antibodies. VHHs are characterized by high stability, small size and 
low immunogenicity while affinity for its target antigens can be as high as that of conventional 
antibodies13-14. VHH 7D12, which binds to domain III of the EGFR molecule, competes for binding 
of EGF and of the therapeutic antibody cetuximab15. However, because of their monovalency 
these molecules are poorly active in cross-linking receptors and inducing internalization16. 
Cell penetrating peptides (CPPs) have become a broadly utilized tool to drive cellular uptake 
of molecules that otherwise do not enter cells17, such as oligonucleotides, nanoparticles, 
peptides and proteins18-22. A peptide corresponding to amino acids 38-59 of the human milk 
protein lactoferrin acts as an effective CPP23-24. This peptide (referred to as hLF) is of specific 
interest as it is expected to be non-immunogenic because of its human origin and also because 
it contains relatively little cationic residues which limits toxicity. 
 So far, the rationale for the use of CPPs has been restricted to the intracellular delivery 
of cargo. Here, we hypothesized that combination with a CPP would endow the VHH with new 
effector functionalities and that combining the receptor targeting capacity of the VHH with the 
internalization-inducing capacity of the CPP should accelerate clearance rate of the receptor 
from the cell surface.
 Conventional methods to conjugate CPPs to proteins are faced with several challenges. 
Expression of CPP-fusion proteins is frequently compromised by poor expression of the 
polycationic peptide stretches. Our attempts to produce a functional VHH-hLF conjugate 
in E. coli was also ineffective (data not shown). For standard protein conjugations using 
side chain functionalities, maintenance of the chemical and biological properties of both 
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conjugate constituents strongly depends on the number and distribution of reactive groups. 
Intein-mediated protein ligation has been used to site-specifi cally introduce handles for click 
chemistry but this is a laborious method25. Alternatively, coupling can be performed by sortase 
A-mediated transpeptidation26-29. 
 Herein, we used the enzyme sortase A for site-specifi c conjugation of 7D12 and the anti-
cMet VHH G230, to GGG-hLF[Fluo] (Figure 1). The hLF peptide was synthesized with a C-terminal 
fl uorescein label to enable detection of cell binding and traffi cking. VHH G2 was included as a 
control since c-MET expression in A431 squamous carcinoma cells, used in this study, is much 
lower than EGFR expression (http://www.proteinatlas.org/.) 
VHH LPETG-8xHis-Vsv
G-8xHis-Vsv
LPET S
O
Sortase A
Sortase A
HS
VHH LPETGGG-
VHH
         GGG-
         GGG- G G G K C F Q W Q R N
     
M R
KHOOC- K R K I C S V P P G R V
     
Fluo
H2N-
=
Figure 1. Scheme of site-specifi c conjugation of a VHH equipped with a C-terminal LPETG amino acid tag 
to GGG-hLF39-58 with sortase A. The used sortase A variant carried a carboxyterminal 6xHis-tag to allow 
a rapid and simple purifi cation of the conjugate via Ni-bead adsorption of the byproducts.By placing the 
LPETG sortase A recognition sequence before the 8xHis-Vsv tags, these tags were removed during the 
reaction.
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RESULTS AND DISCUSSION
Sortase A and VHH 7D12-LPETG-8xHis-Vsv or VHH G2-LPETG-8xHis-Vsv were expressed in 
E.Coli29. After purification of VHHs and sortase A from bacterial lysates, the GGG-hLF[Fluo] was 
coupled to the VHH via sortase-mediated transpeptidation and the VHH-LPETGGG-hLF[Fluo] 
(referred to as VHH-hLF[Fluo], Figure 2) conjugates were purified. For 7D12 and G2, coupling 
efficiencies were 89% and 91% respectively (Figure 3A). The masses observed for 7D12-hLF[Fluo] 
(18410 Da) and G2-hLF[Fluo] (18988 Da) corresponded well to the calculated molecular weights of 
18415.5 Da and 18993.3 Da (Figure 3B). 
 For the non-conjugated VHHs, a cysteine residue was introduced just before the LPETG 
sequence, resulting in VHH-C-LPETG-8xHis-Vsv. The free thiol was used for labeling with 
maleimide fluorescein, resulting in 7D12-C[Fluo]-LPETG-8xHis-Vsv and G2-C[Fluo]-LPETG-8xHis-
Vsv (referred to as VHH-C[Fluo], Figure 2), enabling monitoring of cell association and uptake 
for the VHHs. Successful and efficient conjugation was validated using LC-MS (Figure 3C). 
Of importance, all VHHs and conjugates carried exactly one fluorescein per VHH molecule, 
allowing reliable comparison of cell-associated fluorescence in functional studies.
 
VHH
N C
C[Fluo]-LPETG-8xHis-Vsv  VHH-C[Fluo]
 
VHH
N C
-LPETGGG-hLF38-59[Fluo]  VHH-hLF[Fluo]
Figure 2. Schematic representation of the VHHs and the nomenclature used herein. 
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Figure 3. Analytical characterization of the conjugates. A) Coomassie brilliant blue stained SDS-PAGE 
gel of the reaction products and controls (1 = input VHH-LPETG-8xHis-Vsv, 2 = sortase A cleaved VHH-
LPET, 3 = purified VHH-hLF[Fluo]). Upper picture shows absorption at 680 nm and lower picture shows 
fluorescein signal using UV excitation. LC-MS characterization of B) 7D12-hLF[Fluo] (upper, observed 18410 
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Da, calculated 18415.5 Da) and G2-hLF[Fluo] (lower, observed 18988 Da, calculated 18993.3 Da) and C) 7D12-
C[Fluo] (upper, observed 18262.0 Da, calculated 18265.0 Da) and G2-C[Fluo] (lower, observed 18845.2 Da, 
calculated 18842.9 Da). The left graphs show the UV absorbance spectrum, the middle graphs the total 
mass spectrum of the UV-peak bracketed by arrowheads and the right graphs the deconvoluted mass 
spectrum. 
Next, we assessed the functional consequences of the combination of moieties in the conjugates. 
Cellular binding, uptake and subcellular distribution of 7D12-hLF[Fluo] and G2-hLF[Fluo] were 
investigated in A431 cells using confocal laser scanning microscopy (Figure 4). Unconjugated 
GGG-hLF[Fluo] showed a punctate intracellular staining, indicating endocytic uptake, as typically 
observed for this CPP at concentrations below 10 µM23 (Figure 4). 7D12-C[Fluo] showed intense 
membrane staining. In comparison to the free CPP, 7D12-hLF[Fluo] showed a much stronger 
cell-associated fluorescence than observed for GGG-hLF[Fluo] alone, but the distribution of the 
conjugate was much more endocytotic. 
7D12-C[Fluo] 7D12-hLF[Fluo]
G2-C{Fluo] G2-hLF[Fluo]
GGG-hLF[Fluo]
Figure 4. Cell binding and uptake of the constructs. A431 cells were incubated with 2 µM of the constructs 
for 30 min, washed and imaged by confocal laser scanning microscopy. The scale bar denotes 20 µm.
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Cell-associated fluorescence of the conjugate was consistently lower than that of the free 
VHH. To check whether this was the result of loss of fluorescein fluorescence due to acidic 
pH in endosomes, chloroquin was added after construct incubation to inhibit endosomal 
acidification31. No increase in fluorescence was observed (data not shown). The dissociation 
constant derived from binding under non-internalizing conditions was 11.9 ± 1.2 nM for 7D12 
alone and 25.5 ± 2.5 nM for the conjugate (Figure 5).
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Figure 5. Cell binding of the constructs. Binding of various concentrations of 7D12-C[PS]- and 7D12-C[PS]- 
hLF to the cells was measured in cell ELISAs under non-internalizing conditions using PS fluorescence at 
700 nm as readout. Note that in this experiment IRDye700DX with molecular weight similar to Fluorescein, 
was conjugated to the free thiol.
In agreement with low expression levels of c-Met in A431 cells, G2-C[Fluo] showed no cell-
associated fluorescence (Figure 4). Conjugation of GGG-hLF[Fluo] to G2 induced some uptake, in 
line with the activity of hLF as a CPP but uptake of G2-hLF[Fluo] was much lower than of 7D12-
hLF[Fluo] indicating that the interaction with the EGFR is crucial for efficient internalization. To 
further test EGFR specificity, identical assays were performed with cells of the EGFR-negative 
high-grade astrocytoma cell line E98, and no uptake was seen in these cells except, again, 
for little uptake of GGG-hLF[Fluo] (Figure 6). These experiments also show that affinity of 7D12 
is not determined by the carboxyterminal 8xHis-Vsv tag. This is to be expected since target 
recognition of VHHs is mainly determined by the complementary determining regions (CDRs), 
which are located distant from the carboxy-terminal tags. Indeed the crystallized complex of 
7D12 with EGFR showed that CDR1 and CDR3 contact domain III of EGFR32.
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7D12-C[Fluo] 7D12-hLF[Fluo]GGG-hLF[Fluo]
G2-C{Fluo] G2-hLF[Fluo]
Figure 6. Cell binding and uptake of the constructs. E98 cells were incubated with 2 µM of the constructs 
for 30 min, washed and imaged by confocal laser scanning microscopy. The scale bar denotes 20 µm.
Next, we tested our hypothesis that 7D12-hLF[Fluo] induces EGFR internalization. Under normal 
physiological conditions, internalization of growth factor receptors is a consequence of receptor 
activation. However, internalization can also be induced in the absence of activation through 
crosslinking by antibodies or other binding moieties33-36. A431 cells were incubated with the 
various constructs in presence of LysoTracker Red, and immunostained for early endosome 
marker EEA-1 and EGFR. Colocalization of EGFR and early endosomes/lysosomes was 
increased in cells incubated with 7D12-hLF[Fluo] compared to control cells and cells incubated 
with 7D12-C[Fluo], which indicates that 7D12-hLF[Fluo] induces endosomal uptake of EGFR (Figure 
7A+B). 
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Figure 7. EGFR internalization after incubation with the constructs. A431 cells were incubated with 2 µM 
of the various contructs for 30 minutes or left untreated (control) in presence of LysoTracker Red DND99. 
Subsequently they were fixed, immunostained with anti-EGFR and anti-EEA-1 and imaged (A) Scale bar 
denotes 10 µM. The intensity per pixel of EEA-1/LysoTracker positive EGFR vesicles was quantified (B). * 
indicates significance for p<0.05, ** for p<0.01 and *** for p<0.001.
Besides induction of uptake, conjugation to hLF could also exert its effect by increased blockade 
of EGF binding as compared to 7D12. To address this point, A431 cells were incubated with 
conjugates and subsequently with EGF-biotin and streptavidin-Alexa594. Only 7D12-hLF[Fluo] 
caused near-complete inhibition of EGF binding (Figure 8). Since a major part of the conjugate 
was still membrane bound we conclude that the conjugate blocks the EGF binding site, or 
drives the receptor into a conformation that is incompatible with ligand binding. 7D12-C[Fluo] 
showed only a minor decrease in EGF binding and internalization compared to controls, and 
GGG-hLF[Fluo] did not inhibit EGF binding. To further investigate the separate effects on affinity 
and induction of target internalization, these experiments should be performed with other 
VHHs that bind non-internalizing target proteins. 
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Figure 8. Inhibition of EGF binding and internalization by the constructs. A431 cells were incubated with 2 
µM of the various contstructs for 30 min or left untreated (control), after which they were incubated with 
EGF-biotin and streptavidin-Alexa594 and imaged (A). The scale bar denotes 10 µm. Total fluorescence 
of EGF (both internalized and membrane bound) was measured in regions of interest drawn in the 
corresponding brightfield images (B). ** indicates significance for p<0.01 and *** for p<0.001.
As the most critical aspect in relation to activity, we tested whether the constructs also inhibited 
receptor activation by EGF. To this end we incubated A431 cells with 7D12-C[Fluo] or 7D12-hLF[Fluo], 
using again the G2 variants as controls, followed by a 5-minute EGF activation. After fixation of 
cells immunofluorescent staining of EGFR and phosphorylated EGFR (pEGFR) was performed 
(Figure 9). 7D12-hLF[Fluo], but not hLF[Fluo] or 7D12-C[Fluo] significantly inhibited EGF-induced 
phosphorylation of EGFR. Incubation with constructs without EGF activation did not stimulate 
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EGFR phosphorylation, and as expected, G2 constructs did not interfere with EGFR activation 
by EGF (Figures 10 and 11). These results were confirmed on western blot (Figure 12). The 
lack of inhibition of EGF-induced EGFR activation by 7D12 is not in accordance with findings of 
Roovers et al.37, who described a dose-dependent inhibition of EGF-induced phosphorylation by 
7D12. The discrepancy between these results may be due to the experimental set up, as A431 
cells express higher levels of EGFR than the HER14 cells that were used in the Roovers study. 
Also the difference in concentrations of EGF (16.6 nM as compared to 8 nM in the Roovers 
study), may have affected the results. 
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Figure 9. Inhibition of EGF induced EGFR phosphorylation by the constructs. A431 cells were incubated 
with 2 µM of the various constructs for 30 min or left untreated (control). After serum starvation, cells were 
activated with EGF and fixed. Then cells were immunostained with anti-EGFR or anti-pEGFR (A). Scale bar 
denotes 20 µm. Fluorescence intensities per pixel of the pEGFR signals were quantified (B). ** indicates 
significance for p<0.01, ** for p<0.001. 
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Figure 10. The constructs alone do not activate EGFR. A431 cells were incubated with 2 µM of the 
various constructs for 30 min or left untreated (control). After serum starvation ad fixation, cells were 
immunostained with anti-EGFR (A) or anti-pEGFR (B). Scale bar denotes 20 µm. 
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Figure 11. G2-constructs do not interfere with EGFR activation. A431 cells were incubated with 2 µM of the 
various constructs for 30 min or left untreated (control). After serum starvation, cells were activated with 
EGF. The samples were immunostained with anti-EGFR (A) or anti-pEGFR (B). Scale bar denotes 20 µm.
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Figure 12. 7D12-LPETGGG-hLF38-59 inhibits EGF induced EGFR activation. A431 cells were incubated for 
30 min with either 7D12 or 7D12-hLF. After serum starvation cells were activated with EGF. Control cells 
were not incubated with constructs or EGF. Cytosolic extracts of the cells were immunoblotted (A) and 
normalized pEGFR levels were determined (B). * indicates significance for p<0.05.
In summary, we show that sortase A-mediated conjugation of synthetic CPPs to the anti-
EGFR VHH 7D12 prevents EGF binding and EGFR activation with higher efficacy than 7D12 
alone. Such protocols can be easily implemented for conjugation of other VHHs and overcome 
problems associated with the recombinant expression of CPP fusion proteins. This opens the 
way for further modifications of VHHs to produce VHH drug conjugates or conjugates for in vivo 
imaging. 
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METHODS
Cell culture
Human epidermoid carcinoma A431 cells, carrying an amplification of the EGFR gene38, and 
EGFR negative high grade astrocytoma cells E9839-40, were cultured in DMEM (Lonza, Basel, 
Switzerland) supplemented with 10% fetal calf serum (FCS) (Gibco, Thermo Fisher Scientific, 
Waltham, MA, USA) and 40 µg/ml gentamycin (Centrafarm, Etten-Leur, The Netherlands). 
Cells were incubated at 37°C in 5% CO2 in a humidified atmosphere unless stated otherwise. 
The bacterial strain used for VHH expression was E.Coli ER2566, and the plasmids encoding 
VHH-7D12 and VHH-G2 were a kind gift from Paul van Bergen en Henegouwen (University of 
Utrecht, the Netherlands). 
Peptide modification
The GGG-hLF[Fluo] was purchased from EMC microcollections (Tübingen, Germany). An 
additional lysine residue was introduced at the C-terminus to which carboxyfluorescein was 
coupled. The peptide was dissolved in 50 mM HEPES buffer pH 8.0 to ensure disulfide bridge 
formation24. The concentration of the peptide was determined by measuring the absorbance of 
fluorescein at 492 nm assuming an extinction coefficient of 75 000 M−1cm−1. 
Sortase A expression
Plasmid pGBMCS-SortA (Addgene, Cambridge, MA, USA) was transformed into E. coli ER2566. 
A single, antibiotic-resistant clone was picked and grown over night at 37°C at 200 rpm in 
2xTY medium containing 1% glucose w/v and 50 µg/mL ampicillin (Thermo Fisher Scientific, 
Waltham, MA, USA). The overnight culture was diluted 1/100 in 2xTY supplemented with 50 
µg/mL ampicillin and incubated at 37°C at 200 rpm. At OD600 ≥ 0.6, the protein expression was 
induced with 1.0 mM isopropyl β-D-thiogalactoside (IPTG, Serva, Heidelberg, Germany) at 30°C 
for 3 hrs. Cells were harvested by centrifugation at 3500 rpm for 20 min at 4°C. The cell pellet 
was then resuspended in 50 mM Tris-HCl, pH 7.5 and 150 mM NaCl and lysed by sonication 
at 4°C. The sonicated lysate was centrifuged at 6000 rpm for 15 min at 4°C. The supernatant 
was incubated with Ni-NTA Agarose beads (IBA, Goettingen, Germany) pre-equilibrated with 
50 mM phosphate pH 7.4, and 500 mM NaCl for 1 hr at 4°C. The beads were washed with 50 
mM phosphate buffer pH 7.4, 500 mM NaCl, and 10 mM imidazole (Sigma Aldrich, Saint Louis, 
MO, USA) and the protein was eluted with 50 mM phosphate buffer pH 7.4, 500 mM NaCl, and 
500 mM imidazole. Imidazole was removed by dialysis in a 3.5 kDa membrane against 50 mM 
Tris-HCL pH 7.5, and 150 mM NaCl, and the protein was subsequently concentrated in a 10 
kDa MWCO centrifugal unit (Amicon, Millipore, Billerica, MS, USA). The protein was analyzed 
by SDS-PAGE under reducing conditions and liquid chromatography-mass spectrometry (LC-
MS, Shimadzu HPLC and Thermo Finnigan LCQ Fleet) on a C4 column. Protein concentration 
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was determined by ultraviolet absorbance at 280 nm using a Nanodrop spectrophotometer 
(Thermo Fisher Scientific, Waltham, MA, USA). 
VHH expression
The cDNA encoding the sequences of VHHs 7D12 and G2 (see results Supporting information) 
were PCR cloned from vectors Pur8100-7D12 and Pur8100-G2 into vector pHENIX as SfiI/NotI 
fragment. The pHENIX vector contains a carboxy-terminal sequence encoding the amino-acids 
(C)LPETG with an optional cysteine for maleimide chemistry and the 8xHis and Vsv tag. ER2566 
E.Coli cells were transformed with these plasmids and single, antibiotic-resistant clones were 
picked for both VHHs and grown over night at 37°C at 200 rpm in 2xTY medium containing 
1 % glucose w/v and 50 µg/mL ampicillin. The overnight culture was diluted 1/100 in 2xTY 
supplemented with 50 µg/ml ampicillin and incubated at 37°C at 200 rpm. At OD600 ≥ 0.6, VHH 
expression was induced with 1.0 mM IPTG for 2.5 hrs at 30°C at 200 rpm. The periplasmic 
fraction was obtained by harvesting the cells through centrifugation (4000 rpm, 15 min, 4°C) 
and resuspending the pellet in ice-cold TES (200 mM Tris-HCL pH 8.0, 0.5 mM EDTA, 500 mM 
sucrose). After 20 min incubation on ice, the suspension was centrifuged (5000 rpm, 20 min, 
4°C) and the supernatant containing the VHHs was collected. The pellet was resuspended 
in ice-cold TES with MgSO4, left on ice for 15 min and spun down (5000 rpm, 20 min, 4°C) 
after which the supernatant was collected. The 8xHis-tagged VHHs were purified using Ni-NTA 
sepharose beads as described above for sortase A. After dialysis against 50 mM Tris-HCL pH 
7.5, 150 mM NaCl VHH purity was analyzed by SDS page gel electrophoresis under reducing 
conditions, and VHH concentration was measured by ultraviolet absorbance at 494 nm (ε494,FITC 
= 70.000 M-1cm-1), using a Nanodrop spectrophotometer.
VHH maleimide-fluorescein labeling
VHH-C (typically ~50-250 µM) was incubated with 20 mM TCEP (Thermo Fisher Scientific, 
Waltham, MA, USA) for 15 min at room temperature. TCEP was removed by centrifuge filtration 
in a 10 kDa MWCO centrifugal unit employing 5 cycles against 20 mM phosphate pH 7.0, 150 
mM NaCl, and 5 mM EDTA. Fluorescein-5-maleimide (Thermo Fisher Scientific, Waltham, MA, 
USA, from a 10 mM stock in dimethylformamide) was reacted with VHH-C in a 3:1 molar ratio 
in a thermoshaker at 450 rpm in the dark at room temperature for 2 hrs. Excess fluorescein-5-
maleimide was removed by centrifuge filtration in a 10 kDa MWCO centrifugal unit employing 
4 cycles against 50 mM Tris-HCL pH 7.5, and 150 mM NaCl. The protein was analyzed by SDS-
PAGE gel electrophoresis under reducing conditions and LC-MS. Protein concentration was 
determined by ultraviolet absorbance at 494 nm using the nanodrop.
VHH hLF conjugation 
VHH and GGG-hLF[Fluo] were conjugated using sortase A (figure 1). Sortase A (50 µM final 
concentration) and GGG-hLF[Fluo] (50 µM final concentration) were added to 7D12 (20 µM final 
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concentration) in sortase A buffer (50 mM Tris-HCL pH 7.5, 150 mM NaCl, 10 mM CaCl2). 
The solution was incubated at 30°C at in a thermoshaker at 450 rpm for 5 hrs in the dark. 
Subsequently the reaction mixture was incubated with Ni-NTA sepharose beads to remove the 
6xHis-tagged Sortase A, G-8xHis-Vsv and intact 7D12. Excess GGG-hLF[Fluo] was removed by 
washing the reaction mixture multiple times in a 10 kDa MWCO centrifugal filter unit employing 
6 cycles against 20 mM phosphate, 500 mM NaCl, 20% v/v glycerol, pH 7.5. The product size and 
purity was analyzed by SDS page gel electrophoresis under reducing conditions and LC-MS. 
Determine the Kd with IRDye700DX labeled constructs
To determine the Kd of the constructs, IRDye700DX labeled conjugates were used since these 
can be visualized on the Odyssey scanner (LI-COR, Lincoln, NE, USA). To this end, TCEP 
reduction of the 7D12-C was performed as described above. Then maleimide-PEG4-DBCO 
(Jena Bioscience, Jena, Germany, 10 mM stock in DMF) was allowed to react for 2 hrs at room 
temperature in a thermoshaker (450 rpm) with 7D12-C in a 3:1 molar ratio, yielding 7D12-
C[DBCO]. Excess maleimide-PEG4-DBCO was removed by filter centrifugation over an Amicon 
10 kDa MWCO centrifugal unit employing 4 cycles against 50 mM Tris-HCL pH 7.5 and 150 
mM NaCl. In parallel, IRDye700DX-NHS (LI-COR) was incubated with H2N-PEG3-N3 (Jena 
Bioscience, Jena, Germany) in a 3:1 molar ratio in 100 mM phosphate pH 8.6 and 150 mM 
NaCl for 7 hrs in a thermoshaker, yielding PS-N3. 7D12-C
[DBCO] incubated with PS-N3 in a 1:2 
molar ratio over night at RT yielding 7D12-C[PS]. This conjugate was purified from unconjugated 
PS-N3 by centrifugation over an Amicon 10 kDa MWCO centrifugal unit employing 4 cycles 
against 50 mM Tris-HCL pH 7.5 and 150 mM NaCl. The protein was analyzed by SDS-PAGE gel 
electrophoresis and protein concentration was determined by ultraviolet absorbance at 689 nm 
using the nanodrop. 
 Affinity of the IRDye00DX labeled 7D12 constructs for EGFR was determined in cell binding 
assays. A431 cells (5,000 cells per well), E98 cells (8,000 per well) and SK-OV-3 cells (6,000 per 
well) were seeded in a black 96 clear-bottom wells plate (Falcon, Corning, New York, USA) and 
allowed to grow over night. Then cells were incubated with various concentrations of 7D12-C[PS] 
or 7D12-C[PS]-hLF for 1 hour at 4°C in DMEM supplemented with 10% FCS. Cells were washed 
twice with cold DMEM with 10% FCS and once with cold PBS. Then plates were scanned with 
the Odyssey scanner (LI-COR, Lincoln, NE, USA) using the 700 nm channel. Total fluorescence 
intensity was plotted against conjugate concentration, and Kd’s were determined in Graphpad 
Prism 5.02. 
Cellular uptake of the constructs 
To analyze uptake of the VHH -hLF[Fluo] conjugates in cells, A431 cells were seeded at a density 
of 4x104 /well in 8-well chambered coverglasses (NUNC, Thermo Fisher Scientific, Waltham, 
MA, USA). The next day, cells were incubated with 2 µM of either 7D12-hLF[Fluo], G2-hLF[Fluo], 
GGG-hLF[Fluo], 7D12-C[Fluo], G2-C[Fluo], or the combination of 2 µM 7D12-C[Fluo] with 2 µM GGG-
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hLF in 200 µL phenol red free RPMI 1640 (Thermo Fisher Scientific, Waltham, MA, USA) with 
10% FCS and 20 mM HEPES for 30 min at 37°C, 5% CO2. Subsequently, cells were washed 
twice with RPMI with 10% FCS, and uptake and binding of the fluorescein-labeled constructs 
were analyzed by confocal laser scanning microscopy. After confocal imaging fluorescein 
fluorescence was dequenched by replacing 100 µl medium with 100 µl phenol red free RPMI 
containing 170 µM chloroquine (Sigma-Aldrich Chemie BV, Zwijndrecht) to a final concentration 
of 65 µM. The samples were incubated for 30 minutes and subsequently imaged again with 
the confocal microscope. Confocal laser scanning microscopy was performed on a TCS SP5 
microscope (Leica Microsystems, Mannheim, Germany) equipped with an HCX PL APO 63 × 1.2 
water immersion lens. During imaging, cells were maintained at 37 °C. The 488 nm laser line 
was used for excitation and emission was collected between 500 and 550 nm. 
Endocytosis of EGFR and the constructs
To analyze the influence of the constructs on colocalization of early endosomes and lysosomes 
and EGFR, A431 cells were incubated with the various constructs as described above in 
presence of a 1:1000 dilution of LysoTracker Red DND99 (Life Technologies, ThermoFisher 
Scientific, Waltham, MA USA). The positive control was activated with 100 ng/mL (16.6 nM) EGF 
(PromoCell, Heidelberg, Germany) in serum free RPMI for 20 min at 37°C. Then cells were 
fixed in 2% paraformaldehyde in 0.2 M phosphate buffer pH 7.5 for 10 min at RT and washed 
with PBS. After blocking the free aldehyde groups with 100 mM glycine in PBS for 20 min at 
RT and cell permeabilization with 0.5 % triton in PBS for 15 min at RT, cells were blocked 
with Normal Antibody Diluent (ImmunoLogic, Duiven, The Netherlands) for 20 min at RT. Then 
cells were incubated with mouse-anti-EEA-1 (1:250, 610456, BD Biosciences, Franklin Lakes, 
NJ, USA) and rabbit-anti-EGFR (1:50, D38B1, Cell Signaling Technology, Danvers, MA, USA) 
in Normal Antibody Diluent for 1 hr at RT. After washing with PBS the cells were incubated 
for 1 hr with goat-anti-rabbit AlexaFluor 647 and goat-anti-mouse AlexaFluor 594 conjugates 
(both Life technologies, Thermo Fisher Scientific, Waltham, MA, USA) for visualization of 
bound antibodies. The antibody staining was analyzed with TCS SP5 confocal laser scanning 
microscope (Leica Microsystems, Mannheim, Germany) equipped with an HCX PL APO 63 × 1.2 
water immersion lens. The constructs were visualized as described above and stained EGFR 
was excited with the 633 nm laser line and emission was collected between 672 and 800 nm. In 
a sequential scan lysotracker red and stained EEA-1 were excited with 561 nm laser line and 
emission was collected between 584 and 628 nm. 
Visualization of EGF 
A431 cells were incubated with the constructs as described above. Then, cells were washed 
twice with HBS (10 mM HEPES, 135 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, pH 7.4), 
and incubated for 10 min with 50 nM EGF-biotin (kind gift from Donna Arndt-Jovin, Max Planck 
Institute for Biophysical Chemistry, Göttingen) in HBS with 20 mM glucose and 1% BSA at 4°C. 
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After washing the cells twice with HBS, cells were incubated with Streptavidin-Alexa Fluor 594 
(1:120 Invitrogen Molecular probes, Carlsbad, CA, USA) in HBS with 20 mM glucose and 1% 
BSA at 4°C. Cells were washed twice with HBS and then imaged in HBS 20 mM glucose 1% 
BSA on the SP5 microscope at 37°C (see above).
EGFR activation by EGF after incubation with constructs
To analyze effects on EGFR activation using confocal microscopy, cells were incubated with 
the constructs as described above. Then cells were washed twice with RPMI without FCS and 
incubated with 200 µL RPMI without FCS for 1 hr at 37°C, 5 % CO2, after which the cells were 
either activated or not with 100 ng/mL EGF (16.6 nM) for 5 min at 37°C, 5% CO2. Then cells 
were fixed in 2% paraformaldehyde in 0.2 M phosphate buffer pH 7.5 for 10 min at RT and 
washed with PBS. After blocking the free aldehyde groups and cell permeabilization, cells 
were blocked with Normal Antibody Diluent for 20 min at RT. Then cells were incubated with 
rabbit-anti-phosphoEGFR Tyr1068 (1:800, D7A5, Cell Signaling Technology, Danvers, MA, USA) 
in Normal Antibody Diluent for 1 hr at RT. After washing with PBS the cells were incubated for 
1 hr with goat-anti-rabbit AlexaFluor 647 conjugate for visualization of bound antibodies. The 
antibody staining was analyzed by confocal microscopy. The 633 nm laser line was used for 
excitation and emission was collected between 650 and 750 nm. 
 To analyze effects on EGFR activation using western blot, A431 cells were seeded into 
24-wells plates (Cellstar, Greiner-Bio One, Essen, Germany) at 150,000 cells/well and grown 
over night. Then cells were incubated with 400 µl of either 7D12-LPETGGG-hLF38-59[Fluo] or 7D12-
LPETG-8xHis-Vsv in DMEM with 10% FCS for 30 min at 37°C, 5% CO2. Cells were washed 
twice and incubated with 500 µl serum free DMEM for 1 hr at 37°C, 5% CO2, after which they 
were activated with 500 µl 100 ng/ml EGF in serum free DMEM for 5 min at 37°C, 5% CO2. 
Then cells were washed once with PBS and cytosolic extracts were made in RIPA buffer (Cell 
Signaling Technology, Danvers, MA, USA) according to manufacturer’s protocol. 20 µg of total 
protein was subjected to SDS-PAGE electrophoresis and western blot. Blots were blocked in 
LI-COR blocking buffer in PBS (1:1) and incubated with rabbit-anti-phosphoEGFR (1:1,000) and 
mouse-anti-GAPDH (1:10,000, ab8245, Abcam, Cambridge, UK) for 1 hr at RT, and goat-anti-
rabbitIRDye800 and goat –anti-mouseIRDye680 (both Invitrogen Molecular probes, Carlsbad, 
CA, USA) for 1 hr at RT. The experiment was repeated 3 times and the signals were visualized 
and quantified using the Odyssey system (LI-COR, Lincoln, NE, USA). 
Image analysis
Fiji (pacific.mpi-cbg.de/wiki/index.php/Fiji)41 was used for image analysis. For the quantification 
of the EGF and pEGFR fluorescence, regions of interest (ROIs) were drawn in the brightfield 
image to exclude regions without cells. The mean of the fluorescence signal inside these ROIs 
was measured. Three images per condition were recorded in each experiment. 
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Colocalization of stained EGFR with the early endosomal marker EEA-1 and LysoTracker Red 
DND99 was analyzed by first making a binary mask of the EEA-1/LysoTracker Red image. This 
image was devided by 255 and the Raw integrated density (sum of all pixels) was measured. 
Subsequently the image was multiplied with the EGFR image resulting in an image showing all 
EEA-1/LysoTracker vesicles that are EGFR-positive. The Raw integrated density of this image 
was measured and divided with the value obtained in the first measurement. This results in the 
average EGFR intensity in EEA-1/LysoTracker Red positive vescicles per positive pixel.
Statistics
All experiments were performed at least in duplicate. A one-way ANOVA with post hoc 
Bonferroni was performed in Graphpad prism to check for significance.
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ABSTRACT
Photodynamic therapy (PDT) is an emerging method to treat light-accessible cancers. To 
increase specificity and allow dose reduction, conjugates of photosensitizers (PS) with 
antibodies against tumor-associated antigens have been developed for photoimmunotherapy 
(PIT). However, so far it is unclear whether cellular internalization of these conjugates after 
binding affects PIT efficacy.
 The use of low molecular weight llama single domain antibodies (VHHs, nanobodies) for 
PIT is preferred above full size antibodies because of better tumor penetration. Therefore, we 
functionalized the VHH 7D12, directed against the epidermal growth factor receptor (EGFR), 
with a PS (IRDye700DX). To assess the impact of cellular internalization on activity, the VHHs 
were additionally conjugated to a cell-penetrating peptide (VHH[PS]-CPP).  
 Here we show that upon illumination with near-infrared (NIR) light, both VHH[PS] and 
VHH[PS]-CPP conjugates specifically induce cell death of EGFR expressing cancer cell lines and 
of EGFR-expressing cells derived from surgically obtained ascites from patients with high-
grade serous ovarian cancer. However, VHH[PS] conjugates were significantly more effective 
compared to internalizing VHH[PS]-CPP suggesting that cell surface association is required for 
optimal therapeutic activity.
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INTRODUCTION
Photodynamic therapy (PDT) is a method to induce cell death through administration and activation 
of a photo-sensitizer (PS). When activating the PS with light of the appropriate wavelength, the 
PS is transferred from its ground state into an excited triplet state1 that can return to the ground 
state via transmitting its energy to molecular oxygen, leading to the formation of reactive oxygen 
species (ROS). In general, these ROS are formed through type II photo-oxidative reactions that 
result in the formation of singlet oxygen, a highly toxic and short-lived radical that induces 
peroxidation and breakdown of lipids, proteins and nucleic acids2. 
 For tumors that are amenable for local light application, PDT has a number of advantages as 
compared to other therapies. It is less invasive than surgery and, because of its local character, 
more selective than chemotherapy. Furthermore, the direct cell killing effects of PDT prevent 
development of resistance, as is seen with chemotherapy and most targeted therapies3 and 
may also induce a vaccination effect because PDT-induced necrotic cell death challenges the 
immune system4. PDT has been tested in clinical trials for cancer of the bladder, skin, head 
and neck. Various PSs are now approved as PDT drugs5. 
 There are, however, some issues with PDT that still need to be solved. Currently used 
PSs suffer from low water solubility and dark toxicity. To enhance solubility, significant efforts 
have been made in engineering drug delivery systems that allow tumor-specific targeting of 
PS6-12. Even though antibodies are highly potent targeting vehicles, antibody-PS conjugates for 
photoimmunotherapy (PIT)13-14 have the disadvantage that antibodies have circulation times of 
weeks, increasing the risk of dark toxicity and phototoxicity in light-exposed skin15. To reduce 
circulation time, conjugates of PS with small-sized recombinant llama antibodies (VHHs) have 
been used to induce epidermal growth factor receptor (EGFR)-dependent cell death14,16. The 
small size of these delivery systems also allows faster tumor accumulation and better tissue 
penetration as compared to full-size antibodies, and improves the carrier-to-drug molecular 
weight ratio17.
 The half-life of singlet-oxygen in biological systems is <40 ns, restricting its toxic action 
radius to <20 nm2. Studies using photosensitizers with different physicochemical properties 
that behave differently with respect to cell uptake have shown that intracellular localization 
greatly influences the cellular response to light-induced activation. PSs that localize to the 
mitochondria or cytoplasm are described to induce apoptosis, while necrosis is induced when 
the plasma membrane is the site of action18-19. Furthermore, more efficient membrane binding 
and membrane photooxidation increases phototoxicity of the PS20. 
 Next to relying on internalization of targeted receptors, internalization of VHHs can also be 
triggered by conjugation to cell-penetrating peptides (CPPs)21, a class of peptides that mediate 
cellular uptake of molecules that otherwise do not enter the cell22. Conjugation of the anti-
EGFR VHH 7D12 to the CPP hLF, derived from human lactoferrin23, endows the VHH with the 
capacity to enter the cell24.
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To investigate how the efficacy of PIT is influenced by the subcelullar localization of the PS we 
used a site-selective bioconjugation protocol to functionalize the EGFR targeting VHH 7D12 25-26 
with the PS IRDye700DX. Using sortase A transpeptidation we conjugated hLF to VHH 7D12[PS], 
yielding 7D12[PS]-hLF. We then investigated the efficacy of both constructs on light induced cell 
death and show that the CPP-free non-internalizing variant is more active in inducing cell 
death. 
RESULTS AND DISCUSSION
Preparation and characterization of 7D12-C[PS] conjugates
Targeted PDT of cancers requires high tumor selectivity and specificity, concomitant with a 
lack of dark toxicity. Approaches that improve tumor selectivity of the PS by conjugation to 
antibodies still have major drawbacks due to the long circulation half-lives of these conjugates, 
and poor penetration of these large constructs into poorly perfused tumor areas. To tackle 
these problems, smaller targeting moieties like VHHs are interesting alternative PS carriers. 
Here, the anti-EGFR VHH 7D12 was used as a clinically relevant model VHH to examine 
how subcellular localization of PSs affects PDT efficacy. It was published before that 7D12-
IRdye700DX conjugates can be prepared successfully via NHS-based conjugation to lysines14. 
This approach however, carries a risk of overlabeling of lysines that are involved in antigen 
binding, resulting in reduced affinity. Also, this procedure yields a heterogeneous mixture 
of VHHs, containing a fraction of unlabeled VHHs that may act as competitor for the labeled 
ones. We therefore chose to perform a site-selective reaction at an introduced cysteine at the 
carboxyterminus (Figure 1A). Because IRDye700DX was not available as maleimide conjugate 
at the time of this study, we first coupled a dibenzocyclo-octyn (DBCO)-functionality to the VHH 
and an azide functionality to the PS.
 This enabled us to use the highly specific and bio-orthogonal click reaction between 
azide and DBCO27. 7D12-C[DBCO]-LPETG-8xHis-Vsv (referred to as 7D12-C[DBCO]) and 7D12-
C[PS]-LPETG-8xHis-Vsv (referred to as 7D12-C[PS]) were produced successfully as verified with 
SDS-PAGE electrophoresis (Figure 1B) and LC-MS (Figure 1C). LC-MS verified conjugation of 
only one maleimide-DBCO and PS molecule per VHH, as we have seen before for maleimide-
fluorescein28. This method is generally applicable to all VHHs, as long as these do not carry 
unpaired cysteines in the CDR, and since all reactions occur distant from the VHHs’ antigen 
binding site, this approach is predicted to retain VHH affinity.
 By employing sortase-A-mediated ligation of GGG-hLF (Figure 1D), we successfully 
produced 7D12-C[PS]-LPETGGG-hLF (referred to as 7D12-C[PS]-hLF (Figure 1B, E). Because 
we did not have lasers compatible for detection of IRDye700DX–fluorescence with confocal 
microscopy, we also prepared fluorescein labeled variants 7D12-C[Fluo]-LPETG-8xHis-Vsv 
(7D12-C[Fluo]) and 7D12-LPETGGG-hLF[Fluo] (7D12-hLF[Fluo]).    
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Figure 1. Analytical characterization of the conjugates. A) Scheme of bio-orthogonal conjugation of azide-
functionalized PS to the DBCO-functionalized VHH. B) Upper panel: coomassie brilliant blue (CBB) stained 
SDS-PAGE gel of the reaction products after conjugation of the N3-PEG3-PS to 7D12-C
[DBCO] (1: 7D12-C, 
2: 7D12-C[DBCO], 3: 7D12-C[PS] before column purifi cation, 4: 7D12-C[PS] after column purifi cation). Lower 
panel: visualization of the SDS-page gel at 680 nm before coomassie (left) and of the coomassie-stained 
gel (right) with reaction products and controls of the sortase A conjugation to functionalize 7D12-C[PS]
with GGG-hLF (5: 7D12-C[PS], 6: Sortase A /7D12-C[PS] after 5 hours incubation at 30°C, 7: the fi nal product 
7D12-C[PS]-hLF after Ni-NTA purifi cation). C) LC-MS characterization of TCEP-reduced 7D12-C (upper, 
observed 17837 Da, calculated 17837.6 Da) and 7D12-C[DBCO] (lower, observed 18511 Da, calculated 18512.4 
Da). The left graphs show the total mass spectra, the right graphs show the deconvoluted spectra. D) 
Scheme of site specifi c conjugation of VHH-C[PS] to GGG-hLF with sortase A. E) ESI-ToF characterization 
of 7D12-C[PS] (upper graphs, observed 20495 Da, calculated 20569.7 Da) and 7D12-C[PS]-hLF (lower graphs, 
observed 20724 Da, calculated 20720.2 Da). The left graphs show the total mass spectra, the right graphs 
the deconvoluted spectra. 
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Cellular binding and uptake of 7D12 conjugates
Previous research has shown that hLF is taken up by endocytosis at concentrations below 10 
µM23, and that functionalization of 7D12 with hLF causes increased internalization of the VHH24. 
Here we confirmed these patterns of cellular uptake in A431 and SK-OV-3 cells (Figure 2A). 
Cells were incubated with the conjugates at a concentration of 2 µM at which little vesicular 
uptake of hLF alone was observed (Figure 2B). Vesicular uptake of 7D12-hLF[Fluo] was observed in 
A431 cells, whereas under the same conditions 7D12-C[Fluo] was predominantly associated with 
the plasma membrane. SK-OV-3 cells showed very weak membrane staining after incubation 
with 7D12-C[Fluo], but after incubation with 7D12-hLF[Fluo], intracellular vesicular staining was 
observed, which was more clearly visible after quenching extracellular fluorescence with 
trypan blue (Figure 2A). No binding to or uptake in E98 was observed for both 7D12 conjugates 
(Figure 2C). This latter finding further confirmed that cell association was primarily VHH and 
not hLF driven. 
 It is generally accepted that CPPs lack cell line selectivity, however such experiments 
are typically conducted al medium micromolar concentrations29. The dissociation constant of 
the binding of hLF to cell surface glycosaminoglycans is in the low micromolar range30, while 
reported Kd values of 7D12 binding to cell-associated EGFR is in the order of 10-20 nM14,17,26. 
Cell ELISAs, performed at 4oC to study binding in the absence of internalization, confirmed 
high affinity binding of 7D12-C[PS] and 7D12-C[PS]-hLF to EGFR overexpressing A431 cells (Kd 
= 11.85 ± 1.203 and 25.53 ± 2.514 nM, respectively). At the low micromolar and subnanomolar 
concentrations that we employed in the uptake and PDT assays, respectively, binding of the 
different conjugates is therefore expected to be determined by the 7D12 moiety, rather than 
hLF. This finding has important implications for in vivo applications of CPP-based strategies. 
Except for those tissues that show a high propensity for CPP uptake31, uptake of VHH-CPP 
conjugates is directed by presence of the EGFR. In this case, the CPP module is a modulator of 
subcellular trafficking rather than an unspecific driver of uptake. 
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Figure 2. Cell binding and uptake of the constructs. A) A431 and SK-OV-3 cells were incubated with 2 
µM of 7D12-C[Fluo] and 7D12-hLF[Fluo] and imaged by confocal laser scanning microscopy before and after 
quenching fl uorescence from extracellular located fl uorescein with trypan blue (TB). B) A431 and SK-OV-3 
cells were incubated with 2 µM of GGG-hLF[Fluo] and imaged by confocal laser scanning microscopy before 
and after quenching fl uorescence from extracellular located fl uorescein with trypan blue (TB). C) E98 cells 
were incubated with 2 µM of 7D12-C[Fluo]-LPETG-His8-Vsv, 7D12-C-LPETGGG-hLF
[Fluo], and GGG-hLF[Fluo] and 
imaged by confocal laser scanning microscopy. The scale bars denote 10 µm. 
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hLF mediated uptake of 7D12 is initiated by clathrin mediated endocytosis
In previous work we showed that 7D12-hLF[Fluo] induces internalization of EGFR, which can be 
initiated by clathrin mediated endocytosis (CME) and/or clathrin independent endocytosis32. 
To investigate if the 7D12-hLF[Fluo] induced internalization of EGFR is clathrin-dependent we 
incubated A431 cells with the various CPP constructs in the presence of transferrin-Alexa633 
(Figure 3). Both 7D12-hLF[Fluo] and hLF[Fluo] but not 7D12[Fluo] induced vesicular uptake as seen by 
enhanced transferrin staining that colocalized with the hLF-containing constructs.
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Figure 3. Induction of clathrin-dependent endocytosis by hLF conjugates. A431 cells were incubated for 
30 min with 2 µM of the CPP constructs in presence of transferrin-Alexa633. The scale bar denotes 10 µm.
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PIT efficacy of 7D12-C[PS] constructs in adherent cell cultures
Cell killing assays showed that 7D12-C[PS] conjugates were very potent and specific PDT agents, 
without inducing dark toxicity (Figure 4A). Incubation with PS alone, followed by illumination 
did not induce cell killing under the conditions used (Figure 4B). Although the 7D12-C[PS] 
conjugates that we produced via a two-step click reaction contain only one PS per VHH, these 
induced EGFR-specific cell death very efficiently, with an IC50 value for 7D12-C[PS] on A431 
cells of 87.8 ± 4.3 pM after NIR light illumination with 60 J/cm2. Interestingly, conjugates 
containing hLF were less effective with an IC50 of 234.1 ± 122.7 pM (p = 0.3556) (Figure 4C). In 
the intermediate EGFR expressing SK-OV-3 cells, similar differences were observed between 
7D12-C[PS] (IC50 = 705.1 ± 164 pM) and the internalizing variant 7D12-C[PS]-hLF (IC50 = 2680 
± 323.5 pM) (p = 0.0055). Interestingly, in previous reports it was demonstrated that VHH-PS 
conjugates with higher affinity for EGFR had higher PIT efficacy and it was suggested that 
increased internalization due to higher affinity was responsible for increased photosensitivity14. 
Furthermore, internalizing antibody-PS conjugates were shown to be more effective in PIT 
than non-internalizing antibody-PS33. Our data however show that increased cell surface 
association is a more important determinant. Interestingly, no phototoxicity was induced in 
non-EGFR expressing E98 cells in line with the low cell binding capacity mediated by the CPP 
alone. 
 To further assess the selectivity of the 7D12-C[PS] conjugates, co-culture experiments with 
A431, E98 and SK-OV-3 were performed. These cell types were distinguished by pre-labeling 
them with different membrane associated dyes. Labeled and dead cells were visualized 
immediately, 2 h and 16 h after illumination. Only EGFR expressing cells were killed after PDT 
(Figure 4D). No cell death was observed in the controls (no PS-conjugates added). Parallel 
experiments with monocultures of the cells showed that cell death was induced immediately 
after illumination for the A431 cells, and after 2-16 h for the SK-OV-3 cells (Figure 5). The cell 
death of A431 immediately after PDT suggested that necrosis was induced. Neither A431 and 
SK-OV-3 cells were stained with Annexin-V (not shown), and they did not induce caspase-3 
dependent apoptosis at 4 h after PDT, which further indicates that cells indeed died by necrosis 
(Figure 6). Unconjugated IRDye700DX did not lead to phototoxicity in all used cell types, in 
agreement with previous studies, and did not display dark toxicity. This makes it a suitable 
compound for targeted PDT34. 
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Figure 4. Phototoxicity induced by the constructs in adherent cells. A) Absence of dark toxicity of 7D12-C[PS] 
constructs and PS alone (45 nM) and B) absence of toxicity of non-targeted PS with illumination (45 nM for 
10 J/cm2 and 15 nM for 60 J/cm2). Results are shown as survival relative to untreated cells. C) The relative 
cell viability after incubation with various concentrations of 7D12-C[PS] constructs and illumination with a 60 
J/cm2 total light dose was also determined in SRB assays. D) Co-cultures fluorescently labeled with DiDyes 
were incubated with 15 nM 7D12-C[PS] constructs and illuminated with a 60 J/cm2 total NIR light dose. Cells 
were imaged immediately, 2 and 16 hours after illumination. Controls were illuminated only.
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Figure 5. Specificity and timeframe of induced phototoxicity in adherent cells. Cell mono-cultures 
fluorescently labeled with DiDyes were incubated with 15 nM 7D12-C[PS] constructs and illuminated with a 
60J/cm2 total NIR light dose. Immediately, 2 h and 16 h after illumination they were imaged. Controls were 
illuminated only. 
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Figure 6. Expression of cleaved caspase-3 and GAPDH in A431, SK-OV-3 and E98 2 and 4 h after PDT with 
15 nM 7D12-C[PS] constructs and a 60 J/cm2 light dose.
Efficient PIT with ovarian carcinoma SK-OV-3 spheroids and EGFR positive cells 
in clinical ascites 
To assess effectiveness of the conjugates in a cellular model with more resemblance to the 
in vivo tumor situation, conjugates were incubated with SK-OV-3 spheroids. PIT with SK-OV-3 
spheroids showed efficient cell killing after incubation with 120 nM of the 7D12-C[PS] construct 
and a light dose of 60 J/cm2, illustrated by the majority of cells with picnotic nuclei in the HE 
stained sections, and only a minority of cells in the centre that appeared viable (Figure 7A, 
enlargement in insert). In the 7D12-C[PS]-hLF treated cells, also dead cells with picnotic nuclei 
were observed but to a lesser extent. Control spheres showed only viable cells, indicating that 
the VHH conjugates can penetrate into the spheroid. 
 Finally, cells derived from clinical ascites from women with stage III or IV high-grade serous 
ovarian carcinoma (n=7) were incubated with 15 nM 7D12-C[PS] constructs and illuminated with 
60 J/cm2 NIR light. Phototoxicity was restricted to the EGFR-positive subpopulation of cells, 
as could be observed by costainings for dead cells (Propidium iodide) and EGFR (Cetuximab) 
(Figure 7B). The absence of costaining for dead cells and a population of cells positive for 
another tumor marker (EpCAM) indicated selectivity for EGFR (Figure 7C). SRB assays after 
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Figure 7. Phototoxicity induced by the constructs in ovarian carcinoma spheroids and clinical ascites. 
A) SK-OV-3 spheres were incubated with 15 nM of the 7D12-C[PS] constructs or controls and illuminated 
with a NIR light dose of 60 J/cm2. Sections of agar embedded treated or control SK-OV-3 spheroids were 
stained with HE. Note that the outer layer of cells have picnotic nuclei, visualized more clearly in the 
enlarged insert. B+C) Cultured cells from clinical ascites were incubated with 15 nM of the various 7D12-
C[PS] constructs and illuminated with a total NIR light dose of 60 J/cm2. Dead cells and B) EGFR or C) 
EpCAM expressing cells in an ascites derived cell culture after PDT were imaged. Note the weaker signal 
of cetuximab in the dead 7D12-C[PS] treated samples compared to the live cells in the controls. D) The 
percentage of cell viability in multiple cultures was determined with SRB assays. * = p<0.05, ** = p<0.01. 
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incubation with 7D12-C[PS] constructs and illumination showed significant decreases in overall 
cell viability compared to controls (P<0.001 and P<0.03 for 7D12-C[PS] and 7D12-C[PS]-hLF, 
respectively (Figure 7D). The survival of about 60-70% of the cells is in agreement with the 
notion that ascites also contains numerous non-EGFR-expressing cells (as shown in Figure 
7C) that are expected to survive the treatment. 
 With the use of optical fibers NIR light can be delivered to otherwise inaccessible tumors, 
as has been shown for peritoneal metastasis of ovarian cancer using Verteporfin35. In addition, 
peroperative fluorescent image-guided surgery is gaining momentum36 and could be very well 
extended with compounds comparable to those described here.
CONCLUSION
Targeted PDT is a rapidly increasing field which promises to become of great importance for 
the treatment of light-accessible cancers. Targeted light-induced direct cancer cell death has 
great advantages as compared to currently applied targeted treatments which mostly delay 
progression of cancers, given these ample time to develop resistance. We here describe the 
construction of a highly defined VHH-PS via a controlled bioconjugation method that is easily 
applicable to other VHHs. Despite the fact that every VHH carries only one PS molecule, these 
constructs are highly selective and specific, requiring very low concentrations to induce efficient 
cell killing via necrosis. In 3D-spheroid models, efficient cell killing was observed, indicating 
that these low-weight constructs have good tissue penetrating properties. Furthermore we 
show that conjugation to a CPP decreases binding affinity, and endows the VHH-PS with 
an increased capacity to enter the cell via clathrin-mediated endocytosis. These changed 
properties decreased PDT efficacy, suggesting that association with the cell membrane is 
needed for optimal therapeutic activity. 
METHODS
Cell culture
Human epidermoid carcinoma A431 cells, carrying an amplification of the EGFR gene37, 
human high grade astrocytoma E98 cells without EGFR expression38 and human ovarian 
adenocarcinoma SK-OV-3 cells with intermediate EGFR expression39 were cultured in 
Dulbecco’s Modified Eagle Medium (DMEM) (Lonza, Basel, Switzerland) supplemented with 
10% fetal calf serum (FCS) (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) and 40 µg/ml 
gentamycin (Centrafarm, Etten-Leur, The Netherlands). Cells were cultured at 37°C in 5% CO2 
in a humidified atmosphere.
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Sortase A expression
E.coli ER2566 cells transformed with the plasmid pGBMCS-SortA, encoding His6-tagged 
sortase A with an N-terminal deletion of 59 amino acids40 (Addgene, Cambridge, MA, USA, 
plasmid #21931) were grown to log phase at 37oC, and protein expression was induced with 
1.0 mM isopropyl β-D-thiogalactoside (IPTG, Serva, Heidelberg, Germany) at 30°C for 3 h. 
Cells were harvested, resuspended in ice-cold 50 mM Tris pH 8.0/300 mM NaCl containing 
a protease inhibitor cocktail (Roche, Basel, Switzerland) and lysed by sonication using a 
Bandelin Sonopuls HD2070 sonicator (Bandelin electronic GmbH & Co, Berlin, Germany). 
After centrifugation the supernatant was incubated with Ni-NTA sepharose (IBA, Goettingen, 
Germany) in 50 mM phosphate pH 7.4/500 mM NaCl for 1 h at 4oC. After washing, His6-tagged 
sortase A was eluted from the beads with 500 mM imidazole. The eluate was dialyzed against 
50 mM Tris pH 7.5/150 mM NaCl in a 3.5 kDa dialysis membrane (Spectrum Labs, Los Angeles, 
CA, USA). Protein purity was analyzed by SDS-PAGE gel electrophoresis under reducing 
conditions and mass spectrometry (LC-MS, Shimadzu HPLC and Thermo Finnigan LCQ Fleet) 
on a C4 column. Protein concentration was determined by absorbance at 280 nm using the 
Nanodrop spectrophotometer (LI-COR, Lincoln, NE, USA).
VHH expression 
The cDNA encoding anti-EGFR VHH 7D12 (a gift from Paul van Bergen en Henegouwen, 
Utrecht University, The Netherlands) was recloned in vector pHENIX-C-LPETG-8xHis-Vsv, 
resulting in 7D12-C-LPETG-8xHis-Vsv (7D12-C), the cysteine providing a handle for maleimide 
conjugation, LPETG being a sortase A consensus recognition sequence and the His8-Vsv tag 
allowing Ni-based purification and Vsv-based detection. 7D12-C expression was induced via 
standard methods in E.coli strain TG1. Cells were harvested by centrifugation at 2830 x g 
for 20 min at 4°C, resuspended in ice cold Tris/EDTA/Sucrose (TES) buffer (200 mM Tris pH 
8.0/0.5 mM EDTA/20 % w/v sucrose/protease inhibitor cocktail) and incubated for 20 min on ice, 
followed by centrifugation (4424 x g, 20 min, 4°C). The supernatant was collected and the pellet 
was resuspended in TES buffer supplemented with 15 mM MgSO4, and incubated on ice for 20 
min. After centrifugation, both supernatants were pooled and protein was purified with Ni-NTA 
sepharose as described for sortase A. 
IRDye700DX conjugation 
All steps involving IRDye700DX were performed in the dark. 7D12-C was incubated with 20 
mM tris(2-carboxyethyl)phosphine TCEP (Thermo Fisher Scientific, Waltham, MA, USA) for 15 
min at room temperature to reduce the free thiol group of the cysteine. TCEP was removed in 
a 10 kDa MWCO centrifugal unit (Amicon, Millipore, Billerica, MS, USA) employing 5 washing 
cycles with 20 mM phosphate pH 7.0/150 mM NaCl/5 mM EDTA. Maleimide-PEG4-DBCO 
(Jena Bioscience, Jena, Germany, 10 mM stock in DMF) was allowed to react for 2 h at room 
temperature in a thermoshaker at 450 rpm with 7D12-C in a 3:1 molar ratio, yielding 7D12-
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C[DBCO]. Excess maleimide-PEG4-DBCO was removed by filter centrifugation in a 10 kDa MWCO 
centrifugal unit employing 4 washing cycles with 50 mM Tris pH 7.5/150 mM NaCl. The protein 
conjugate was analyzed by LC-MS, and protein concentration was determined by ultraviolet 
absorbance at 309 nm using the Nanodrop spectrophotometer.
 In parallel, IRDye700DX-NHS (LI-COR, Lincoln, NE, USA from now on referred to as PS-
NHS) was incubated with H2N-PEG3-N3 (Jena Bioscience, Jena, Germany) in a 3:1 molar ratio 
in 100 mM phosphate buffer pH 8.6/150 mM NaCl for 7 h at RT in a thermoshaker at 450 rpm, 
yielding PS-N3. Subsequently 7D12-C
[DBCO] was incubated with PS-N3 in a 1:2 molar ratio o/n 
at RT in a thermoshaker at 450 rpm, yielding 7D12-C[PS]. This conjugate was purified from 
unconjugated PS-N3 by centrifugation in a 10 kDa MWCO centrifugal unit employing 4 washing 
cycles with 50 mM Tris pH 7.5/150 mM NaCl. The protein was analyzed by SDS-PAGE gel 
electrophoresis under reducing conditions and with electrospray ionization time-of-flight mass 
spectrometry (ESI-ToF) on a JEOL AccuTOF-CS (JEOL, Tokio, Japan) . Protein concentration 
was determined by measuring absorbance at 689 nm (ε = 165000 M-1cm-1, assuming 1:1 
complete labeling) using the Nanodrop spectrophotometer. 
Functionalization of 7D12-C[PS] with hLF
GGG-hLF or GGG-hLF(Fluo] (synthesized by EMC microcollections, Tübingen, Germany) was 
dissolved in 50 mM HEPES pH 8.0 at 5-10 mM, to ensure intramolecular disulfide bridge 
formation that is required for CPP activity30. The carboxyfluorescein moiety was coupled to a 
C-terminal lysine residue. Subsequently sortase A (80 µM final concentration) and GGG-hLF 
(100 µM final concentration) were added to 7D12-C[PS] (20 µM final concentration) in 50 mM 
Tris pH 7.5/150 mM NaCl/10 mM CaCl2. The sortase reaction was allowed to proceed for 5 h 
at 30°C in a thermoshaker at 450 rpm, after which the reaction mixture was incubated with 
pre-washed Ni-NTA sepharose beads to remove the 6xHis-tagged sortase A, G-8xHis-Vsv and 
unreacted 7D12-C[PS]. Excess GGG-hLF was removed from the Ni-NTA agarose supernatant 
by centrifuge filtration in a 10 KDa MWCO centrifugal unit employing 6 cycles against 20 mM 
phosphate pH 7.5/500 mM NaCl. Purity and concentration of the VHH conjugate was analyzed 
by SDS-PAGE gel electrophoresis and ESI-ToF. Protein concentrations were determined by 
measuring absorbance at 689 nm using the Nanodrop spectrophotometer. 
Fluorescein labeled constructs for confocal microscopy applications
For confocal microscopy applications, 7D12 constructs directly labeled with fluorescein were 
produced. 7D12-C was reduced with 20 mM TCEP as described above. Then fluorescein-5-
maleimide (Thermo Fisher Scientific, Waltham, MA, USA, 10 mM stock in DMF) was reacted 
with reduced 7D12-C in a 3:1 molar ratio in 20 mM phosphate pH 7.0/150 mM NaCl/5 mM EDTA 
for 2 h at RT in a thermoshaker at 450 rpm. Excess fluorescein-5-maleimide was removed by 
centrifuge filtration in a 10 kDa MWCO centrifugal unit employing 4 washing cycles with 50 mM 
Tris pH 7.5/150 mM NaCl. 7D12-hLF[Fluo] was prepared using sortase A as described above, using 
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50 µM sortase A, 50 µM GGG-hLF[Fluo] and 20 µM 7D12 in 50 mM Tris pH 7.5/150 mM NaCl/10 mM 
CaCl2. The product was purified using Ni-NTA sepharose and filter centrifugation as described. 
Protein conjugates were analyzed by SDS PAGE gel electrophoresis under reducing conditions 
and LC-MS. Protein concentration was determined by measuring absorbance at 494 nm (ε = 
75000 M-1cm-1, assuming 1:1 complete labeling) using the Nanodrop spectrophotometer.
Cell uptake assays with confocal microscopy
Cellular uptake of the different fluorescein-labeled 7D12 conjugates was examined with 
confocal microscopy on a TCS SP5 microscope (Leica Microsystems, Mannheim, Germany) 
equipped with an HCX PL APO 63 × 1.2 water immersion lens. During imaging, cells were 
maintained at 37°C. The 488 nm laser line of the argon laser was used for excitation and 
emission was collected between 500 and 550 nm. A431, E98 and SK-OV-3 cells (30,000, 50,000 
and 30,000 cells per well, respectively) were plated in 8-well Lab-Tek borosilicate coverglass 
chambers (NUNC, Thermo Fisher Scientific, Waltham, MA, USA) and allowed to adhere and 
proliferate for 48 h. Then cells were incubated for 30 min at standard culture conditions in 
200 µl phenol red-free RPMI/10% FCS, supplemented with 2 µM of 7D12-C[Fluo], 7D12-hLF[Fluo], 
or GGG-hLF[Fluo]. Subsequently, cells were washed twice with phenol red-free RPMI/10% FCS 
containing 20 mM HEPES and were imaged by confocal microscopy. Acidic pH in lysosomes 
reduces Fluorescein fluorescence. To investigate if this effect leads to an underestimation op 
7D12-hLF[Fluo] uptake, we treated cells with 65 µM chloroquine, which increases the lysosomal 
pH and thereby enhances fluorescein fluorescence41. The samples were imaged once more, 
and to quench extracellular fluorescence, 0.4% trypan blue (Sigma Aldrich, Saint Louis, MO, 
USA) was added to the wells before imaging for a third time42.
Study of cell uptake mechanism with confocal microscopy
To detect clathrin-dependent endocytosis, cells were co-incubated with the constructs as 
described above and 100 µg/ml transferrin-Alexa Fluor 633 (Life Technologies, Thermo Fisher 
Scientific, Waltham, MA, USA). After 30 min, the cells were washed and colocalization of 
transferrin and the constructs was detected by confocal microscopy. Fluorescein was excited 
with the argon laser at 488 nm and emission was detected between 500 and 550 nm. Alexa Fluor 
633 was excited with the 633 nm helium-neon laser and detected between 650 and 715 nm.
In vitro PDT assays with adherent cell cultures 
A431, E98 and SK-OV-3 cells were cultured in clear 96-well plates (Costar, Greiner-Bio 
One, Essen, Germany). At 80% confluency cells were incubated for 30 min with different 
concentrations of 7D12-C[PS], 7D12-C[PS]-hLF or equimolar concentrations of PS alone in 
DMEM/10% FCS. Controls were incubated with DMEM/10% FCS only. Cells were washed twice 
with warm DMEM/10% FCS. Immediately after washing, plates were illuminated with 100 
mW/cm2 for 600 s, reaching a total light dose of 60 J/cm2, using a standardized light emitting 
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diode device (690 ± 10 nm) as described in43. To determine dark toxicity, cells were incubated 
with the highest used concentration of the conjugates without subsequent illumination. After 
overnight incubation a sulforhodamine-B-assays (SRB) assay was performed as described in44 
to determine total protein content. Results were expressed as cell viability relative to controls 
(untreated illuminated cells). Half maximal inhibitory concentration (IC50) of the various 
conjugates were determined in GraphPad Prism 5.02 (LaJolla, CA, USA). 
 To examine selectivity of PDT-induced cytotoxicity with the different conjugates, 5x105 cells 
were labeled with DiO (A431 and SK-OV-3) or DID (E98) dye (Life technologies, Thermo Fisher 
Scientific, Waltham, MA, USA) according to manufacturers protocol. Mixtures of A431, E98 and 
SK-OV-3 cells were plated and subjected to PDT as described above. Immediately, 2 h and 
16 h after illumination cells were incubated with 1 µg/ml propidium iodide (Thermo Fisher 
Scientific, Waltham, MA, USA) in PBS for 15 min. Cells were visualized with the EVOS FL digital 
inverted fluorescence microscope (Thermo Fisher Scientific, Waltham, MA, USA) using the 
RFP LED light cube (Propidium Iodide), the GFP LED light cube (DiO labeled cells) and the Cy5 
LED light cube (DiD labeled cells).
Mechanism of cell death 
To check if apoptotic cell death was induced by 7D12-C[PS] conjugates, cells were treated with 
15 nM 7D12-C[PS] conjugates and illuminated as described. Immediately, 2 h and 20 h after 
illumination cells were incubated with 1:250 Annexin-V-Alexa488 (Life Technologies, Thermo 
Fisher Scientific, Waltham, MA, USA) and 1 µg/ml propidium iodide in 10 mM HEPES pH 
7.4/140 mM NaCl/2.5 mM CaCl2 to stain apoptotic and dead cells, respectively. Stained cells 
were visualized with the EVOS. As a positive control, cells were treated with 2 µM staurosporin 
for 4 h at 37°C
 Furthermore, extracts of treated cells 2 h and 4 h after illumination and of staurosporin 
treated control cells were made with RIPA buffer (#9806, Cell Signaling Technology, Danvers, 
MA, USA). 20 µg of total protein was run on an 8% SDS-PAGE gel, and electroblotted on a 
nitrocellulose membrane (GE healthcare, Little Chalfont, USA). Blots were stained with rabbit-
anti-cleaved-Caspase-3 (Asp175) (1:1000, #9661, Cell Signaling Technology) and mouse-anti-
GAPDH. Blots were visualized on the Odyssey scanner.
In vitro PDT assays with spheroids
Because 3D cell cultures better recapitulate clinical tumors than adherent 2D cell cultures, 
we grew SK-OV-3 cells as tumor spheroids. To this end, 96-well round bottom culture plates 
were coated with 100 µl/well 1% agarose (Sigma Aldrich, Saint Louis, MO, USA) in DMEM/
F12 medium (Gibco, Thermo Fisher Scientific, Waltham, MA, USA). SK-OV-3 cells (30,000/well) 
were seeded in 100 µl DMEM/F12 medium containing 0.3% BSA. Three days after seeding, the 
spheres were incubated for 30 min or 1 h at 37°C in DMEM/10% FCS and 120 nM 7D12-C[PS], 
7D12-C[PS]-hLF, PS alone or medium only. After washing with DMEM/10% FCS spheres were 
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illuminated with a 60 J/cm2 total light dose. After overnight incubation at 37°C, spheres were 
fixed in Unifix (Klinipath, Duiven, The Netherlands) at RT, and embedded in agar. 4 µM sections 
were stained with hematoxylin and eosin. 
Ex vivo PDT assays with clinical ascites samples 
All experiments with patient materials were performed according to institutional guide lines. 
To examine whether PIT with our conjugates could be an option for treatment of ovarian cancer 
we tested our constructs on cells, freshly derived from malignant ascites of patients diagnosed 
with high-grade serous ovarian carcinoma. Ascites was filtered through a 70 µm cell strainer. 
Nucleated cells were isolated by centrifugation on Ficoll, according to the manufacturer’s 
instructions (Sigma Aldrich, Saint Lois, MO, USA) and cultured in RPMI/10% FCS/40 ug/ml 
gentamycin. For PDT experiments, cells were seeded at 10,000 cells per well in a 96-well plate 
and grown until >50% confluency. After incubation with 15 nM of the 7D12-C[PS], 7D12-C[PS]-hLF 
or PS alone for 30 min, cells were illuminated with 60 J/cm2 total light dose. The next day, cell 
viability was determined using the SRB assay. In parallel experiments, ascites-derived cells 
were incubated with 15 nM of the different 7D12-C[PS] conjugates, illuminated and incubated 
overnight. The next day, cells were incubated with either 1 µg/ml cetuximab for 20 min and 
goat-anti-human Alexa488 (1:200 Thermo Fisher Scientific, Waltham, MA, USA) for 20 min to 
verify EGFR expression, or mouse-anti-EpCAM (1:200 Abcam, Cambridge, UK, ab7504) and 
donkey-anti-mouse Alexa488 (1:200 Thermo Fisher Scientific, Waltham, MA, USA) to verify 
EpCAM expression, and with 1 µg/ml Propidium iodide (Thermo Fisher Scientific, Waltham, 
MA, USA) to visualize dead cells. Propidium iodide and bound antibodies were visualized using 
the EVOS microscope.
Statistics
Experiments were performed at least in duplicate, and within experiments all measurements 
were done in triplicate. IC50 values were determined in Graphpad Prism and statistical 
significance was checked with a Student’s T-test. To check for significance of other data a 
one-way ANOVA with post hoc Bonferroni was performed in Graphpad Prism; * = p<0.05, ** = 
p<0.01, *** = p<0.001.
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ABSTRACT
Recombinant llama heavy-chain antibody fragments (VHHs) are promising tools in the field of 
targeted nanomedicine. 7D12, a VHH against the epidermal growth factor receptor (EGFR) that 
is overexpressed in various cancers, has been evaluated as an effective cancer-targeting VHH 
in multiple studies. The small size of VHHs (15-20 kDa) results in a low circulation half-life, 
which can be disadvantageous for certain applications. A solution to this problem is to attach 
VHHs to the surface of nanoparticles to increase the hydrodynamic radius of the conjugate. 
This approach simultaneously allows the incorporation of different VHHs and/or other targeting 
moieties and therapeutic components into one structure, creating multispecificity and versatility 
for therapy and diagnosis. Here, we present the construction of highly defined 7D12-containing 
nanoparticles by utilizing thermo-responsive diblock elastin-like peptides that reversibly self-
assemble into micellar structures. The resulting particles have a hydrodynamic radius of 24.3 
nm + 0.9 nm and retain full EGFR-binding capacity. We present proof of concept of the usability 
of such particles by controlled incorporation of a photosensitizer and show that the resulting 
nanoparticles induce EGFR-specific light-induced cell killing. This approach is easily extended 
to the controlled incorporation of various functional modules, improving therapy and diagnosis 
with targeted nanomedicine
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INTRODUCTION 
The variable region of heavy-chain antibodies found in cameloids, called VHH, is of great interest 
to the field of nanomedicine1-3. VHHs are thermo- and pH-stable proteins that are well tolerated 
by the human immune system. Their affinity can equal or even supersede that of ‘conventional’ 
antibodies. In combination with cytotoxic agents, tumor-targeting VHHs can specifically recognize 
and kill cancer cells4-5. Although their small size of 15-20 kDa allows deeper tissue penetration 
than conventional antibodies, it also results in a low circulation half-life. 
 Nanoparticles decorated with VHHs have been developed to overcome the short blood-
circulation time by increasing the hydrodynamic radius; the nanoparticle structure furthermore 
enables increased and more versatile drug loading6-8. Decoration with VHHs usually follows 
particle formation, and encapsulation or attachment of a desired payload is typically achieved 
during particle formation or via an additional coupling step. This procedure makes it difficult 
to precisely assess and reproducibly control the resulting VHH concentration on the particles’ 
surface and the VHH-to-payload ratios. Controlling these parameters is essential to achieve 
maximum efficacy with minimal side effects. Thus, there is a clear need for optimally defined 
and controlled VHH-displaying nanoparticles.
 Elastin-like peptides (ELPs) are biocompatible polypeptides that form amorphous 
coacervates in a temperature-dependent fashion9-11. They are composed of repeating 
pentameric units with the sequence glycine-X-glycine-valine-proline (GXGVP), where X can 
be any amino acid11-12. ELPs reversibly transform from a soluble, disordered state below the 
transition temperature to an assembled state consisting of type-II β-turns, type-I β-turns and 
β-strands above the transition temperature13-16. This behavior is thermodynamically driven: at 
the transition temperature, solvation of the protein backbone becomes entropically unfavorable. 
The conformational change and exposure of hydrophobic residues followed by assembly results 
in liberated water molecules, lowering the total energy of the system. Further increases in 
temperature enhance this effect. This so-called lower critical solution temperature (LCST) 
highly depends on the nature of the guest residue X, with hydrophilic residues raising the LCST 
and hydrophobic residues lowering it. ELP length, concentration and presence of salts also 
affect the LCST17. 
 VHH-ELP fusion proteins have previously been synthesized with the aim to allow easy 
purification via temperature cycling, followed by VHH cleavage via introduced protease-sensitive 
tags18. ELP-based nanoparticles have been prepared out of amphiphilic block copolymers, 
either by employing ELP diblock polypeptides with different guest residues and hence different 
LCSTs9-10,19, or by coupling ELPs with low LCST to hydrophilic polymers such as poly(ethylene 
glycol)20. Given the excellent bio-compatible properties of ELPs21-22, we envisioned the possibility 
of integrating VHH-ELP expression systems with the nanoparticle-forming potential of ELPs.
 Here we report the use of an ELP diblock polypeptide (ELPDB) to create self-assembling 
theranostic VHH-nanoparticles. The ELPDB was composed of a ‘hydrophilic’ and a ‘hydrophobic’ 
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block, terms that relate to the solvation state of the ELP block at physiological conditions. The 
hydrophilic block consisted of 60 pentamers with alanine or glycine guest residues in a ratio 
of 3 to 2. The hydrophobic block contained 60 pentamers with isoleucine as guest residues. 
We used the VHH 7D12 that targets the epidermal growth factor receptor (EGFR)23-24. Fc5, 
an unrelated VHH directed against the endothelial receptor Cdc50A, was used as control25. 
Well-defi ned composite nanoparticles were reproducibly made by combining 7D12-ELPDB
or Fc5-ELPDB fusion proteins with ELPDB as molecularly dissolved species at predetermined 
ratios, followed by heating the solution above the LCST of the hydrophobic block (Figure 
1). The 7D12-decorated ELP micelles were able to selectively target tumor cells that (over)
express EGFR. Upon incorporation of a third ELPDB to which the photosensitizer IRDye700DX 
was conjugated, the composite nanoparticles could be used for highly effective and specifi c 
photoimmunotherapy (PIT).
Heat 
Cool 
= Hydrophobic ELP block
= Hydrophilic ELP block
= VHH
= Photosensitizer
= EGFR
light activation
Figure 1. Schematic representation of photodynamic therapy with self-assembling recombinant Llama 
heavy-chain antibody fragments (VHHs). Amphiphilic diblock elastin-like polypeptides (ELPDB) are mixed 
at low temperatures with ELPDB functionalized with a photosensitizer and ELPDB functionalized with a 
VHH directed against epidermal growth factor receptor (EGFR) at a known ratio. Upon heating to 37°C, 
components spontaneously assemble into supramolecular structures simultaneously displaying VHHs 
and photosensitizer. Only EGFR expressing cells die after incubation with particles and subsequent 
illumination.
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RESULTS AND DISCUSSION
The VHH-ELPDBs were prepared by cloning cDNA sequences coding for 7D12 and Fc5 in frame 
with ELPDB. An intervening cysteine residue was introduced as a handle for maleimide-based 
modification. Fusion proteins were successfully expressed in BLR(DE3) Escherichia coli cells 
by auto-induction (Figure 2). The sequences were preceded by a pelB leader sequence to direct 
the protein to the periplasm of E.coli. The slightly oxidative milieu in the bacterial periplasm 
allowed the proper formation of internal disulfide bonds present in 7D12 and Fc5. The proteins 
were purified by inverse-transition cycling. ELPDB and VHH-ELPDB fusion proteins were 
obtained in > 95% purity with 20-50 mg/L yield (Table 1, Figure 2A). Molecular masses of the 
protein samples were measured via electrospray ionization time-of-flight spectrometry (ESI-
ToF) and agreed well with the predicted masses (Table 1, Figure 2B). The N-terminal formyl 
methionine of ELPDB was cleaved off as expected26. For 7D12-ELPDB and Fc5-ELPDB, complete 
removal of the pelB sequence was observed. For 7D12-ELPDB, an additional peak was found. 
7D12 contains an N-terminal glutamine, which is known to be converted in an autocatalytic 
or enzymatic step to pyroglutamate, resulting in the loss of ammonia, explaining the 18 Da 
difference27. Fc5-ELPDB, which does not contain N-terminal glutamine, did not show this side 
product (Table 1).
Table 1. Overview of proteins used in this study. 
Construct Yield (mg/L)1 Theoretical mass 
(Da)2
Found mass (Da)3 Labelling efficiency 
(%)4
ELPDB 43 48198 48198 NA
7D12-ELPDB 33 63049 63031 & 63049 NA
Fc5-ELPDB 47 61903 61904 NA
Alexa647-ELPDB NA 49037 49036 61 + 2
PS-ELPDB NA 49951 49951 Quantitative
7D12FL-ELPDB NA 63475 63457 & 63475 89 + 12
Fc5FL-ELPDB NA 62330 62332 88 + 3
1Yield specifies obtained product per liter of bacterial culture. 2The theoretical mass was determined with 
ExPASy (http://www.expasy.org/) excluding the N-terminal methionine for ELPDB or the pelB sequence for 
7D12-ELPDB and Fc5-ELPDB (see SI). 3Mass found after deconvolution of mass spectrum. 4Percentage of 
labeled protein.
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Figure 2. Characterization of expressed proteins and formed nanoparticles. A) SDS-PAGE of ELPDB (silver-
stained, absence of aromatic amino acids in the ELP prevents Coomassie Brilliant Blue (CBB) staining), 
7D12-ELPDB and Fc5-ELPDB (stained with CBB). B) Mass spectra and deconvoluted masses of a) ELPDB, b) 
7D12-ELPDB and c) Fc5-ELPDB. C) Particle formation and aggregation of ELPDB nanoparticles as determined 
by spectrometry. Left) A 10 µM solution of ELPDB, 7D12-ELPDB or Fc5-ELPDB in PBS was gradually heated at 
1°C/min. Right) Zoom-in showing the slight increase in turbidity at the fi rst transition temperature around 
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25°C for ELPDB consistent with particle formation. The VHH-ELPDB constructs directly transition into bigger 
aggregates at a similar transition temperature as determined by DLS. D) Size-exclusion chromatography 
coupled to multi-angle light scattering of nanoparticles containing 100% ELPDB, 10% 7D12-ELPDB or10% 
Fc5-ELPDB. E) Evaluation of nanoparticle stability as a function of the fraction of 7D12-ELPDB or Fc5-ELPDB. 
X-axis represents the ratio of VHH-ELPDB to ELPDB in the micelles.
Table 2. Results from SEC-MALS measurements of the different nanoparticle formulations.
Sample Rh (nm)
1 Rrms (nm)
2 ρ3 Mass (kDa)4 Monomers 
per micelle5
ELPDB 24.0 + 0.5 17.2 + 0.1 0.72 + 0.02 10300 + 15 214
10% 7D12-ELPDB 24.6 + 0.6 17.4 + 0.1 0.71 + 0.02 9958 + 17 200
10 % Fc5-ELPDB 24.3 + 0.6 19.8 + 0.3 0.81 + 0.02 10470 + 16 211
1Hydrodynamic radius. 2Radius of gyration. 3Radius of gyration divided by the hydrodynamic radius. 4Average 
molecular mass. 5Monomers per micelle calculated with the weighted average molecular mass of ELPDB 
particles and monomers. See Figure 2D for SEC-MALS data.
ELPDB nanoparticles were stable between 25°C and 55°C (Figure 2C). For characterization, 
purified ELPDB, 10% 7D12-ELPDB, 10% Fc5-ELPDB were heated to 37oC after which hydrodynamic 
radius, radius of gyration and molecular weight were determined by size-exclusion 
chromatography, followed by multi-angle light scattering (SEC-MALS) (Figure 2D). The 
hydrodynamic radius of particles with purified ELPDB was approximately 24 nm (Table 2). The 
ratio of radius of gyration to hydrodynamic radius, an indication of the morphology of particles, 
was close to the theoretical value of a homogeneous sphere (0.778)28-29. The mass distribution 
(with an average of 10.3 MDa) revealed that particles consisted of on average 214 monomers 
per micelle, in agreement with comparable ELP particles11. 
 In order to determine the maximum possible functionalization degree of the nanoparticles 
with VHH, we proceeded by systematically mixing ELPDB with different percentages of 7D12-
ELPDB or Fc5-ELPDB. We observed a transition point at 50% 7D12-ELPDB and 60% Fc5-
ELPDB, respectively. Above this ratio, uncontrolled aggregation resulted in micrometer-sized 
aggregates or coacervates (Figure 2E). The loss of particle stability can be explained by a 
geometrical model. Assuming a homogenous sphere with a radius of 24 nm, consisting of 
214 monomers, each exposed monomer terminus occupies a surface of 33.8 nm2, or a sphere 
with a radius of approximately 2 nm. Since the radius of VHHs is around 2-3 nm30, it is highly 
plausible that steric hindrance at high VHH-ELPDB ratios occurs, leading to rearrangement 
and/or aggregation. 
 Incorporation of 10% VHH-ELPDB resulted in well-defined micelles with physicochemical 
characteristics similar to ELPDB micelles (Table 2, Figure 2D). This percentage should result in 
a display of approximately 20 VHH molecules per micelle.
Since the LCST of ELPDB is concentration dependent, we determined the critical micelle 
concentration (CMC) by dynamic light scattering (DLS) and found that the CMC is lower than 
100 nM (Figure 3). 
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 In order to mimic in vivo conditions we investigated the effect of the presence of human 
serum (HS) on the particle properties. ELP micelles in HS were shown to be stable for at 
least 2 h at 37°C, and furthermore could be reversibly assembled in a temperature-dependent 
manner (Figure 4).
Figure 3. Concentration range of ELPDB under assembling conditions with dynamic light scattering (DLS).
Figure 4. Stability of ELPDB particles in human serum (HS). The temperature-dependent change in derived 
count rate shows the formation of larger species, which increases the total amount of light scattered, 
conform to the transition of ELPDB monomers to micelles (data not shown) in the sample containing ELPDBs 
(HS + ELP). As aggregation into precipitates was not observed with visual inspection, these data strongly 
indicate stable particles in the timeframe shown.
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Figure 5. A) Obtained masses from a) Fc5FL-ELPDB, b) 7D12FL-ELPDB c) Alexa647-ELPDB and d) PS-ELPDB. B) 
SDS-PAGE of fl uorescein-labeled 7D12 and VHH-ELPDB constructs by visualized by UV illumination.
To separately follow the fate of VHH-ELPDB and ELPDB after cellular uptake of composite 
micelles, we labeled VHH-ELPDB with fl uorescein-5-maleimide (FL), yielding 7D12FL-ELPDB
and Fc5FL-ELPDB (Figure 5A+B). ELPDB was labeled with Alexa647-N-hydroxysuccinimide (NHS) 
ester or IRDye700DX (PS) via NHS chemistry at the N-terminal amino group of ELPDB, yielding 
Alexa647-ELPDB and PS-ELPDB, respectively (Table 1, Figure 5A).
 FL-fl uorescence-based fl ow cytometry, performed at 4°C to prevent self-assembly 
into micelles and internalization, showed that monomeric 7D12FL-ELPDB, but not Fc5FL-
ELPDB, effectively bound to EGFR-expressing A431 cells (Figure 6A), demonstrating that the 
7D12 moiety had retained its EGFR affi nity. 7D12FL-ELPDB binding was slightly less than the 
7D12FL control, indicating that the fusion to ELPDB may induce some steric hindrance at low 
temperatures. No binding to the EGFR-negative E98 cell line was observed for either 7D12FL-
ELPDB or Fc5FL-ELPDB. These experiments clearly illustrate that the specifi city of 7D12 remains 
unchanged in the context of a fusion protein with ELPDB, and that ELPDB itself did not show 
aspecifi c binding to the cell lines tested.
 We next prepared micelles by heating a mixture of ELPDB, Alexa647-ELPDB and VHHFL-
ELPDB (85:5:10) to 37°C, and analyzed in vitro binding and uptake by measuring cell-associated 
FL fl uorescence and Alexa647 fl uorescence in fl ow cytometry experiments. 7D12FL-Alexa647-
ELPDB micelles associated with A431 cells but not with EGFR-negative E98 cells (Figure 6B).
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 Incubation with composite 7D12FL-Alexa647-ELPDB micelles resulted in 44% higher cell-
associated FL fluorescence relative to the situation in which equal concentrations of (monomeric) 
7D12FL were used, indicating a multivalency and avidity effect of 7D12FL induced by particle formation. 
Of note, incubation of A431 with 7D12FL-Alexa647-ELPDB micelles also resulted in cell-associated 
Alexa647 fluorescence (Figure 6B), and fluorescence microscopy revealed membranous and 
intracellular colocalization of both Alexa647 and FL (Figure 6C), indicating that 7D12FL associated 
with the cells as part of intact micelles. Fc5FL-Alexa647-ELPDB micelles showed little background 
association with A431 cells. Altogether, these data show that composite 7D12FL-Alexa647-ELPDB 
micelles that target tumor cells in an EGFR-specific manner can be created.
 Unfortunately, 7D12 binds to EGFR only in a cell context31. Since the VHH is internalized 
upon EGFR binding at 37 oC, it is difficult to quantitatively compare avidity effects of 7D12FL in 
micellar or monomeric form, because at 37oC results will always be biased by internalization 
effects. Future studies with other VHH-ELP constructs that can be used in cell-free systems 
may provide important answers on the subject of avidity. 
 In an effort to determine the CMC of the functionalized particles in vitro, we varied the 
concentration of all components, maintaining the same ratios. As shown in Figure 6D, 7D12-
induced binding and uptake of Alexa647-ELPDB occurred at concentrations as low as 160 nM 
(VHH concentration of 16 nM), showing the presence of co-functionalized micelles and agreeing 
with results obtained by DLS. Using lower ELPDB concentrations for more accurate determination 
of the CMC was not feasible due to insufficient fluorophore signal to noise ratio. For a more 
accurate determination in vitro we used the photodynamic therapy assay as described below.
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Figure 6. Cellular binding and uptake of VHHFL-ELPDB monomers and micelles, respectively. A) Cell-
associated FL fl uorescence as determined with fl ow cytometry after cold (4°C) incubation with 1 µM 7D12FL, 
7D12FL-ELPDB or Fc5FL-ELPDB monomers. B) Cell associated FL and Alexa647 fl uorescence as determined 
with fl ow cytometry after warm (37 °C) incubation with 10 µM (refers to total ELPDB concentration) of 
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7D12FL-Alexa647-ELPDB micelles or Fc5FL-Alexa647-ELPDB micelles. Note that there is some unexplained 
non-specific background binding of Alexa- ELPDB but not of VHHFL-ELPDB C) Microscopy of A431 cells 
visualizing cell-associated FL and Alexa647 fluorescence after incubation with VHHFL-Alexa647-micelles. 
The scale bar denotes 50 µm. D) Cell-associated FL and Alexa647 fluorescence as determined with flow 
cytometry after warm (37 °C) incubation of A431 cells with a concentration range of 7D12FL-Alexa647-ELPDB 
micelles or Fc5FL-Alexa647-ELPDB micelles. * indicates significance with p<0.05, ** indicates significance 
with p<0.01, *** indicates significance with p<0.001. 
To test whether EGFR-targeting ELPDB-based micelles can be used in a therapeutic manner, 
we prepared 7D12FL-ELPDB micelles containing the photosensitizer IRDye700DX, conjugated to 
ELPDB (PS-ELPDB). Of note, the micelles with different compositions of VHHFL-ELPDB and PS-
ELPDB monomers, all have a hydrodynamic radius of 29-34 nm, as measured by 
DLS (Table 3).
Table 3. Hydrodynamic radius of different ELPDB micelle compositions as measured by DLS (mean 
intensity).
Composition Hydrodynamic radius (nm)
100 % PS - ELPDB 30.7 + 10.2
2 % 7D12FL - ELPDB, 98 % PS-ELPDB 32.2 + 10.0
2 % Fc5FL - ELPDB, 98 % PS-ELPDB 29.3 + 6.4
10 % 7D12FL - ELPDB, 10 % PS -ELPDB 33.8 + 13.5
10 % Fc5FL - ELPDB, 10 % PS -ELPDB 33.4 + 14.0
ELPDB 30.5 + 8.4
 To achieve maximum drug loading while maintaining sufficient targeting capacity, we 
prepared micelles containing 2% VHHFL-ELPDB and 98% PS-ELPDB. Cell-killing efficiency of 
these micelles was compared to cell killing by monomeric 7D12, directly conjugated with 
IRDye700DX (7D12PS). A431 or E98 cells were incubated with 7D12FL-PS-micelles or equimolar 
amounts of 7D12PS prior to illumination. 7D12FL-PS-ELPDB micelles actively killed A431 cells in 
a light-dependent and 7D12-specific manner with an EC50 concentration of 82.7 pM compared 
to 121.5 pM for the 7D12PS control. (Figure 7A). This indicates that micelles were formed already 
at a VHH concentration as low as 82.7 pM, corresponding to an ELPDB concentration of 4.1 nM. 
No toxicity was observed towards E98 cells, proving that 7D12-mediated binding and/or uptake 
is necessary for toxicity. Control micelles composed of 2% Fc5FL-ELPDB and 98% PS-ELPDB 
showed no light-dependent toxicity upon illumination of either A431 or E98 cells. Importantly, 
no dark toxicity of either particle was found (Figure 7B). The cell-killing efficiency of 7D12-
ELPDB particles pre-incubated in human serum at 37°C for up to 4 hours, was surprisingly 
increased compared to particles diluted in DMEM/10%FCS (Figure 7C), indicating that particles 
are stable and therapeutically active in 100% serum. 
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Figure 7. Phototoxicity induced by VHHFL-PS-ELPDB micelles in A431 and E98 cells. A) Relative cell viability 
after incubation and illumination with either 7D12FL-PS-ELPDB micelles, Fc5FL-PS-ELPDB micelles or 7D12PS 
control. B) Relative cell viability after incubation without illumination with either 7D12FL-PS-ELPDB micelles 
or Fc5FL-PS-ELPDB micelles or 7D12PS control. Note the absence of dark toxicity. C) Efficacy of PDT in 
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A431 cells after incubation of the VHHFL-PS-micelles in human serum (HS). The graphs depict the relative 
cell viability after incubation with either 7D12FL-PS-micelles or Fc5FL-PS-micelles that are pre-incubated 
for 30, 120 or 240 min in HS and subsequent illumination. HS only (HS control) and 7D12FL-PS-micelles 
or Fc5FL-PS-micelles directly diluted in DMEM (DMEM control) were taken as controls. D) Fluorescence 
microscopy of DiD labeled A431 (green) and DiO labeled E98 (blue) (co-)cultures that are incubated with 
propidium iodide (red) after incubation with 30 nM 7D12-ELPDB or Fc5-ELPDB based PS-ELPDB particles or 
equimolar VHH 7D12PS and illumination. The scale bar denotes 100 µm.
 The cell-specificity of the particles was further confirmed by co-culturing DiO-labeled 
A431 (green) and DiD-labeled E98 (blue) cells and performing photo-immunotherapy as 
described above. By staining dead cells with propidium iodide, it was observed that only EGFR 
expressing A431 cells died (Figure 7D). Thus, targeted photoimmunotherapy with 7D12FL-
PS-ELPDB micelles is highly specific for target-expressing cells without harming neighboring 
target-negative cells.
 The used light dose of 60 J/cm2 is physiologically relevant; clinical studies reported safe 
use of light doses up to 125 J/cm2 in for example non-small cell carcinoma in the lung and 
cervical cancer32. Still, the penetration depth of near-infrared light is below 1 cm, and therefore 
this treatment will often have to be combined with surgery.
 Assuming Poisson distribution, 2% VHH-ELPDB are sufficient to ensure that ~ 98% of all 
particles contain at least one targeting moiety. This leaves ample opportunities to combine 
several targeting groups in one particle and to further optimize their composition.
CONCLUSION
In conclusion, we have shown successful self-assembly of VHH-ELPDB conjugates into micelles 
that can be used for targeted photodynamic therapy in vitro and potentially in vivo. The 24 nm 
radii of these micelles are considered excellent for nanomedicine; large enough to avoid rapid 
clearance from the circulation, yet small enough to extravasate and penetrate the intercellular 
space of tumors. The system allows implementation of multiple VHHs to generate multi-
targeted drug delivery nanoparticles. Spontaneous micelle formation required concentrations 
as low as 4.1 nM. Further efforts will focus on validating the in vivo stability and activity of ELPDB 
nanoparticles. Combining the system with therapeutic and diagnostic molecules may result in 
an interesting theranostic platform. 
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METHODS
Cloning and protein expression
The VHHs 7D12 and Fc5 were used in this study; 7D12 is directed against EGFR, and Fc5 
targets the luminal brain endothelial cell protein Cdc50A33. 7D12 and Fc5 were expressed as 
fusion products with ELPDB and 7D12-C-LPETG-8xHis-Vsv, hereafter 7D12, was produced as 
a control for the in vitro studies. The gene sequences encoding for ELPDB, pelB-Fc5-ELPDB 
and pelB-7D12-ELPDB were cloned into pET-24a(+) (Novagen) expression vectors34, by recursive 
directional ligation, transformed into E.coli BLR(DE3) cells and grown on agar plates containing 
30 µg/mL kanamycin overnight at 37°C. A single colony was grown overnight at 30°C, 250 rpm 
in LB medium containing 50 µg/mL kanamycin and 0.5% w/v D-glucose. The overnight culture 
was diluted to an OD600 of 0.1 in filter-sterilized AIM TB medium (Formedium) containing 6 g/L 
glycerol, 0.005% Antifoam 204 and 50 µg/mL kanamycin. Cells were grown at 300 rpm at 37 °C 
for 20 hours. For 7D12-ELPDB and Fc5-ELPDB, the culture was shifted to 30 °C after 4 hours of 
growth.
 The pHENIX-7D12-C-LPETG-HIS-VSV plasmid was transformed in E.coli strain ER2566. 
Cells were grown at 37°C in 2xTY medium containing 3.5% (w/v) glycerol and 50 µg/ml 
ampicillin till an OD600 of 0.6-0.8. Protein expression was induced with 1.0 mM isopropyl β-D-
thiogalactoside (IPTG, Serva, Heidelberg, Germany) at 30°C for 2.5 hrs. 
Protein extraction and purification
Cells were collected by centrifugation at 2000 g, 4°C for 30 minutes. For cytoplasmic extraction, 
1 g of wet cell pellet was resuspended in 2 mL lysis buffer (50 mM Tris-HCl pH 8.0, 25 mM NaCl, 
1 mM EDTA, 0.1 mM PMSF, cOmplete™ Protease Inhibitor Cocktail, 0.5 mg/mL lysozyme) and 
incubated for 4 h at 4°C. Lysis was followed by sonication on a Branson Sonifier 250 (power 
level 2-4, 12 cycles of 10 s sonication, 10 s breaks). Cell debris was collected by centrifugation 
at 15,000 g at 4°C for 15 min. Residual DNA was precipitated by adding 0.5% w/v poly(ethylene 
imine) and removed by centrifugation at 15,000 g at 4°C for 15 min. ELPDB was precipitated 
by adding a saturated solution of (NH4)2SO4 up to 10-25 v/v%. Proteins were collected by 
centrifugation at 15,000 g at 4°C for 15 min. The pellet was resuspended in phosphate buffered 
saline and centrifuged to remove insoluble contaminants at 15,000 g at 4°C for 20 min. This 
cycle was repeated until sufficient purity was achieved, usually after 2-4 cycles. ELPs were 
resuspended in MilliQ, desalted on a HiPrep 26/10 (GE Healthcare Life Sciences) with an AKTA 
Explorer 10 (GE Healthcare Life Sciences) at 1 mL/min MilliQ. Residual salt concentration was 
below 0.001 mg/mL as determined by conductivity. The ELP solution was filter-sterilized with 
0.22 µm PES syringe filters (Nalgene) and freeze-dried. Yield was determined by weighing and 
varied around 43 mg/L culture (Table 1).
 For periplasmic extraction of 7D12, 7D12-ELPDB and Fc5-ELPDB, 1 g of wet cell pellet was 
resuspended in 10 ml extraction buffer A (0.2 M TRIS pH 8.0, 0.5 mM EDTA, 20 w/v% sucrose, 0.1 
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mM PMSF, cOmplete™ protease inhibitor cocktail) and incubated for 30 min at 4°C. Cells were 
pelleted by centrifugation at 2000 g for 30 minutes at 4°C and the supernatant collected. The 
extraction was repeated with extraction buffer B (0.2 M TRIS pH 8.0, 15mM MgSO4, cOmplete™ 
protease inhibitor cocktail). Both supernatants were pooled before further processing. ELPs 
were precipitated as described above. Yield was determined by integration of the absorbance 
at 280 nm after separation with a Bio-Sec 5 300 Å column on an Agilent Bio-Inert HPLC with 
a flow rate of 1 mL/min PBS (Table 1). Aliquots were flash-frozen in liquid nitrogen and stored 
at -80°C. 7D12 was purified using Ni-NTA sepharose (IBA, Goettingen, Germany) by incubating 
the extraction supernatant with pre-equilibrated Ni-NTA sepharose for 1 h at 4°C, and after 
washing, the proteins were eluted with 500 mM imidazole. The eluate was dialyzed against 50 
mM Tris-HCl pH 7.5 and 150 mM NaCl.
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
Proteins were run under reducing conditions on 12% SDS-PAGE gels. Gels were either silver-
stained in the case of ELPDB or stained with coomassie brilliant blue (CBB) in the case of 
7D12, 7D12-ELPDB and Fc5-ELPDB. Purity was calculated from integrated pixel intensity after 
scanning the gels with ImageJ (https://imagej.nih.gov/ij/).
Electrospray ionization – time of flight mass spectrometry (ESI-TOF)
Mass was determined by ESI-TOF on a JEOL AccuTOF. Freeze-dried samples were resuspended 
in MilliQ to a concentration of 10 µM, samples containing buffer were first desalted with MilliQ 
using Amicon Ultra-0.5 spin filter units (Millipore, 10 kDa MWCO). All samples were acidified 
with 0.1% formic acid upon injection. Deconvoluted spectra were obtained using MagTran 1.03 
b2. 
Size-exclusion chromatography followed by multi-angle light scattering (SEC-
MALS)
For SEC-MALS, the samples were separated on a Bio-Sec 5 1000 Å column (Agilent) at 0.4 mL/
min; the mobile phase was 0.1 M phosphate buffer pH 7.0 at 35 °C. 7D12-ELPDB and Fc5-ELPDB 
were reduced with a molar excess of TCEP to avoid dimer formation prior to injection for 20 
minutes at 4°C. Samples were equilibrated at 35°C before injection of 20 µL. Light scattering 
data were collected on a DAWN HELEOS II MALS detector (Wyatt) and differential refractive 
index was measured on an Optilab T-rex refractometer (Wyatt). Dn/dc values were determined 
theoretically35.
Alexa647-ELPDB and PS-ELPDB
Freeze-dried ELPs were resuspended in 50 mM NaHCO3 pH 7.84. Alexa647-NHS ester and IRDye 
700DX-NHS ester were resuspended in DMSO and added drop-wise to the protein solution. The 
molar ratio ELPDB to NHS ester was 1:1 in the case of Alexa 647 and 1:1.3 in the case of IRDye 
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700DX. The reaction was allowed to proceed for 4 hours at 21°C, 300 rpm. Unreacted dye was 
removed by dialysis against MilliQ using Amicon Ultra-0.5 spin filter units (Millipore, 10 kDa 
MWCO). The volume of the dialyzed protein samples was determined; efficiency of conjugation 
was determined by measuring dye concentration and weighing protein samples after freeze-
drying. Concentrations of the dyes were determined at 650 nm (ε = 270,000 cm-1M-1) and at 689 
nm (ε = 165,000 cm-1M-1) for Alexa647 and IRDye700 DX, respectively. Mass was determined by 
ESI TOF (Table 1).
7D12FL and 7D12PS
Fluorescein-5-maleimide and maleimide-PEG4-DBCO (Jena Bioscience, Jena, Germany) were 
conjugated to 7D12. The free thiol of the C-terminal cysteine in 7D12 was reduced by incubation 
with 20 mM TCEP for 15 min at RT. TCEP was removed by dialysis to 20 mM phosphate buffer 
pH 7.0, 150 mM NaCl and 5 mM EDTA in a 10 kDa MWCO centrifugal unit (Amicon, Millipore, 
Billerica, MS, USA). The VHH was incubated with either maleimide-5-fluorescein or maleimide-
PEG4-DBCO in a 1:3 molar ratio for 2 hrs at RT. Excess of maleimide probes was removed by 
dialysis to 50 mM Tris-HCl pH 7.5 and 150 mM NaCl in a 10 kDa MWCO centrifugal filter unit. 
IRDye700DX-NHS ester (LI-COR, Lincoln, NE, USA) was incubated with H2N-PEG3-N3 (Jena 
Bioscience, Jena, Germany) in a 3:1 molar ratio for 7 h in 100 mM phosphate pH 8.6 and 150 
mM NaCl. Subsequently 7D12DBCO was incubated with PS-N3 in a 1:2 molar ratio o/n at RT. 
7D12PS was purified by filter centrifugation in a 10 kDa MWCO filter unit using 50 mM Tris-HCl 
pH 7.5 and 150 mM NaCl. Protein purity was analyzed with SDS-PAGE gel electrophoresis, and 
concentration was determined by measuring ultraviolet absorbance at 495 or 689 nm for FL 
and PS conjugates, respectively. Aliquots were stored at -80°C.
7D12FL-ELPDB and Fc5FL-ELPDB
7D12-ELPDB and Fc5-ELPDB were dialyzed to 0.1 M phosphate buffer pH 7.0. TCEP was added 
in a ratio of 20:1 to reduce the introduced cysteine. Fluorescein-5-maleimide was dissolved 
in DMSO and added to 7D12-ELPDB at a ratio of 10:1. Unbound Fluorescein-5-maleimide was 
removed by dialysis using Amicon Ultra-0.5 spin filter units (Millipore, 10 kDa MWCO). Labeling 
efficiency and protein concentration were determined by integration of the absorbance at 280 
and 495 nm after separation with a Bio-Sec 5 300 Å column on an Agilent Bio-Inert HPLC with 
a flow rate of 1 mL/min 0.1 M NH4HCO3 pH 8.62 (Table 1). Mass was determined by ESI TOF. 
7D12FL-ELPDB and Fc5FL-ELPDB were flash-frozen in liquid nitrogen and stored at -80°C.
Dynamic light scattering and stability of ELP particles in human serum
Samples were diluted to a final concentration of 2 µM in PBS. Measurements were performed 
on a Malvern Zetasizer Nano. Samples were incubated for 5 minutes at 37°C before data 
collection. Reported values are averages of 3 independent measurements. For particle stability, 
10 µM of 2% 7D12FL-ELPDB, 98% PS-ELPDB was added to human serum. Human serum alone, 
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to which an equal volume of PBS alone was added, was taken as control. Light scattering 
data was collected at 4°C and 37°C. Aggregation was inspected visually. Reported values are 
averages of 3 independent measurements.
Cell culture
Human epidermoid carcinoma A431 cells with amplification of EGFR and high grade astrocytoma 
E98 cells without EGFR expression were cultured in DMEM (Lonza, Basel, Switzerland), 
supplemented with 10% FCS (Gibco) and 40 µg/ml gentamycin (Centrafarm, Etten-Leur, The 
Netherlands). Cells were cultured at 37°C in 5% CO2 in a humidified atmosphere.
Flow cytometry
To determine functionality of 7D12FL-ELPDB monomers, binding to A431 and E98 cells was 
determined under non-internalizing conditions at 4°C. A431 and E98 cells were dissociated 
from culture flasks using 10 mM EDTA in PBS and transferred to V-bottom shaped 96-wells 
microplates (BD Biosciences, Franklin Lakes, NJ, USA) at 5 x 105 cells per well. Cells were 
blocked with PBA (PBS, 0.5% BSA and 2% FCS) for 10 minutes at 4 °C, after which they were 
incubated with 1 µM 7D12FL-ELPDB or controls Fc5FL-ELPDB and 7D12FL in PBA for 30 min at 4°C. 
After washing twice with cold PBA, cell-associated fluorescence was quantified on the Cyan 
flow cytometer (Beckman Coulter, Fullerton, CA, USA) with parameter FL-1. To determine 
uptake of VHH functionalized ELP nanoparticles and compare this to monomeric VHHs, A431 
and E98 cells were grown to 80% confluency in 8 well chambered Lab-Tek chambers (NUNC) 
after which cells were incubated with a concentration range of pre-warmed 7D12FL; 10% 
7D12FL-ELPDB, 5% Alexa647-ELPDB, 85% ELPDB particles or 10% Fc5FL-ELPDB, 5% Alexa647-
ELPDB, 85% ELPDB particles in DMEM with 10% FCS for 30 min at 37°C. Cells were washed 
twice with warm DMEM with 10% FCS, dissociated with trypsin and taken up in PBA, and 
cell associated fluorescence was quantified on the Cyan flow cytometer with parameters FL-1 
and FL-8. Experiments were performed in triplicate and statistical significance was tested 
with an unpaired Student’s T-test. Furthermore, cells were imaged after incubation with 
ELPDB particles (or equimolar VHH of 7D12FL) on the EVOS microscope using LED cubes GFP 
(Fluorescein) and Cy5 (Alexa647).
In vitro PDT assays
A431 and E98 cells were cultured in clear 96 wells plates till 80% confluency. Then cells were 
incubated with a concentration range of pre-warmed 7D12PS or 2% 7D12FL-ELPDB, 98% PS-
ELPDB particles or 2% Fc5FL-ELPDB, 98% PS-ELPDB particles in DMEM with 10% FCS for 30 
min at 37°C. Cells were washed twice with warm DMEM with 10% FCS, and subsequently 
cells were illuminated with 100 mW/cm2 for 600 sec, reaching a total light dose of 60 J/cm2, 
using a standardized light emitting diode device (690 ± 10 nm). Cells were incubated with 729 
nM of 10% 7D12-ELPDB 10% PS-ELPDB, 10% Fc5-ELPDB 10% PS-ELPDB particles or 72.9 nM 
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7D12PS without subsequent illumination to determine dark toxicity. Cell viability was quantified 
using sulforhodamine B (SRB) colorimetric assays, and results were expressed as cell viability 
relative to untreated illuminated cells. 
 To examine selectivity of PDT-induced cytotoxicity, 5x105 cells were labeled with DiO (A431) 
or DID (E98) dye (Life technologies, Thermo Fisher Scientific, Waltham, MA, USA) according 
to manufacturers’ protocol. A431, E98 or 1:1 mixtures of the cells were plated and subjected 
to PIT with 30 nM of the particles or equimolar VHH concentrations of the 7D12PS control as 
described above. Four hours after illumination, cells were incubated with 1 µg/ml propidium 
iodide (Thermo Fisher Scientific, Waltham, MA, USA) in PBS for 15 min. Cells were visualized 
with the EVOS microscope using the RFP channel (Propidium Iodide), the GFP channel (DiO 
labeled cells) and the Cy5 channel (DiD labeled cells).
Stability of ELPDB particles in human serum
Stability of ELPDB particles in serum was evaluated further by incubating 96 nM [ELP] 2 % 
7D12FL-ELPDB, 98 % PS-ELPDB or 2 % Fc5FL-ELPDB, 98 % PS-ELPDB in freshly obtained human 
serum (HS) for either 30 minutes, 2 hours and 4 hours at 37°C. Subsequently the 96 nM stocks 
were diluted in DMEM with 10% FCS and PDT assays were performed with A431 cells as 
described earlier. Cell viability was compared to controls incubated with diluted serum without 
PS-ELPDB micelles and with PS-ELPDB micelles directly diluted in DMEM with 10 % FCS. 
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METABOLISM IN CANCER
Alterations in cancer metabolism
Research into the metabolism of cancer cells dates back almost a century, when Otto Warburg 
found that cancer cells divert to glycolysis over oxidative phosphorylation, even in the presence 
of oxygen (Warburg effect)1-2. A number of theories were proposed to explain this phenomenon, 
like adaptation to hypoxia and inability to perform oxidative phosphorylation due to mitochondrial 
defects1,3. However, now it has become increasingly clear, that the glycolytic switch is the 
result of oncogenic transformation, involving activation of oncogenes and inactivation of tumor 
suppressor genes. Like for non-malignant cells that need to support high proliferation rates 
(e.g. activated T-cells), tumors have increased uptake of glucose and glutamine that are needed 
for efficient biosynthesis of macromolecules. Activation of key oncogenic signaling pathways 
(e.g. PI3K/Akt/mTORC, Myc), or inactivation of tumor suppressors (e.g. p53) due to mutations 
affect cancer cell metabolism by direct upregulation of nutrient transporters and enzymes in 
key anabolic growth pathways, including glycolysis and glutaminolysis4.
 In addition, metabolic enzymes themselves can act directly as oncogenes or tumor 
suppressors. Inactivating mutations in fumarate hydratase (FH) and succinate dehydrogenase 
(SDH) cause an accumulation of the enzyme substrates fumarate and succinate, and mutations 
in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) cause depletion of α-ketoglutarate (α-KG) 
and accumulation of the oncometabolite D-2-hydroxyglutarate (D-2-HG). The mechanism of 
enhanced tumorigenesis is thought to be the effect of these changed metabolite concentrations 
which alter epigenetic modulation. The exact mechanisms are, however, difficult to unravel, 
since besides changes in these metabolite concentrations, other compensatory mechanisms 
come into play to supply cells with nutrients that are needed for survival and proliferation. 
In chapter 2, we described a novel R314C mutation in IDH1, that is defective in isocitrate 
processing, but unlike the well-known IDH1-R132H mutation, lacks D-2-HG production. 
Studies using the enzyme that is the result of this mutation could be helpful in distinguishing 
between the effects of D-2-HG and the induced metabolic rewiring to compensate impaired 
α-KG production. 
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Identification and inhibition of altered metabolic pathways
Better understanding of the metabolic dependencies of cancer cells is essential to identify the 
aspects of metabolism that are most suitable for therapeutic interference. Accurate techniques 
that measure levels of metabolites are based on cutting-edge analytic platforms that include 
high-performance liquid chromatography (HPLC), liquid chromatography mass spectrometry 
(LC-MS) and nuclear magnetic resonance (NMR) for metabolic profiling, and stable isotope 
labeling to study fluxes of labeled metabolites. Cancer cells cannot be considered as isolated 
metabolic units as there are extensive interactions between cancer cells and non-neoplastic 
cells in the tumor stroma. As it is challenging to model an accurate tumor microenvironment 
in cell culture, direct analysis of metabolic fluxes in intact tumors is increasingly considered 
as important. Fluor-18-deoxyglucose positron emission tomography (18F-FDG-PET) is widely 
used in clinical practice and allows for direct assessment of tumor glucose uptake. More 
recently, newer PET tracers have been developed to monitor additional metabolites, including 
glutamine and choline. D-2-HG levels in patients with gliomas harboring an IDH1 mutation can 
be quantified noninvasively using magnetic resonance spectroscopy5. Besides quantification of 
metabolites and metabolite fluxes as a read-out of pathway activity, RNA expression data have 
also been used for prediction of active pathways in a non-targeted6 or targeted fashion7.
Synthetic lethality
Alterations in cell metabolism may be the result of oncogenic events as decribed, and vice 
versa classical features of cancer such as increased proliferation and migration may be a 
consequence of altered metabolism. Therefore inhibition of oncogenic alterations may reverse 
metabolism of cancer cells, and inhibition of metabolic enzymes may reverse the neoplastic 
phenotype8. Furthermore blocking metabolic pathways with specific inhibitors may sensitize 
cells to toxic therapies in a synthetic lethality approach. As an example, increasing oxidative 
stress in a cancer cell with metabolic inhibitors (e.g. of enzymes that produce NADPH) may 
enhance the efficacy of radiotherapy or chemotherapy, as we have described for EGCG and 
radiotherapy in RCC in chapter 3. Furthermore inhibition of autophagy could inhibit the 
catabolic pathways that cancer cells upregulate as a response to chemotherapy. Lastly, cells 
with an altered metabolic state can become dependent on certain tyrosine kinase pathways, 
and synthetic lethality can be achieved by inhibiting this pathway, as has been described for 
IDH1-mutant cholangiocarcinomas and inhibition of the Src family kinases by dasatinib9. 
NANOMEDICINE
VHHs as tumor targeting agents
Monoclonal antibodies and antibody-drug conjugates (ADCs) have found their way in clinical 
practice as effective tumoricidal compounds. Examples are trastuzumab, the antibody against 
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human epidermal growth factor receptor 2 (HER2), that significantly improved the prognosis 
for women with HER2-positive breast cancer, and the anti-CD30 antibody brentuximab coupled 
to vedotin, ABT-414, described to be effective for relapsed Hodgkin lymphoma and systemic 
anaplastic large cell lymphoma. Full potential of such molecules is hampered since their large 
size of about 150 kDa restricts tumor penetration after intravenous infusion and therefore 
results in a suboptimal biodistribution10-11. Development of bispecific antibodies, binding two 
different epitopes, opens up a wide range of applications, such as direction of specific immune 
cells to tumor cells or simultaneous inhibition of two oncogenic pathways. Currently, over 
50 bispecific antibodies are evaluated in clinical trials, and catumaxomab (targeting EpCAM 
and CD3) and blinatumomab (targeting CD19 and CD3) are already approved for clinical use12-
13. However, there are still critical hurdles that have to be overcome, such as large-scale 
production, purity and immunogenicity.  
 For these reasons, the variable heavy chain domains of single chain llama antibodies, 
(VHHs), which are approximately 10 times smaller and consist of only one domain, are 
interesting alternatives. Basically, anti-tumor VHHs can be categorized into four groups. 
1. Monomeric VHHs with intrinsic therapeutic activity
In the context of cancer therapy, mostly VHHs targeting growth factor receptors have been 
developed. Binding of the VHHs to these receptors or their ligands can inhibit oncogenic 
signaling and thereby inhibit cell proliferation, as has been described for epidermal growth 
factor receptor (EGFR)14-15, tyrosine-protein kinase Met (c-Met)16-17 and vascular endothelial 
growth factor receptor (VEGFR)18. Next to inhibition of growth factor receptors, allosteric 
inhibition of protein function could also be of use in tumor targeting. An example is a VHH that 
neutralizes carbonic anhydrase-IX (CAIX) enzymatic activity by binding to the catalytic site of 
this pH-regulating enzyme19. 
 Though most research has been performed on targeting of extracellular proteins, 
intracellular proteins are promising therapeutic targets as well, especially since VHHs can 
withstand the reducing environment of the cytosol. An important limitation is that VHHs 
generally are not able to penetrate the cell membrane, and therefore other strategies are 
being developed to transport VHHs into cells. VHHs could be expressed as intrabodies20-21 by 
transfection of cells, however, such a gene therapy-approach presents with serious safety 
concerns in vivo and therefore is so far restricted to a preclinical research setting. Other 
possibities for intracellular delivery of proteins include the use of nanocarriers22, nanoparticles23 
and supercharged proteins. Furthermore, systems as used by bacteria, such as the type III 
secretion system (T3SS), to translocate proteins into eukaryotic host cells can be employed24-25. 
In chapter 6 we describe increased internalization via clathrin-mediated endocytosis of the 
anti-EGFR VHH 7D12, conjugated to a cell-penetrating peptide (CPP). Besides CPP-induced 
depletion of the EGFR-7D12-CPP complex at the cell surface and associated inhibition of EGFR 
receptor signaling, the CPP-based approach could also be used for internalization of a VHH 
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with an intracellular target. A major challenge, however, is that entrapment in the endosomes 
could lead to lysosomal hydrolysis of the protein before it reaches its target. To overcome this 
limitation, various approaches are being investigated, like pH-sensitive endosomolytic peptides 
to achieve endosomal escape26, or conjugation to cyclic deca-arginine, which was found to 
directly transduce large cargo into the cytosol27.  
2. Multimeric VHHs 
Because of the single-domain characteristic, molecular manipulation for generating 
multivalent of multispecific VHHs is relatively easy. In tandem cloning of two VHHs with a linker 
peptide yields a bivalent molecule with higher avidity for the antigen28, and crosslinking of a 
target by a VHH multimer can induce apoptosis and other signaling cascades29. Furthermore, 
simultaneous inhibition of two tumor targets with bispecific VHHs has been shown to increase 
anti-tumor efficacy30. Redirection of T-cell activity with bispecific constructs is a promising 
cancer-immunotherapy approach31-32, however, up to now only combinations of a tumor 
targeting VHH with a T-cell targeting single-chain variable fragment have been made. Since 
anti-CD833 and anti-PD-1 VHHs have been developed, combination of these with a tumor 
targeting VHH would be an interesting approach. Besides genetic engineering, VHHs can 
also be equipped with a LPETG amino acid sequence which can be employed to make tail-to-
tail specific constructs as we have described in chapter 5. In this situation both N-terminal 
domains are fully functional, which ensures full binding capacity. 
3. VHHs coupled to effector domains 
Since not all VHHs have an inherent therapeutic effect, and since treatment with conventional 
anti-cancer drugs often leads to development of resistance by the tumor cells, coupling of 
VHHs to a toxic protein, peptide or chemical group to induce immediate cell killing may be 
advantageous. This approach combines the advantages of the high tumor-specificity of the 
VHH with the cytotoxic effects mediated by the effector group. Genetic fusion of VHHs with 
protein-toxins34-35 or peptide tags as marker for cytotoxic CAR-T cells36 have been shown to 
induce cell death in in vitro systems. 
 A widely applied strategy for introduction of effector groups is random conjugation to the 
amino group of lysine side chains. Since multiple lysines are present in the VHH sequence, this 
strategy is difficult to control and therefore leads to heterogeneous end-products. Furthermore, 
interference with lysines in the binding site could compromise functionality. A more site-
specific labeling strategy involves introduction of a C-terminal cysteine, since with maleimide 
chemistry only this residue is labeled37, as we have confirmed in chapter 5. Furthermore we 
and others38-39 have employed sortase A mediated transpeptidation for introduction of GGG-X 
or polyethylene glycol (PEG)x-X molecules. Using this toolbox with conjugation strategies, 
virtually any compound can be conjugated site-specifically to a VHH. 
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Conjugates can be tailor-made for specific therapeutic applications, such as photodynamic 
therapy. Preclinical studies have shown that 7D12-photosensitizer (PS) conjugates rendered 
EGFR-expressing cells sensitive to light-induced death in vitro40 and in an orthotopic mouse 
model in vivo41. In chapter 7, we introduced a PS molecule site-specifically at the C-terminus 
of 7D12, and we confirmed effectivity of these conjugates in vitro. Furthermore we have shown 
that subcellular localization influences activity, since membrane bound 7D12-PS induced cell 
killing with higher efficacy than internalized 7D12-CPP-PS. To examine if this is a general 
concept, this approach should be applied to VHHs targeting other membrane proteins. 
Furthermore, various VHH-radionuclide conjugates are being developed for both alpha 
and beta radionuclide therapy. An in vivo study with 177Lu-labeled anti-HER2 VHH efficiently 
prevented tumor growth in a xenograft model of HER2-positive breast cancer42. Though fast 
kidney clearance is advantageous for imaging, it can cause nephrotoxicity and suboptimal 
absolute tumor uptake which is disadvantageous for therapy. Diminishing kidney clearance 
is therefore of great importance, and this can partly be done by eliminating the C-terminal 
histidine-tag which normally is present in the sequence42. Since we have introduced an LPETG 
amino acid tag preceding the 8xHistidine-tag in the VHH sequences, this can easily be realized 
by sortase A mediated cleavage. 
 The small size of VHHs enables fast tumor accumulation and blood clearance, both 
contributing to a high tumor-to-background ratio at early time points after injection, which is 
advantageous for imaging purposes. Conjugation of VHHs to near infrared fluorescent groups 
enables optical imaging43-44 as early as 30 minutes post injection. Furthermore labeling with 
radionuclides is employed for nuclear imaging. This has successfully been done with VHHs 
targeting EGFR45-46 and HER247. Currently bimodal VHH agents for combined nuclear and 
optical imaging are being developed, which could be used for image guided surgery. 
4. VHH-targeted nanoparticles
Another way for specific drug delivery is encapsulation of drugs in VHH-targeted nanoparticles. 
These can act as carriers for hydrophobic drugs, overcoming problems such as poor 
solubility, limited stability and rapid clearance. Surface modification with targeting moieties 
such as VHHs can enhance selective delivery to tumor cells. Functionality of VHH- targeted 
liposomes48-49, micelles50, polymersomes51 and albumin-based nanoparticles23, 52 has been 
assessed. In chapter 8 we describe effective in vitro cell killing induced by an ELP-based 
micelle functionalized with both 7D12 and PS. Though these results are encouraging, in vivo 
complete tumor eradication is probably not reached with photodynamic therapy as the only 
modality, since the efficacy of the technique is highly dependent on an optimal biodistribution 
of the PS-conjugate in combination with optimal light-accessibility of the cancer cells to be 
killed. Therefore dual therapies with e.g. PDT and chemotherapy could be advantageous, and 
these ELP-based micelles would provide a system to transport both agents selectively to the 
tumor cells.
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IS THERE A FUTURE FOR COMBINATION OF METABOLIC INHIBITION AND 
NANOMEDICINE?
Next generation sequencing supplies us with enormous amounts of data on the molecular 
events causing cancer. Numerous drugs are available that target specific pathways, facilitating 
personalized medicine. Although such personalized therapies may prolong survival, the 
inherent genetic instability of tumors ultimately leads to therapy resistance in most cancers. 
To overcome this, multiple therapies could be combined to induce synthetic lethality, or 
compounds should induce immediate cell death so cells simply do not have time to develop 
resistance. There are several applications in which combinations of metabolic inhibition and 
nanomedicine could be useful:
-  Since oncogenic signaling and altered metabolism are highly intertwined, adjuvant 
targeting of metabolism might improve efficacy of VHH-mediated inhibition of oncogenic 
signaling. 
-  The majority of interesting metabolic targets is localized intracellularly, and therefore 
therapies are focusing on the use of small molecule inhibitors or metabolic analogs. 
However, VHHs are also very suitable for inhibition of specific metabolic enzymes, since 
they are able to bind to sites that are normally not accessible to antibodies (e.g. enzymatic 
pockets) due to their small size 53-54. One hurdle that has to be taken is efficient intracellular 
delivery of VHHs.
-  One of the pitfalls of metabolic inhibition is that it also affects healthy cells. Therefore, to 
diminish delivery of metabolic inhibitors to healthy tissues, they could be encapsulated in 
nanoparticles decorated with tumor specific VHHs. 
To conclude, many challenges and applications lie ahead for both unraveling cancer metabolism 
and development of VHHs as a theranostic platform. Though cancer metabolism is a widely 
studied field, the degree and variety of ways in which tumor cells rewire their metabolism is not 
fully known. In the future we will gain more knowledge about drivers of the altered metabolism, 
and about ways to deprive cells from their essential metabolites. The conjugation platform 
that we optimized for VHHs, can be expanded with all kinds of targeting vehicles (e.g. DARPins, 
affibodies) and therapeutic or diagnostic compounds (e.g. other PSs, radionuclides, CPPs). 
Ultimately both targeting of rewired metabolism and a nanomedicine based platform could be 
combined for development of efficient cancer therapies. 
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SUMMARY
Cancer is a multifactorial disease, involving many processes that drive malignancy, described 
as the hallmarks of cancer. These hallmarks are the result of a range of mutational events that 
alter signaling pathways. Drugs inhibiting specific pathways have been developed, however due 
to tumor heterogeneity and plasticity it is becoming clear that blocking of multiple pathways 
in a synthetic lethality approach, or immediate cell killing with a cytotoxic therapy is a more 
practical strategy. Altered metabolism has (re)gained interest and inhibition of metabolic 
pathways on which tumor cells depend for survival could be employed in tumor targeting. 
This thesis describes both targeting of tumor metabolism and development of a VHH-based 
nanomedicine platform for inhibition of altered signaling pathways or induction of direct 
cytotoxicity. 
Deranged metabolism in cancer
Metabolic rewiring in cancer cells can be the result of altered signaling pathways due to 
mutations in oncogenes and tumor suppressor genes. These mutations often cause increased 
activity of transcription factors such as HIF, MYC and SREBP, promoting an anabolic program 
resulting in increased protein synthesis, glycolytic flux and lipid synthesis. 
 Furthermore, an increasing number of mutations are found in genes encoding metabolic 
proteins such as the TCA enzymes FH, SDH and IDH. In 2008, heterozygous hotspot mutations 
in the IDH1 and IDH2 genes were found in the majority of low-grade and secondary high-
grade gliomas. These mutations mostly involve Arg132 in IDH1 and Arg172 or Arg140 in IDH2, 
and cause a neomorphic gain-of-function. Whereas IDHs convert isocitrate to α-KG with 
simultaneous reduction of NADP+ to NADPH, the IDH mutants reduce α-KG to D-2-HG while 
oxidizing NADPH. D-2-HG is a proposed oncometabolite, acting via competitive inhibition 
of α-KG-dependent enzymes that are involved in metabolism and epigenetic regulation. In 
chapter two we describe a novel heterozygous mutation in the cytosolic IDH1, IDH1R314C. This 
mutation was discovered in a high grade glioma by high throughput sequencing. The mutated 
protein lacks isocitrate-to-α-KG conversion activity due to reduced affinity for NADP+, and 
differs from the IDH1R132 mutants in that it does not produce the oncometabolite D-2-HG. 
Therefore it represents a valuable tool to study the effects of IDH1-dysfunction on cellular 
metabolism in the absence of 2-HG production. 
 Another mutated protein that causes a rewiring of cellular metabolism is VHL, which 
is mutated in 80% of renal cell carcinomas, resulting in stabilization of HIF-1α and/or HIF-
2α, even under normoxic conditions. This leads to constitutive expression of metabolic HIF 
target genes, such as glucose transporters, glycolytic enzymes and lactate exporters, together 
orchestrating aerobic glycolysis. Furthermore inhibition of pyruvate shuttling into the TCA 
causes increased glutamine-driven reductive carboxylation to maintain the production of 
citrate for lipid biosynthesis. Though HIF-1α and HIF-2α are highly similar in structure, they 
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have distinct effects on cellular metabolism. In chapter three we investigated the cellular 
metabolism of two VHL-impaired ccRCC cell lines, SKRC-17 (expressing only HIF-2α) and 
SKRC-7 (expressing both HIF-1α and HIF-2α). We show that SKRC-17 cells are more dependent 
on glutamine for cell proliferation compared to SKRC-7 cells. Furthermore we show that the 
marked differences in cell metabolism translate in differential sensitivity to inhibitors EGCG 
and 6-AN.
Tumor targeting with VHHs
Besides a deranged metabolism, tumor initiation and progression can be caused by multiple 
other signaling pathways, like the ones induced by activated tyrosine kinase receptors (e.g. 
EGFR, MET, PDGF, VEGF). Monoclonal antibodies inhibiting these activated receptors have 
been developed, and besides passive tumor targeting these antibodies can also be conjugated 
to drugs to induce direct cytotoxicity. Though these antibodies are shown to have therapeutic 
potency, they also have several disadvantages like their size (~150 kDa), which limits tumor 
penetration, and their long circulation half-life. Heavy chain domains of single chain llama 
antibodies (VHHs or nanobodies) are an interesting alternative. Because of their small size (~15 
kDa) they have better tissue penetrating properties, and furthermore they have other advantages 
such as low production cost, high water solubility, low immunogenicity and high thermo,- and 
pH stability. A number of VHHs with high affinity and specificity have been developed binding 
tyrosine kinase receptors such as EGFR, HER2 and MET, which are all expressed on tumor 
cells. An alternative approach is targeting of the tumor neo-vasculature in order to stop tumor 
growth. In chapter four we describe identification of a novel tumor targeting VHH, C-C7, via in 
vivo biopanning of a llama VHH phage display library in an orthotopic mouse model of diffuse 
glioma. We showed that C-C7 recognizes a subpopulation of tumor blood vessels in clinical 
glioma samples, and furthermore it recognizes activated endothelium and macrophages in 
atherosclerotic lesions. Via yeast-2-hybrid screens we identified dynactin-1-p150Glued as the 
target of C-C7. 
 Conjugation of VHHs to diagnostic or therapeutic nanoparticles, peptides, proteins or 
drugs offers many opportunities for optimized targeted therapy in cancer. In chapter five, we 
aimed to combine several conjugation strategies in a modular approach for bioorthogonal VHH 
modification and conjugation. We employed sortase-A mediated transpeptidation to introduce 
chemical click moieties to the C-terminus of VHHs, which then can be used for conjugation to 
other groups. In this way we were able to make tail-to-tail bispecific VHHs and VHH-targeted 
nanoparticles. Besides introduction of click chemistry moieties, we also employed sortase-A 
mediated transpeptidation to introduce a cell pepetrating peptide (CPP) to the C-terminus of 
andi-EGFR VHH 7D12 in chapter six. We found that conjugation to the CPP led to 1) more 
efficient blocking of ligand binding and 2) increased endocytic optake of the whole 7D12-EGFR 
receptor complex. The net result was that 7D12-CPP more efficiently blocked ligand activation 
compared to 7D12 alone. 
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Besides for inhibition of oncogenic signaling pathways, which often is not curative, VHHs 
could be used for targeted delivery of cytotoxic agents to cancer cells. A class of interesting 
cytotoxic moieties are photosensitizers (PS), which cause cell death via induction of reactive 
oxygen species (ROS) after illumination with light of a specific wavelength. VHHs conjugated to 
PSs have been described to induce cell death of target expressing cells, however the effect of 
subcellular localization of the VHH-PS construct is largely unknown. Therefore we compared 
activity of internalizing 7D12-PS-CPP and the membrane bound 7D12-PS in chapter seven. 
We showed that both of these constructs very efficiently induced cell death of EGFR expressing 
cells, however the membrane bound construct was more potent. 
 Another way to deliver toxins or drugs to cells is via conjugation to or encapsulation in 
nanoparticles like liposomes, micelles and polymersomes. This could not only increase 
the dose of toxin or drug delivered to the tumor but also overcome other issues like poor 
solubility or stability. Elastin like peptides (ELPs) are protein polymers which can reversibly 
transform from a soluble state to an aggregated state above a certain transition temperature. 
ELP-based nanoparticles can be prepared out of amphiphilic diblock copolymers. In chapter 
eight, we report the use of an ELP diblock (ELPDB) polypeptide for creation of self-assembling 
theranostic 7D12-PS decorated ELP micelles. We showed that we could make well-defined and 
stable micelles by combining 7D12-ELPDB with PS-ELPDB and heating the mixture above the 
transition temperature of the hydrophobic block. The 7D12-PS decorated ELP micelles were 
able to selectively kill tumor cells that (over)express EGFR. 
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SAMENVATTING
Er zijn verschillende factoren van invloed op het ontstaan van kanker, en deze zijn samengevat 
in de 8 zogenaamde kenmerken van kanker (“hallmarks of cancer”). Deze kenmerken 
zijn het resultaat van een reeks van mutaties die ervoor zorgen dat de activiteit van 
intracellulaire signaleringspaden veranderd. Er zijn medicijnen ontwikkeld die de activiteit 
van deze signaleringspaden kunnen remmen, maar doordat er een hoop verschillen zijn 
tussen tumorcellen in éen tumor, en gezien tumorcellen zich aan kunnen passen, lijken 
combinatietherapieën waarbij je meerdere paden tegelijk remt, of therapieën die de cel direct 
doden in plaats van remmen in groei, meer effectief. In dit proefschrift beschrijven we ten 
eerste hoe het metabolisme van een tumorcel kan veranderen en hoe je deze verandering 
aan kunt grijpen om tumorgroei te remmen. Ten tweede beschrijven we de ontwikkeling van 
een nanogeneeskunde (“nanomedicine”) platform gebaseerd op llama antilichaam domeinen 
(VHHs), en een aantal toepassingen hiervan.
Ontspoord metabolisme in kanker
Kankercellen hebben vaak een aangepast metabolisme zodat ze aan alle bouwstoffen kunnen 
komen die nodig zijn voor de snelle groei. Dit komt onder andere door mutaties in zogenaamde 
oncogenen en tumorsuppressorgenen. Vaak komen deze mutaties voor in transcriptiefactoren 
zoals HIF, MYC en SREBP, en ze zorgen voor een verhoogde omzetting van glucose naar 
lactaat (glycolytische flux) en een verhoogde productie van eiwitten en vetten. Ook zijn er 
mutaties gevonden in genen die coderen voor de metabole eiwitten zelf. In 2008 werd er in de 
meerderheid van laaggradige en secundaire hooggradige gliomen mutaties gevonden in de 
IDH1 en IDH2 genen. De mutaties zorgen ervoor dat het IDH enzym een nieuwe functie krijgt. 
Normaal zetten IDH enzymen isocitraat om naar α-KG, waarbij NADP+ gereduceerd wordt naar 
NADPH. De gemuteerde enzymen zetten echter α-KG om naar D-2-HG waarbij ze NADPH 
oxideren naar NADP+. Er is dus een netto vermindering van α-KG en NADPH levels, en een 
verhoging van D-2-HG levels. D-2-HG wordt gezien als een oncometaboliet omdat het zorgt 
voor veranderingen in epigenetica en metabolisme. In hoofdstuk 2 beschrijven wij een nieuwe 
heterozygote mutatie in het cytosolische enzym IDH1, IDH1R314C. Deze mutatie is ontdekt in 
een hooggradig glioom middels high throughput sequencing. Het gemuteerde eiwit zet geen 
isocitraat om naar α-KG doordat het verminderde affiniteit voor NADP+ heeft. Het verschilt van 
het IDH1R132 mutante eiwit doordat het geen α-KG omzet naar D-2-HG. Daarom kan het een 
relevant model zijn om te bestuderen wat het effect is van verminderde α-KG productie zonder 
dat de effecten van D-2-HG hiermee interfereren.
 Een ander gemuteerd eiwit dat zorgt voor veranderingen in het metabolisme van een cel 
is VHL, dit eiwit is gemuteerd en daardoor inactief in meer dan 80% van de niercelcarcinomen 
(NCC). Normaal zorgt VHL voor de afbraak van transcriptiefactoren HIF-1α en/of HIF-2α, en 
bij afwezigheid van VHL zijn deze dus in verhoogde mate aanwezig in de cel. Daardoor is er 
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constante expressie van target genen van HIF, zoals glucosetransporters, eiwitten die actief 
zijn in de omzetting van glucose naar lactaat, en lactaat exporters. Deze eiwitten samen zorgen 
voor een verhoogde glycolytische flux. In de normale situatie wordt glucose omgezet naar 
pyruvaat, en dat kan in de citroenzuurcyclus gebruikt worden voor productie van energie en 
citraat, dat belangrijk is bij productie van vetten. Dit proces wordt geremd in cellen met VHL 
mutatie, en om te compenseren voor de verminderde productie van citraat wordt glutamine 
opgenomen en omgezet naar citraat. In hoofdstuk 3 hebben we gekeken naar het metabolisme 
van twee verschillende niercelcarcinoom cellijnen met een VHL mutatie, SKRC-17 en SKRC-
7. We hebben laten zien dat SKRC-17 cellen meer afhankelijk zijn van glutamine dan glucose 
voor celgroei, en dat dit ertoe leidt dat ze gevoeliger zijn voor remming van paden die glutamine 
omzetten naar citraat.
Tumor targeting met VHHs 
Naast veranderingen in metabolisme, kunnen tumorvorming en tumorgroei ook veroorzaakt 
worden door activatie van andere signaleringspaden, zoals de paden die aangestuurd worden 
door zogenaamde tyrosine kinase receptoren (bijvoorbeeld EGFR, MET, PDGF, VEGF). Er 
zijn verschillende antilichamen ontwikkeld die aan deze receptoren binden en hun functie 
remmen. Bovendien kunnen er ook stofjes aan deze antilichamen gekoppeld worden waardoor 
je de cel waaraan ze binden meteen dood maakt. Deze antilichamen zijn veelbelovend in de 
kliniek, maar omdat ze redelijk groot zijn (~150 kDa), kunnen ze soms niet geheel de tumor 
binnendringen. Lama antilichaam domeinen, of VHHs, zijn ongeveer 10 keer zo klein (~15 kDa) 
en om deze reden een interessant alternatief. Ook hebben ze andere voordelen zoals lage 
kosten voor productie, hoge oplosbaarheid in water, lage immunogeniciteit en hoge thermo,- 
en pH stabiliteit. Er zijn VHHs ontwikkeld tegen verschillende tyrosine kinase receptoren (EGFR, 
HER2, MET), die allemaal voor komen op tumorcellen. Je zou behalve tegen de tumorcellen, ook 
therapien kunnen ontwikkelen tegen de nieuw gevormde bloedvaten in tumoren. In hoofdstuk 
4 beschrijven we de identificatie van een nieuw VHH, C-C7, via een selectieprocedure in een 
muismodel van glioom. We laten zien dat C-C7 een deel van de bloedvaten in glioom, en daarbij 
geactiveerde bloedvaten en macrofagen in atherosclerose herkent. We hebben dynactin-1-
p150Glued geïdentificeerd als het eiwit waar C-C7 aan bindt. 
 Het koppelen van VHHs aan diagnostische en therapeutische nanodeeltjes, eiwitten of 
medicijnen biedt vele kansen voor doelgerichte therapieën (“targeted therapies”) in kanker. In 
hoofdstuk vijf hebben we verschillende strategieën gecombineerd om bepaalde groepen aan 
VHHs te koppelen. Ten eerste hebben we het enzym sortase-A gebruikt om zogenaamde click 
groepen (moleculen die specifiek met elkaar reageren) aan de VHHs te hangen. Deze click 
groepen hebben we gebruikt om twee VHHs aan elkaar te koppelen, of om nanodeeltjes te 
maken waarbij VHHs aan het oppervlak gekoppeld zitten. We hebben sortase-A ook gebruikt 
om een cell penetrating peptide (CPP), een klein eiwit dat makkelijk cellen binnengaat, aan 
een anti-EGFR VHH 7D12 te koppelen in hoofdstuk 6. We hebben de functie van dit 7D12-
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CPP vergeleken met het normale 7D12. We hebben gezien dat 7D12-CPP zorgde voor meer 
efficiënte blokkade van binding van het stofje dat normaal de EGFR activeert. Bovendien zorgde 
het CPP ervoor dat het hele complex van 7D12-CPP met de EGFR opgenomen werd in de cel, 
waardoor het ook niet meer geactiveerd kon worden. Het netto resultaat was dus dat 7D12-
CPP beter was in het remmen van de EGFR activatie dan 7D12 alleen.  
 VHHs kunnen dus gebruikt worden voor remming van geactiveerde oncogene paden, zoals 
voor EGFR, maar dit zorgt vaak alleen voor remming van celgroei en niet voor celdood en 
dus genezing. Een photosensitizer (PS) is een molecuul dat na belichting met licht van een 
specifieke golflengte zorgt voor de vorming van zuurstofradicalen, die heel schadelijk zijn voor 
een cel en daardoor celdood veroorzaken. Andere onderzoeksgroepen hebben al laten zien dat 
wanneer je een VHH aan een photosensitizer koppelt je celdood van specifiek de tumorcellen 
kunt veroorzaken. Er is echter nog niet bekend wat het effect is op de localisatie van het VHH-
PS eiwit. We hebben daarom in hoofdstuk 7 de effecten van 7D12-PS-CPP, dat opgenomen 
wordt door cellen, vergeleken met de effecten van 7D12-PS, dat vooral aan de buitenkant van 
de cel op het membraan blijft zitten. We hebben laten zien dat beide eiwitten zeer effectief 
celdood kunnen veroorzaken na belichting, maar het membraangebonden eiwit was meer 
effectief dan de internaliserende variant. 
 Een andere manier om medicijnen bij tumorcellen te krijgen is door het aan nanodeeltjes 
te koppelen of in nanodeeltjes in te sluiten. Hierdoor kun je niet alleen de effectieve dosis 
verhogen, maar het kan ook gebruikt worden voor medicatie die anders slecht oplosbaar is 
of niet stabiel is in waterige omgeving zoals bloed. Elastin like peptides (ELPs) zijn polymeren 
die reversibel kunnen transformeren van een oplosbare staat naar een geaggregeerde staat 
wanneer je ze boven een bepaalde transitietemperatuur verhit. Je kunt ELP nanopartikels 
maken met polymeren die uit 2 delen met ieder een andere transitietemperatuur bestaan 
(diblock copolymeren). In hoofdstuk 8 hebben we een ELP diblock copolymeer gebruikt om 
nanodeeltjes te maken met 7D12 en PS op het oppervlak. We laten zien dat deze nanodeeltjes 
in staat waren om alleen cellen met EGFR op hun oppervlak te doden na belichting. 
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Het misschien wel meest gelezen, of in ieder geval eerst gelezen, onderdeel van dit boekje. 
Natuurlijk zijn er erg veel mensen die ik wil bedanken, en ik hoop enorm dat ik niemand 
vergeet, daar gaat ‘ie dan!
Ten eerste natuurlijk het promotieteam. Pieter, Roland, mijn promotoren, bedankt voor het 
klaar staan wanneer dat nodig was. Roland, wij hebben met name overleggen gehad voor de 
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onzinnig was, en heldere visie over welke proeven nodig waren voor publicatie zijn altijd erg 
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naar Finland gegaan voor een tweede stage met het vooruitzicht op een promotieplek in jouw 
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(bijna) onbegrensde kennis van de meest uiteenlopende onderwerpen. Focus was soms ver 
te zoeken in overleggen, maar er kwamen altijd tientallen nieuwe ideeën uit een uurtje praten 
gerold. Soms frusterend, maar vooral erg leerzaam dat out-of-the-box denken. Bedankt voor 
de leuke tijd! 
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gezellige pauzes (als het even kon buiten in de zon, waanzinnige woensdag), en vrijdagmiddag,- 
of vierdaagseborrels. Anneke, wij vormden in het begin met z’n tweeën het kleine tumor 
targeting groepje. Ik heb dat altijd heel gezellig gevonden, en bewonderde jouw kennis van 
het muizenwerk. Verder waren de borrels waarbij jij dronken was na 2 roseetjes ook altijd erg 
goed. Sander, ik schaamde me voor mijn labjournaals toen we jouw precieze bedrijfsmatige 
systeem van werken te zien kregen. Jouw kennis van chemie heeft het VHH werk een boost 
gegeven en dankzij jouw voorwerk heb ik leuke artikelen af kunnen maken. Krissie, partner-
in-crime op het lab maar ook daar buiten. Wij hebben de metabole verschrikking geprobeerd 
aan te pakken, en goede planningen gemaakt voor het om-en-om uitnemen van SRB platen, 
zodat er toch iemand kon gaan stappen. Samen stappen geeft soms problemen, omdat we 
beiden een rem missen, maar dit heeft ook tot onvergetelijke dagen/avonden/nachten geleid 
in oa Whistler, Vancouver en vooral in Nijmegen. Succes als wetenschappelijke zakenvrouw bij 
Bayer. Corina, het schrijfwonder. Ik ben zo jaloers op jouw plezier in schrijven, en het gemak 
waarop het lijkt te gaan. Bedankt voor de fijne vervanging van Anneke links van me naast 
de boom, en heel veel succes met je nieuwe baan bij Charles River. Rene, oude kletskous. 
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rubriek op nu.nl. Daarnaast was je altijd even behulpzaam, je hoefde maar hardop een vraag 
te denken en jij stond al achter het bureau mee te kijken, bedankt daarvoor en succes met het 
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groot maken van het onderzoek in de neurochirurgie. Tessa, begonnen als stagiaire in de groep 
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and the hospitality in Kuopio, and Petri and Einari, many thanks for the (technical) support. 
Jos en Rene bedankt voor de hulp bij het maken van de micellen. VHHs tot expressie brengen 
en vooral selecteren is nog niet zo makkelijk. Ik heb hier veel tijd aan besteed maar soms 
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